Page last updated: 2024-11-04

salicylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID338
CHEMBL ID424
CHEBI ID16914
SCHEMBL ID1967
MeSH IDM0029886

Synonyms (1646)

Synonym
BIDD:ER0602
bdbm26193
phenol derivative, 7
2-hydroxybenzoate, i
chembl424 ,
CHEBI:16914 ,
MLS000069653 ,
o-carboxyphenol
smr000059163
2-carboxyphenol
KBIO1_000301
DIVK1C_000301
2-hydroxy-benzoic acid
ortho-hydroxybenzoic acid
einecs 200-712-3
ionil-plus
brn 0774890
acido o-idrossibenzoico [italian]
nsc 180
sebucare
salicylic acid [usan:jan]
duofilm
trans-ver-sal
domerine
acido salicilico [italian]
SGCUT00012
D00097
salicylic acid (tn)
salicylic acid (jp17/usp)
SPECTRUM_000948
o hydroxybenzoic acid
ortho hydroxybenzoic acid
acid, o-hydroxybenzoic
acid, 2-hydroxybenzoic
acid, ortho-hydroxybenzoic
2 hydroxybenzoic acid
acid, salicylic
salicylic acid, reagentplus(r), >=99%
occlusal
verrugon
keralyt
IDI1_000301
SMP2_000145
benzoic acid,2-hydroxy salicylic acid
inchi=1/c7h6o3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8h,(h,9,10
freezone
duofil wart remover
stri-dex
kyselina 2-hydroxybenzoova [czech]
advanced pain relief callus removers
dr. scholl's corn removers
dr. scholl's wart remover kit
cmc_13852
salicylic acid soap
orthohydroxybenzoic acid
hsdb 672
saligel
clear away wart remover
acidum salicylicum
k 537
ai3-02407
ionil plus
ccris 6714
benzoic acid, 2-hydroxy- (9ci)
ionil
dr. scholl's callus removers
epa pesticide chemical code 076602
caswell no. 731
advanced pain relief corn removers
duoplant
salicylic acid (6ci,8ci)
2-hydroxybenzenecarboxylic acid
kyselina salicylova [czech]
UPCMLD-DP126:001
liquid
C00805
o-hydroxybenzoic acid
69-72-7
2-hydroxybenzoic acid
salicylic acid collodion
rutranex
wln: qvr bq
benzoic acid, 2-hydroxy-
nsc-180
phenol-2-carboxylic acid
SALICYLIC ACID ,
retarder w
nsc180
salicylic acid, tech.
psoriacid-s-stift
salonil
salicylic acid, >=99%, fg
salicylic acid, bioxtra, >=99.0%
TO_000004
salicylic acid, plant cell culture tested
UPCMLD-DP126
NCGC00159447-02
DB00936
salicylic acid, acs reagent, >=99.0%
NCGC00159447-04
salicylic acid & sulfur soap
sebulex
KBIO2_003996
KBIOSS_001428
KBIO2_001428
KBIO2_006564
NINDS_000301
OPREA1_040343
salicyclic acid
STK258681
salicylic acid, puriss. p.a., >=99.0% (t)
E9A559BE-383B-4F83-BC02-3031D03D558A ,
ksc-11-207-4
KUC106694N
BMSE000252
salicylic acid rs
fema no. 3985
lamivudine impurity, salicylic acid-
H0206
AKOS000118979
NCGC00159447-05
NCGC00159447-06
tox21_303109
cas-69-72-7
dtxsid7026368 ,
NCGC00257065-01
dtxcid206368
NCGC00259022-01
tox21_113453
tox21_201471
H1342
HMS2233A10
mediplast pads
akurza cream
dhs sal shampoo
duofilm wart remover
o414pz4lpz ,
akurza lotion
salicylicum acidum
salex cream
durasal
hydrisalic gel
duoplant gel
kyselina 2-hydroxybenzoova
unii-o414pz4lpz
acido salicilico
acido o-idrossibenzoico
salicylic acid [usp:jan]
ec 200-712-3
kyselina salicylova
p&s shampoo
propa ph peel-off acne mask
salex lotion
S4539 ,
FT-0674502
29656-58-4
benzoic acid, hydroxy-
BP-12826
FT-0645123
salicylic acid [mart.]
salicylic acid [usp-rs]
salicylic acid [usp]
salicylic acid [inci]
mesalazine impurity h [ep impurity]
dl-lysine acetylsalicylate impurity a [ep impurity]
acetylsalicylic acid impurity c [ep impurity]
acidum salicylicum [who-ip latin]
2-hydroxybenzoic acid [fhfi]
salicylic acid [ep impurity]
salicylic acid [mi]
salicylic acid [ep monograph]
salicylic acid [who-dd]
salicylic acid [vandf]
sulfasalazine impurity h [ep impurity]
lamivudine impurity c [ep impurity]
salicylic acid [jan]
salicylic acid [hsdb]
salicylicum acidum [hpus]
carbasalate calcium impurity c [ep impurity]
salicylic acid [green book]
salicylic acid [usp monograph]
salicylic acid [who-ip]
EPITOPE ID:124929
gtpl4306
bazuka extra strength gel
HMS3373M19
CCG-212792
HY-B0167
anti-blemish
o-hydroxy benzoic acid
hydroxy-benzoic acid
2-hydroxy benzoic acid
SCHEMBL1967
TS-03583
fostex (salt/mix)
sebulex (salt/mix)
component of tinver (salt/mix)
sebucare (salt/mix)
domerine (salt/mix)
pernox (salt/mix)
benzoic acid, o-hydroxy-
component of fostex medicated bar and cream (salt/mix)
salicylic acid & sulfur soap (salt/mix)
component of keralyt (salt/mix)
component of solarcaine first aid spray (salt/mix)
retarder sax (salt/mix)
duofilm (salt/mix)
salicylic acid, british pharmacopoeia (bp) reference standard
AB00489876_15
OPERA_ID_582
mfcd00002439
J-509667
F2191-0216
salicylic acid, tested according to ph.eur.
salicylic acid, saj first grade, >=99.0%
salicylic acid, united states pharmacopeia (usp) reference standard
salicylic acid, certified reference material, tracecert(r)
phenol-2-carboxylate
2-hydroxybenzenecarboxylate
azurechelin
salicylic acid, 1.0 mg/ml in acetonitrile, ampule of 1 ml, certified reference material
salicylic acid, p.a., 99.0%
salicylic acid, pharmaceutical secondary standard; certified reference material
salicylic acid, european pharmacopoeia (ep) reference standard
salicylic acid, vetec(tm) reagent grade, 98%
salicylic acid, lr, >=99%
salicylic acid 1.0 mg/ml in acetonitrile
SBI-0051510.P003
8052-31-1
salicylic acid acs grade
FT-0674503
2-hydroxobenzoic acid
salicylic acid,(s)
BCP09067
fema3985
Q193572
HMS3885B08
salicylic-acid
D70842
NCGC00159447-01
c6h4(oh)cooh
EN300-16723
PB48023
solv x
acne advanced cleansing
sensitive skin deep cleaning astringent
leader therapeutic dandruffanti-dandruff, anti-seborrheic dematitis and anti-psoriasis
first aid beauty fab acne spot treatment
medicated acne shower
papis creams psoriasis
keranique anti dandruff shampoo
medicated callus removers
clarifying pressed powder
salex
ped x callus removers, medicated
clearskin professionaldeep pore cleansing scrub
strataclear
narasoo healing
clearskinclear emergency instant spot treatment
home health psoriasis
oily sk specific solutions
viper acne body wash
elf sand acne fighting foundation
acne defense foaming cleanser
salicylic acid 2.00%
antidandruffshampoo
nutrixylanti-dandruff
stridex
yat tip tor
phisoderm anti blemish body wash
xtracare dandruff hair wash
target up and up foaming body wash acne treatment
blackhead solutions 7 day deep pore cleanse and scrub acne medication
acne toner serum
nixoderm unguento
clear acne face moisturizer
neutrogena stubborn texture daily cleanser
sulfasalazine impurity h (ep impurity)
clear and cover acne treatment concealer clear and cover acne treatment concealer2 linen
jinhancho
oxy deep pore cleansing pads
dermatouch acnecare moisturizer
blemfree
quick action
oxy 3 in 1 acne pads
neutralyze clearing serum
callus removal foot pack
noxzemaantiblemish
clean and clear essentials deep cleaning
clenziderm daily care foaming cleanser
derma pella acne wash for oily skin
salicylic acid (usp:jan)
la roche posay laboratoire dermatologique effaclar pore refining acne treatment
walgreens medicated callus removers
anti-blemish cleanser
antiac acne clearing
clearskinprofessional daily correcting
clarifying toner2%
skinceuticals clarifying exfoliating cleanser
acne shave cream
deep cleaning astringent
alumier md hydrasmooth non-comedogenic moisturizer
eradikate salicylic acid acne treatment
dr. groot anti-dandruff scalp care
overnight clearing
acne control apricot scrub
skin pharmacy advanced acne therapy pore refining facial mask
neutrogenaskin clearing blemish concealer-fair 05
cocokind postbiotic acne serum
clearskinclear emergency intensive treatment
blemish clearing facial wipes
exuviance daily acne peel
zitlox salicylic acne
aveda scalp remedy dadruff
clear acne bodypaulas choice
skin perfecting acne and blemish wash
neutrogena stubborn body acne treatment
clarity clear skin essentials
soft servicesclearing mist
hasol intensive
cvs clarifying acne body wash-pink grapefruit
maximum strength one step wart remover strips with salicylic acid
skin rescue set
atrix antibacterial wash
yes to tomatoes detoxifying charcoal sleeping mask
peace out acne
facial cleanser
meijer foaming cleanseracne medication
phisodermclean anti-blemish facial cleanser
amazon basics acne washacne treatment
pimple correct 2% salicylic acid acne treatment
blemish vanishing
age bright clearing serum
salicylic acid acne treatment
re-fresh scalp care
let me clarify
neutrogenaskin clearing blemish concealer-buff 09
killa extra strength 4 pack
cvs health advanced acne spot treatment
isomers clear skin acne treatment gel
drs. acne clear
neutrogena blackhead eliminating daily scrub
good molecules acne foaming cleanser
nu skin clear actionacne medication toner
maetria miracle recipe premiumshampoo
neutrogena skinclearing mineral-honey beige
start so fresh
aveeno clear complexion foaming cleanser
clear and cover acne treatment concealer clear and cover acne treatment concealer9 almond
clearasil rapid rescue deep treatment wash
clear improvement pore clearing moisturizer
neutrogenaskin clearing blemish concealer-light 10
neutrogena stubborn body acne cleanser and exfoliator
clearskinblemish clearing 2-in-1 treatment and hydrator
pacifica acne warrior body wash
avalon organics antidandruff
walgreens acne control gel
gnc pet wellness ultra medicated anti-seborrheic
stridexmaximum
dermarestpsoriasis medicated skin treatment
dermarestpsoriasis medicated scalp treatment
bareminerals blemish rescue skin-clearing loose foundationtan nude 3.5w
dermatouch acnecare pads
clear gel corn remover
yes to tomatoes detoxifying charcoal mud mask
one step clear wart remover
epielle exfoliating scrubexfoliating scrub
cetaphil gentle clear clarifying acne cleanser
ped x corn removers, medicated
rhodd acne body so ap
salic-2
puripatch for acne treatment
retinol clearing
vichy laboratoires normaderm phytoaction acne control moisturizer
3 in 1 cleanser
clear medicated corn removers
salicylic acid serum 2%
meoly liquid wart corn remover
natural pure balancing hair
proactiv acne body wash
cvs daily acne clearing scrub
neutrogena rapid clear treatment pads
wartovir wart remover
bleackhead removing medicated scrubdaylogic
equate corn and callus remover
clear away wart removers
nuvileo skin perfecting acne
dr. scalp spicule complex
clearasil ultra rapid action
satos corn and callus remover
dermaclear bha spot treatment
maximum strength wart remover with salicylic acid
one-step corn remover
pedi-quick onestep corn removers
lqd acne blemish treatment control
bha cleanser
ultimate daily face wash
prosoria scalp
neutrogena skinclearing mineral-buff
acne correcting cleanser
acne solutions liquid makeupsalicylic acid acne treatment
innbeauty project acne serum
scholls wellness company llcduragel callus remover
saliclylic acid
clear smart charcoal blackhead scrub
prosoria psoriasis treatment
elf blemish control face primer clear
apple cider vinegar anti-dandruff leave-in
anti-acne
gly-sal 5-2 pads
2% salicylic acid
acneen
bareminerals blemish rescue skin-clearing loose foundationmedium beige 2.5n
granex foam acne treatment
acni spot
oribe serene scalp anti dandruff
psocleeradvanced psoriasis
wart remover gel tube
pedi-quick one step callus removers
okay facial scrub
walgreens dandruff itchy dry scalp defense plus vitamins and botanicalsanti-dandruff
yes to tomatoes roller ball spot stick
dr. pelo scalp tonic
perricone acne relief calming and soothing clay mask
aveeno clear complexion cleanser
clearasil active lightweight face and body
salicylic acid 1.5%
clean and clear essentials deep cleansing tonersensitive skin
micropoint for blemishes
almay clear complexion concealer
acne control outsmart acne clarifying treatment
slmd salicylic acid body wash
miss spa clear blemish patches
dermala acne treatment
la roche posay laboratorie dermatologique effaclar medicated cleanser
assured acne cream
no zit sherlock acneoil control
clearing mattifier
clearasil daily cleardaily pore cleansing pads
neutrogena body clear body wash pink grapefruit
dr. iaso ac booster
acne treatment clear gel-maximum strength
lancell huitomo hair loss prevention hair growing tonic
soft services clearing mist breakout tonic
clear smart clear complexion toner
bath and beautycharcoal acne scrub
st. ives
rida hair research institute
plantar wart remover
salicylic acid (usp monograph)
mark.get treatment anti-acne overnight treatment
maximum strength wart remover strips
phisoderm clear confidence face scrub
bareminerals blemish rescue skin-clearing loose foundation
raf five-spot on salicylic acid roll-on acne treatment
clear and cover acne treatment concealer clear and cover acne treatment concealer
proactiv extra strength formula toner
clearasil ultraacne plus marks wash and mask
clear and cover acne treatment concealer clear and cover acne treatment concealer11 coffee
clearskindays overnight dual correcting
raf five-clear the way salicylic acid acne treatment pads
frontman fade
blistex stridex spot and t-zone acne cleargel
refinecomplexion clearing pads
cerasoothesa ear cleaner
bareminerals blemish rescue skin-clearing loose foundationfair 1c
dermesse pad treatment 2.0
skin clearify moisturizer
witch hazel pore clarifying toner8 oz
acne relief calming treatment and hydrator
clear and cover acne treatment concealer clear and cover acne treatment concealer6 honey
compound wmaximum strength one step invisible
derma pella acne care
dhs sal
kerastase paris k symbiose scalp renewal micro exfoliating scrub antidandruff treatment
clear and cover acne treatment concealer clear and cover acne treatment concealer10 walnut
aveeno clear complexion daily cleansing pads
liquid corn and callus remover
better braids medicated leave in conditionermedicated
proactiv deep cleansing body wash
yourgoodskinactive treatment tonic
dry it out acne spot treatment
tula skincare breakout breakthrough acne toner pads
bareminerals blemish rescue skin-clearing loose foundationfairly medium 1.5c
dr. groot anti-dandruff scalp care 2 in 1
zo skin health skin normalizing system therapeutic treatment for red, sensitized skin
b-lucid targeted body acne gel
fresh detox 2 in 1 anti-dandruff shampoo
acne solutions clarifying
pur 4-in-1 correcting primer
liva clean
neutrogena rapid clear
somxl
signature care acne treatment
neutrogena skinclearing mineral-tan
salicylic acid wash
clixit acne control body wash
daily care foaming cleanseracne treatment
dermaclear pads
0.5%salicylic acid
denorex extra strength
wart remover liquid
neutrogena scalp therapy anti-dandruff extra strength
warticide
body wash
bensal hp
ephiderm spot treatment
dr throwers oily skin facial astringent
laboflex acne spot care
unblemish refining acne wash
kiehls since 1851 dermatologist solutions breakout control acne treatment facial
okay body wash
dermad anti-itch therapeutic
resurfacing treatment pads
clarifying toner salicylic acid 1%
seacret active clear facial wash
instanatural acne cleanser
anti acne cotton tablets
revitealizeanti dandruff
clearasil daily clearoil-free daily face wash sensitive
equate one step corn remover pad
dandruff shampoo
bareminerals blemish remedy acne treatment gelee cleanser
clearasil active deep cleansing face and body wash
aftasepticinstant pain relief
sunday riley ultra-clarifying acne treatment face
isomers clear skin acne treatment lotion
rite aid renewalacne
cbdmedic acne treatment
clear acne face cleanser
milani erase base blemish control primer salicylic acid
clear and cover acne treatment concealer clear and cover acne treatment concealer9.5 chai
pharma clear cleanser
dandruff reliefdaylogic
zapzyt acne wash cleanser
inward agas acue cleansing foam
lerosett high-content organic acne treatmentbotanically based
callicide corn and callus remover
bareminerals blemish rescue skin-clearing loose foundationneutral deep 5.5nw
thatzit acne treatmentmax
harmon face values blemishes and blackheads apricot scrub
okay facial wash
cvs health blackhead clearing scrubacne medication
clearasilultra rapid action daily face wash
dermatouch acnecare facial scrub
neutrogena scalp therapy anti-dandruff itchy scalp
amazon basics acne wash
okay facial toner
dermesse pad treatment 0.5
psoriasis medicated moisturizer
natureplex psoriasis
acne free blackhead removing scrub 2 salicylic acid with charcoal
dermaclear bha cleanser
creamy foam cleanser
naturopathica chill chocolate vine detox tonic
neutrogena acne proofing daily scrub
walgreens corn remover
elf beige acne fighting foundation
witch hazel moisture anti-dandruff shampoo
in the clear acne serum
bareminerals blemish rescue skin-clearing loose foundationsoft medium 2cn
oily sk cleansing
eradikate clarifying acne
clear and cover acne treatment concealer clear and cover acne treatment concealer13 fudge
stridex naturally clear
acne moisturizer
bareminerals blemish rescue skin-clearing loose foundationwarm tan 4.5cn
almay clear complexion liquid makeup for oily skin
liquid wart corn removal mask
eradikate acne mark fading
thatzit acne treatment
daily cleansing
one step wart remover clear strips
clarity clear skin essentialsdeep-cleaning astringent
some by mi aha bha pha 30 days miracle toner
dusel psoriasis dead sea salt therapy
bodewell psoriasis scalp relief treatment
emergency zit treatmentacne
paulas choice clear body acne
okay blemish control apricot scrub
anabiose puriheal
clean follicle tonic
bioreblemish fighting ice cleanser
miss spa banish microneedle spot treatment
better braids medicatedmedicated
apothecare
keep the peace acne-calming cream cleanser
clear and cover acne treatment concealer clear and cover acne treatment concealer2.5 bisque
signature care blemish and blackhead control
zo skin health offects correct and conceal acne treatment (light)
well at walgreens blemish and blackhead control apricot
corn and callus remover
asepxia charcoal acne bar
ultra clear treatment
nelly devuyst ph toner bioacne
neutrogena skinclearing mineral-natural beige
nu skin clear actionacne medication night treatment
acne shave moisturizer
damage repair anti-dandruff shampoo
pro clear serum
hero pore release blackhead clearing
bareminerals blemish rescue skin-clearing loose foundationlight 2w
up and upblemish controlling apricot scrub
phisoderm clear confidence body wash
acnisal
natriaacne treatment
neutrogena deep clean purifying cooling gel scrub
clarifybotanical clarifying wash
id anti acne
proactiv clear zone body pads
treatonic wart remover
clearasil daily cleardaily facial scrub
acne cleansing pads
dhs sal4 oz.
ultrasal-er
skin medica purifying foaming wash
triderma psoriasis control body wash
acne wash daily cleanser
inixial perfection stop blemishes salicylic acid 2% acne treatment
acne warrior clearing astringent
salicylic gel
yourgoodskinanti-acne base
atrix clarifying toner
salicylic acid 0.19%
scholls wellness company llccorn removers
dr. lift acne cleanser
vircin advanced wart treatment
nelly devuyst micellar foam bioacne
cvs triple action astringent
biorewitch hazel pore clarifying cleanser
up and updual effects moisturizer
acne treatmentmeijer
shaant pore purifying face scrub
bioredaily detox acne toner
patchology the blemish buster breakout box 3-in-1 acne treatment
perricone acne relief gentle exfoliating toner
smooth frizz anti-dandruff shampoo
clear-n-smooth acne-pimple medication
aurocin ceradermear cleaner
daily cleansersalicylic acid acne treatment
nas pore refining scrub
neutrogena scalp therapy anti-dandruff scalp build-up control
samsali wart remover pads
equate 2% salicylic acid acne treatment pad
artistry studio done with zit acne treatment clearing gel
vibrant color with rose essence anti-dandruff shampoo
blemish bully acne spot treatment
virasal
acne wash
one step wart remover
vichy laboratoires normaderm bha exfoliating acne treatment
acne control rapid relief acne spot treatment
ultra clear foaming cleanser
elf buff acne fighting foundation
acne advanced treatment system
nutricentials here you glow exfoliating toner
clear and cover acne treatment concealer clear and cover acne treatment concealer5 beige
blemish control blotting paper
compound wliquid-first aid
yes to tomatoes detoxifying charcoal cleanser
clinique acne solutions cleansing foam
neutrogena all in 1 acne control daily scrub
blackhead cleaning scrub
clearasil ultraacne clearing scrub
psoracare
cerave developed with dermatologists acne control acne treatment
mark. back up plananti-acne back treatment
saliskin wash
clearskin professionalinvisible blemish treatment
natural acne solutions 3 step regimen
acne fighting spot gel
bareminerals blemish rescue skin-clearing loose foundationmedium 3c
four season essence
paulas choiceanti-redness
rosemary and salicylic acid acne clearing moisturizer
bodewell psoriasis calming
arctiva psoriasis cream
the better skin co.zit no more kleanse
cetaphil gentle clear mattifying acne moisturizer
ouai anti-dandruff
pink grapefruit foaming acne scrubdaylogic
acneworx
hill country essentials apricot scrub blemish and blackhead control
clenziderm pore therapy
kiehls since 1851 blue herbal acne spot treatment
keep it clear acne foam cleanser
broda acne
clearasilultra acne plus marks treatment
multi-action clear-acne clearing treatment
cvs health blackhead clearing scrub
corn and callus remover kit
clearasil stubborn acne control 5in1 daily pads
yourgoodskin
canafarma spot on acne treatment
foaming acne scrubfor a cleaner, clearer complexion
scantily pad
neutrogena stubborn blackheads daily serum
zo skin health offects correct and conceal acne treatment (medium)
compound w one step pads
incredibly clear acne spot
dial acneacne
salicylacne-1% clearing gel
acne advanced clarifying hydrator
kiehls since 1851 dermatologist solutions expertly clear acne treating and preventing
acne face cleanser
no zit sherlock acnepurifying cleanser toner
killa acne extra strength
phisoderm anti-blemish gel cleanser
clearasilultra 5 in 1
botanic skincare acne defense treatment
clear up cleansing
acne cleansing wipes
clear and cover acne treatment concealer clear and cover acne treatment concealer8 amber
lamivudine impurity c (ep impurity)
the inkey list succinic acid acne treatment
dollar general acne spot medication
vichy laboratoires normaderm phytoaction deep cleansing
asepxiafacial cleansing
cetaphil acne relief body wash
zhangguang 101 hair max 101b
asepxia scrub acne bar
confiche anti-hair lossshampoo
asepxia acne wipes
basic essentials astringent
equate beauty
peace out acne hero routine
clear skin days clarifying cleanser and mask
glytone acne treatment
111medco 2% salicylic acid cleansing bar
breakout clearing overnight treatment
clear proof blemish control toneracne medication
scrub so clean acne-fighting super scrub
cvs pore unclogging scrub
i dew care fix my zit acne geltreatment
dont be shy acne
glo skin beauty clear skin cleanser
asepxia neutral acne bar
acne toneracne clearing system
blue herbal spot treatment salicylic acid acne treatment
clearasil rapid rescue deep treatment pads
clear pore serum
nelly devuyst serum bioacne
amino ex500ml
salicylic acid 0.5%
clearskinblemish clearing acne body wash
sa foaming cleanser
soft services
meijer blackhead clearing scrub
bareminerals blemish rescue skin-clearing loose foundationmedium tan 3.5cn
hope in a bottle
salicylic acid 5.9%
kleer-plex targeted acne pen
acne relief cream
suffusionsa ear cleaner
body spray
clear exfoliating solutionpaulas choice
la roche posay laboratoire dermatologique effaclar clarifying
oars and alps purifying scalp scrub
leader therapeutic dandruff
clean getaway bag
clearasilultra 5-in-1 exfoliating wash
anti dandruff
clear smart blemish spot treatment
biotop professional 02 eco dandruff
dial acne control deep cleansing body wash
mark. save the dayanti-acne concealer
wartstick
charcoal blackhead clearing scrub
haircare physicians recommended
yat tip xiao
aveeno positively radiant clear complexion foaming cleanser
clearasil rapidly clear acne solutions
bareminerals blemish rescue skin-clearing loose foundationneutral medium 3n
foaming cleanserjafra
verruguin liquid wart remover
clear skin days spot eraser stick
clearcalm non-drying acne treatment
inixial perfection matt balancing care salicylic acid 2% acne treatment
dr. c. tuna acne clear complexion cleanser
pacifica acne warrior body scrub
peace out acne serum
bareminerals blemish rescue skin-clearing loose foundationdeepest deep 6c
anti-blemish matte primer
charcoal acne scrubhelp clear acne blemishes
stop spot
so totally clean deep pore cleanser
clearasil stubborn acne plus marks one minute mask
clear corn remover strips
cerave developed with dermatologists acne control cleanser
cvs clarifying acne body wash-pink grapefruitacne treatment
mosco
dr.luke liquid wart remover mask
x out cleansing body
dg bodytonic
anti acne clarifying face wash
neutrogena acne proofing cleanser
antidandruffshampooconditioner
clear future corrective treatment
wart remover medicated discs
scholls wellness company llcone step corn removers
two step jelly mask-brightening and nutrition
id anti-acne toner clarifying face plus body treatment
psoriasis treatment cream
skincoach clean
xalix
spotless cleanser
personal care acne control
clean and clear essentials deep cleaningastringent
bioelementsspotless cleanser
activ o2 acne treatment
isomers clear skin acne spot treatment
cvs deep cleansing astringent
therapeutic hydrogel
enfuselle acne clarifying
raf five-after hours salicylic acid moisturizing
md acne customized hydrating cleanser
oxyadvanced care 3 in 1 retexturizing cleansing pads
oxy overnight acne reducing patches
e.l.f skin acne-treating body mist
mattifying tonicjafra
family care ultra acne treatment
salicylic acid (mart.)
28.5% salicylic acid
phisodermclean anti-blemish body wash
clear proof pore purifying serumacne medication
skin pharmacy advanced acne therapy clarifying daily cleanser
butt and thighsacne treatment
scalp revival
aspire treat so deep
dr. c. tuna acne pore purifying toner
dt exfoliating cleanser
clear days aheadoil-free salicylic acid acne treatment cleanser
nas toner
clear wart remover strips
clearasil rapid rescue body treatment
naturopathica chlorophyll and salicylic acid spot treatment
moderate acne treatment
triderma acne gel face wash
one step clear medicated corn remover
acne control clarifying cream cleanser
stridex conditioning acne scrub
veraciti
salicylic acid cleanser
aspire cleanser so fresh
exfoliating and clarifying face wash
bareminerals blemish rescue skin-clearing loose foundationneutral ivory 2n
acne prone
dermazorpsoriasis and seborrheic dermatitis
angryhead premium
meijer blackhead clearing scrubacne medication
nelly devuyst purifying bioacne
dr young ac control ac out spot stop serum
clear cell salicylic clarifying pads
seborasershampoo
solva-ker
clearasil daily clearoil-free daily face wash
one step wart remover strips
the inkey list c 50 serum
nexiclear acne treatment
clearskinblemish clearing foaming cleanser
medicated wash
clearskinblemish clearing acne pads
acne cleanser w/ salicylic acid
molluscum contagiosum treatment
acne washkissable
nuvileo acne face wash
hyvee blemish controlling apricot scrub
acne deep pore cleansing wash
sebobalance spot control
kenkoderm psoriasis moisturizing
almay clear complexion liquid makeup
ultra clear foaming cleanser acne
medicated acne pads
broda acne spa
corn removers
clearasil ultraovernight face
next cell medicalacne cleansing wipes
offects te-pads acne pore treatment
krogerdaily face wash
salicylic acid (usp-rs)
clearskindays acne clearing drops
nizoral psoriasis
acne body wash
kleer-plex penetrating acne
soraresal
celestyhyperpigmentation series ultra brightening gel cleanser
cln acne cleanser
cvs daily pore clearing pads
clearasilultra acne plus marks daily scrub
better braidsmedicated
miracle rash repair
rejuvaderm medispa acne back
acne control superclean body wash
even better clinical acne solutions
oxy cleansing pads
sinsin corn band
liquid wart remover
atrix acne treatment
salicylic acid 3%
msm scalp essence signature
artistry studio rose all day anti acne toner pore refresher
full and strong anti-dandruff conditioner
asd 3-in-1
dr. sheffield psoriasis medicated moisturizer
skin clearify mask
bioarpil
xtracare deep cleaning astringent
damage repair anti-dandruff conditioner
kingskin
elf acne fighting foundation caramel
scalp
glovers medicated anti-dandruff scalp
clenziderm pore therapyacne treatment
roothouse encore
mu lab yeco solu tion bp refresh ex
saliskin
stridexsensitive
clearskinblackhead eliminating cleanser
full and strong anti-dandruff shampoo
proactiv clarifying night
clean and clear advantage acne spot treatment
acne treatment maximum strength
stridexessential
no zit sherlock acnespot treatmentspot treatment
spot on acne patch
salicylic acid 3.0%
clear acne body
acne solutionsspot healing acne medication
acnezzol base
home health everclean antidandruff
clearasil ultra rapid actionscrub
skinceuticals silymarin cf acne treatment
wart remover with salicylic acid
stridex xl face and body pads
salisylic acid 1%
acne defense spot treatmentmerle norman
almay clear complexion blemish armor
salicylic acid spot treatment
oxytotal care vitamin c serum
hair green mugungjin tonic
dermad jock itch therapeutic
scholls wellness company llcclear away wart removers
clenziderm daily care foaming cleanseracne treatment
natural acne solutions clarifying toner
dr.different scaling toner for oily skin
neutrogena skinclearing mineral-nude
zenotri scalp essence
apple cider vinegar anti-dandruff conditioner
almay clear complexion blemish healing spot concealer
compound wmaximum strength fast acting liquid
asepxia liquid acne cleanser
peace out acne day dot
neutrogena rapid clear acne eliminating spot
scholls wellness company llcliquid corn and callus remover
so fresh so clean maximum acne treatment
stridex essential
neutrogenaskin clearing blemish concealer-medium 15
gold bond ultimate psoriasis relief cream
alumier md acne balancing serum
walgreenspink grapefruit
proactiv blackhead dissolving
get-gone-acne body cleanser
neoracomplexion clearing
elf caramel acne fighting foundation
clear skin days brightening peel pads
rite aid acne pads, daily cleansing pads
salvax
molluscum contagiosum treatment pen
apple cider vinegar itch relief anti-dandruff conditioner
bye-bye pimples
cvs psoriasis medicated
yes to tomatoes acne fighting scrub and cleanser
st. ives blemish and blackhead control
salisylic acid 17%
no zit sherlock acnecorrecting
cantu guava ginger anti dandruff
rush salicylc acid complexion pads
salicylic acid (usp)
wartrin wart remover
acne cleanserawaken by quality choice
neutrogena skinclearing mineral-natural ivory
yes to tomatoes daily pore scrub
scholls wellness company llcduragel corn remover
phisoderm
clearasilultra acne plus marks pads
medicated corn remover
first aid beauty fab pharma white clay acne treatment
epionce purifying wash
sannuo wart remover
clearasil ultrarapid action seal-to-clear
amino ex hair tonic500ml
walgreens foaming acne scrubpink grapefruit
family dollaroil free acne wash
walgreens dandruff itchy dry scalp defense plus vitamins and botanicals
cytokine 8
aspire scrub so clean
avene cleanance acne medicated clearing gel cleanser
charcoal acne scrub
clear days ahead
purity made simple
clear proof blemish control toner
acne clarifying cream
acne control body wash
neutrogena body clear body scrub
tiege hanley daily moisturizing acne
supersmooth acne clear 5 min mask
clear future deep pore cleanser
neutrogena t/sal therapeutic
vichy laboratoires normaderm daily gentle cleanser
zo skin health skin normalizing system with rozatrol booster serum
clean and clear essentials deep cleansing toner
complexion clear acne treatment
caribbean beauty-scalp treatment mask
specific beauty clarifying wash acne treatment cleanser
gm collin puracne
clearasil rapid rescue deep treatment scrub
aveeno clear complexion daily moisturizer
bareminerals blemish rescue skin-clearing loose foundationfairly light 1 nw
alumier md acne clarifying cleanser
hair-loss recovery shampooblock
meijer foaming cleanser
meijeroil free acne wash pink grapefruit foaming scrub
dual effects moisturizer
acne reparatif
acne clarifying cleanser
vitale sensitive scalp 12 in 1 instant relief anti dandruff spray
sinsinpas corn remover
celestyoil control series mattifying foam cleanser
cleansing wipes
acne wipes
anti-blemish concealer
sea breeze actives deep-clean astringent
clinical emergency zit stickacne treatment
365 anti dandruff shampoo
dry skin relief bar
acne face moisturizer
spotless cleanserbioelements
hyr facial and body acne
sea breeze actives clear-pore astringent
wart removers
up and upacne wash
neutrogena skinclearing mineral-classic ivory
extra thick callus removers
even and clear cleanser
clearasil ultra
multi-action clear-acne clearing treatment2% salicylic acid
so fresh so clean mild acne treatment
neutrogena
callus removers
caring mill one-step corn removers
actiogen acne dots treatment
oripan gold 80g
salicylic acid pimple patches
365 anti dandruff shampoo conditioner 2 in 1
stay pure acne treatment
maximum strength one step wart remover strips
acne solutionscleansing foam
pro clear foam
glycare acne
acne relief retinol treatment and moisturizer
clearing tonic
visco-gel medicated round callus removers
clarity clear skin essentialsfoaming cleanser
scalpcv68
la roche posay laboratoire dermatologique effaclar antiacne pore refining acne treatment
awaken by quality choice ultra clean daily face wash
one-step wart remover tan
pca skin intensive clarity treatment
scholls wellness company llcds extra thick callus remover
vibrant color with rose essence anti-dandruff conditioner
paulas choice
liquid wart corn remover
walgreens daily repair psoriasis moisturizer
angryhead premium hair tonic
killa extra strength 2 pack
sebum clearing masque
vichy laboratoires normaderm phytoaction acne control daily moisturizer
puriface hydrogel cleansing foam
clearskin pore penetratingblack mineral mask
glytone acne clearing toner
ultra thin corn removers
clarity clear skin essentialsacne treatment
nelly devuyst cleansing bioacne
bha cleanser2%
noxzema
ac out spot stop serum
cetaphil gentle clear triple-action acne serum
clearskin professionalacne mark treatment
salicylacne-2% clearing serum
celestyacne series deep cleansing gel
oxy cleansing padsdaily defense
clearasilultra blackhead scrub
skin renewing cream
well at walgreens pink grapefruit
acne scrub
mediplast
skin clearify cleanser
m skin care blemish patches
active clear facial wash
biore
salicylic acid acne patches
peach and lily peaches slices acne clarifying cleanser
deep pore charcoal acne scrub
quita callos corn and callus remover
dg deep cleaning astringent sensitive skin
pharma clear moisturizer
cvs acne spot treatment
purifying clay mask
acne clear body cleanser
clearing skin wash
pharmaskincare acnecare toner
multi vitamin acne clearing
all acne treatment
acetylsalicylic acid impurity c (ep impurity)
pimple potion retinal plus salicylic acid acne treatment
wart remover pads
liquid callus remover
cliniqueclarifying makeup
st. ives blemish and blackhead facial
zernel scalp rejuver essence
la roche posay effaclar medicated cleanser
clear reflection complexion
treat so deep acne-fighting treatment
acne treatment daytime
salicylic acid 2%
bareminerals blemish remedy acne clearing treatment serum
apple cider vinegar itch relief anti-dandruff shampoo
eradikate mattifying acne
clearskin professionalclear pore thermal mask
3-1 acne treatment pads
acne control clarifying cleanser
oxy volcanic ash detox scrub
anti acne calming corrector
2% salicylic acid suitable for oily or acne-prone skin
acne-pimple medication
lmnoop psoriasis treatment cream
medicated apricot scrub
psoriasintherapeutic shampoo and body wash
botanic heal boh acne sensitive fo am cleanser
clear and cover acne treatment concealer clear and cover acne treatment concealer01 ivory
resurfacing acne swipes
clearasil gentle prevention daily clean pads
clear smart clear pore hydrator
acne solutions liquid makeup
skinpharmacy advanced acne therapy pore refining facial mask
vichy laboratoires normaderm acne control moisturizer
activ o2 acne treatment cleansing bar
neutrogena body clear body wash
oxyadvanced care maximum strength 3-in-1 acne pads
frisco care advanced ear cleanser
acne treatment pads
walgreens apricot scrub acne treatment
grahams natural psoriasis and dermatitis
dr. c. tuna acne blemish control serum
nu skin clear action acne medication night treatment
renardblanc acne cleansing bar
wartstick plantar
salicyllic acid
clearasil ultra rapid actiondaily face wash
psoriapalm non-greasy psoriasis
mark.break out plan
neora
clearskin blemish clearingovernight treatment
neutrogena scalp therapy anti-dandruff daily control
dr young ac control u line clearing mist
cvs scalp relief
klearactil
acne warrior body scrub
verruguin
clear days aheadovernight repair salicylic acid acne treatment pads
well at walgreenspink grapefruit
pore release 2 salicylic acid acne treatment
cerave developed with dermatologists psoriasis cleanser
uforic wart remover
sebobalance purifying sebo-absorbing mask
acne defense spot treatment
selsun blue naturals itchy, dry scalp
nas max strength spot treatment
oripan gold 100g
salicylic serum1 percent
noxzemaantiblemish daily scrub
fyenacel calming shooter cellandir hair loss-shampoo
elf zit zapper
medicated wart remover
salicylic face and body wash
clearasil ultradaily face wash
atopalm acne controlling
shaant hydrating body scrub
clearasil gentle prevention daily clean wash
acne cream
avalon organics antidandruff conditioner
clearasil ultraacne plus marks daily scrub
arca regeneration head spa
yes to tomatoes acne clearing facial toner
clearasilultra 5 in 1 exfoliating wash
defense acne care 2% salicylic acid
clearasil stubborn acne control 5in1 one minute mask
kenkoderm psoriasis
clearskin blackhead eliminatingdaily astringent
curl moisture anti-dandruff shampoo
caring mill acne control body wash
yes to tomatoes detoxifying spot treatment
clear days aheadoil-free salicylic acid acne treatment and moisturizer
yes to tomatoes acne fighting spot treatment
clean and clear acne triple clear exfoliating scrub
biorecharcoal acne clearing cleanser
mother dirt dailywith salicylic acid
elf porcelain acne fighting foundation
vanibiss butt and thighs acne treatment cream
dial acne control deep cleansing face wash
neutrogenaskin clearing blemish concealer-deep 20
verrustat wart remover
differin acne clearing body scrub
dr. joe lab acne control clarifying cleanserdr joe lab
some by mi aha bha pha 30 days miracle serum light
mg217 psoriasis
antibacterial medicated toner-2% salicylic acid
quitacallos
one step wart removers
dermatouch acnecare cleanser
cornstick
soothion acne treatment formula
smart release mandelic8 percent
oxy volcanic ash acne face wash
mizon acence blemish out pink spot
acne defense foaming cleansermerle norman
spot check
psoriasis relief cream
pharma clear acne treatment
cover and conceal blemish concealer
jumiso no pain no gain ac cure spot
acne care charcoal cleanser
dr throwers oily skin facial cleanser
preparing tonic
hydrogel clear wart remover
salicylic acid wart remover
acne defense face wash
clear smart clarifying cleansing foam
personal care sensitive skin deep cleaning astringent
first aid beauty anti-dandruff scalp serum
aveeno positively radiant clear complexion daily moisturizer
acne advanced clarifying masque
repiel smart foot peeling perfect care
glytone acne self-foaming cleanser
dhc salicylic acne wash
raf five-wash away salicylic acid gel cleanser
acne control clarifying body spry
acne lab foam cleanser
compound w for kids one step strips
universal glow daily defense spf 40
bioelementsactive astringent
acne and line correcting serum
verucide physician formula
amazon basics acne blackhead clearing scrub
clearprep fx
salicylic acide
trulyclear
age defying blemish treatment
acne topical treatment
carahen scalp revitalizing serum mist
acne wash facial cleanser pink grapefruit
wart remover set
clearasilultra rapid action scrub
natural peeling triactive acne
clear and cover acne treatment concealer clear and cover acne treatment concealer12 cocoa
dr. pelo scalp-shampoo
asepxia bb liquid acne treatment
triderma psoriasis control
apple cider vinegar anti-dandruff pre-wash
clearasil stubborn acne control 5in1 exfoliating wash
neutrogena skinclearing mineral-soft beige
all clear face wash acne control
psoriasis cream
tula skincare breakout breakthrough acne clarifying toner pads refill
toner
yourgoodskinrapid rescue treatment
one-step wart remover clear
acne relief maximum strength spot gel
oxytotal care creamy facial cleanser
the inkey list salicylic acid cleanser
acne control acne body wash
l bri pure n natural deep clean toner
wart remover gel pen
plantar wart removers
equate anti dandruff
dermaer psoriasis therapeutic
panoxyl clarifying exfoliant
id clarifying body
corn and callus remover liquid
home health psoriasis medicated scalp and body wash
exfoliating cleanser
damoae therapy tonic
acne tonerbiolements
glytone acne clearing cleanser
dermad atopic dermatitis therapeutic
healthy skin cleanser
equate beauty quick action pads salicylic acid acne treatment
keralyt3 percent
salicylic acid 6 percent
tonicacne clearing treatment
the better skin co.zit no more
acne drying
ala-septic
clearasil ultra rapid actionface scrub
bareminerals blemish rescue skin-clearing loose foundationneutral tan 4n
cvs clarifying body wash
acne control body hand and face bar
kiehls since 1851 blue herbal acne cleanser treatment
cure-aid corn plasters
extra thick callus remover
salicylic aclid
salicylic acid gel
deep cleansing foaming acne scrub
acne treatment daily cleansing bar
equate acne treatment body pads
extra thick callus removers with salicylic acid
clear up prep
spot stopper acne spot treatment
bareminerals blemish rescue skin-clearing loose foundationgolden nude 3.5nw
daytime moisturizer
leahue madhuca
walgreens foaming acne scrub
tula acne clearing and tone correcting gel
meijer clarifying body wash
okay facial serum
serious skincare continuously clear acne medication for problematic skin dry lo pro all-over treatment
skinlycious glow exfoliant
m skin care microneedle blemish patches
belei oilfree facial cleansing wipes
proactiv plus complexion perfecting hydrator
biorewitch hazel pore clarifying toner
pacifica bacne warrior
scalp hydrate anti-dandruff shampoo
skin restoring acne serum
phisoderm clear confidence daily gel face wash
gly-sal 2-2 pads
salicylic acid (ep impurity)
blemish control basics kit
nusaderm medicated
spa cology skin clearing body wash salicylic acid acne treatment pink grapefruit
acne fighting putty primer
curl moisture anti-dandruff conditioner
well at walgreens spot acne treatment
neutrogena rapid clear 2 in 1 fight and fade toner
la prairie switzerlandcellular blemish control
one step corn remover
iaso intensive clear booster
rapid action daily face washdaylogic
nusaderm
every man jack charcoal face scrub
oxygenetix oxygenating foundationacne control
clean and clear dual action moisturizer
bareminerals blemish rescue skin-clearing loose foundationwarm deep 5.5n
replenix acne solutions gly-sal 2-2 foaming cleanser
foaming acne scrub
pharmacys prescription 8 oz acne control
yes to tomatoes two-step nose
breakout clearing all over toner
clearasil ultraacne plus marks spot
daily face washcvs
celestyacne series clarifying treatment pads
body acne treatment
kleer-plex advanced acne care system
yes to tomatoes daily repair treatment
vibrant color anti-dandruff conditioner
deep pore acne scrub
medicated callus removers extra thick
okay nourishing peppermint scrub and mask
advanced acne therapy
sa acne spot treatment
differin acne clearing body wash
kroger dual effects moisturizer
medicated plantar wart remover
breakout clearing foaming wash
itch no more
2%salicylic acid
revive acne reparatif acnetreatment gel
personal caredeep cleaning astringent
nas targeted spot treatment
prep everyday clear acne
mark. blemish banisheranti-acne body treatment pads
carahen hair-loss recovery
no7 laboratories acne treatment
aha/bha swipes
clear future mattifying treatment
asepxia softening acne bar
micro exfoliating cleanser
all clear exfoliating face wash
nu skin clear actionacne medication foaming cleanser
scalp hydrate anti-dandruff conditioner
yourgoodskinblackhead clearing scrub
breakout clearing booster
bioseb
clarity clear skin essentialsacne spot treatment
nu skinclear action acne medication day treatment
vmv hypoallergenics id skin-buffing cleansing scrub
naturopathica colloidal silver and salicylic acid acne clearing cleanser
perfect me serum
compound w total care wart and skin kit
acne patches with salicylic acid
eradikate clarifying acnecleanser
yes to tomatoes acne fighting mist
salicylic acid (ep monograph)
clear future intensive spot treatment
mark. help wantedanti-acne exfoliating cleanser
clear skin days clarifying serum
dr. pelo scalp tonic sheet
pca gel
i dew care clean zit away acne foaming cleanser
simply vital acne face cream
clear and cover acne treatment concealer clear and cover acne treatment concealer7 olive
equate cleansing pads
clearasil ultraon-the-go rapid action wipes
clear blemish treatmentjafra
clear proof clarifying cleansing gelacne medication
dermarestpsoriasis medicated
deep relief acne (blemish) treatment
gly-sal 10-2 pads
clearskinblackhead eliminating deep treatment mask
dr joe lab clarifying toner
cover fx mattifying primer plus acne treatment
salicylic acid 2.0%
bareminerals blemish rescue skin-clearing loose foundationgolden beige 2.5nw
walgreens foaming body wash acne treatment
hairitage power punch anti-dandruff pre-wash booster
leahue madhuca tonic
balancing act
evening moisturizer
axe acne control 2% salicylic acid
bansbao skin brightening and spots-removing
acne and blemish target
advanced acne spot treatmentcvs
acne blu salicylic acid pads
foaming cleanser
acne spot treatment2% bha
witch hazel pore clarifying toner
thayers blemish clearing balm
look at me invisible acne
proactiv clean acne clearing hydrator
clearasil ultra rapid actionface wash
bosye benefiting hair lotion
image skincare clear cell clarifying acne spot treatment
cvs healthacne fighting moisturizer
apple cider vinegar anti-dandruff shampoo
biorepore unclogging scrub
liquid wart remover mask
salicylic acid cotton sheet
aveda outer peace acne relief pads
almay clear complexion makeup
inixial perfection purity salicylic acid 0.5% acne treatment
up and updeep clean toner
exfo tonic acne treatment
clarisonic pore and blemish cleanser acne treatment
clear-n-smooth anti-blemish
blemish correcting serumsensitive
natures cure body acne treatment
premier solutions liquid corn and callus remover
patchology breakout box 3-in-1 acne treatment
terrasil wart removalmax
pediquick onestep wart removers
dr. joe lab acne control clarifying cleanser
wartrolwart remover
oripan gold
salicylic acid swab
blackhead clearing scrug
ageloc lumispa treatment cleanser acne
clear and cover acne treatment concealer clear and cover acne treatment concealer4 sand
peace out acne day and night duo
mg217 psoriasis therapeutic conditioner
clarifast one step acne treatment
peach and lily peaches slices acne exfoliating toner
acne solutions clearing concealeracne medication all skin types
almay clear complexion pressed powder
acneclir
clarifying toner
every man jack face wash
salicylic acid (1%)
butt and thighs
cvs pharmacyclear skin daily moisturizer
phace bioactive clarifying serum
walgreens all purpose psoriasis wash
super spot remover acne treatment
medibac clearing complex
clear proof clarifying cleansing gel
acne treatment gel
clearskinclear emergency intensive cream cleanser
bhs beautiful hair and scalp
sugar rush no bullzit acne spot treatment
clear skin
family wellnessliquid wart remover
bareminerals blemish rescue skin-clearing loose foundationmedium dark 5cn
vichy laboratoires normaderm bha exfoliating serum acne treatment
gold mountain beauty drying
men plus care advanced acne clear face plus body cleanser
skinceuticals blemish plus age defense acne treatment
obeo hair
oily sk balancing i
clear acne spot treatment
mediceuticals x-dermadry scalp and hair treatment
elf clear blemish control face primer
blackhead solutions self-heating blackhead extractor acne medication
evenly plus psoriasis care
yes to booty-ful paper mask-detoxified plus acne-free
acne solutionscleansing bar for face and body
biosebmousse
nelly devuyst mask bioacne
dermaclear serum
it cosmetics bye bye breakout concentrated derma serum acne treatment
dermad antifungal therapeutic
dr. karrs acne-statin
dermad psoriasis therapeutic
stridexnaturally clear
biorecharcoal acne scrub
smart release mandelic11 percent
differin acne clearing body
gel callus remover
solutions acne control spot treatment
blackhead scrub
higher education rush clear complexion wipes with 2% salicylic acid
proactiv plus retexturizing toner
skinceuticals silymarin cf acne treatment antioxidant
hairsanity step 2
salicylic acid 2% gel
acne cleansing
shiseido ibuki multi
some by mi charcoal bha pore clay bubble mask
bodewell psoriasis soothing
pureskin liquid wart corn removal mask
celladix acne control gel cleanser
as i amdry and itchy scalp care treatment
acne spot treatmentwalgreens
witch hazel moisture anti-dandruff conditioner
ambi even and clear exfoliating wash acne treatment
zapne
st. ivesblemish and blackhead control apricot scrub
gmc medical acne
acne warrior body wash
prickly pear and salicylic acid acne clearing tonic
cvs fast clearing medicated pads
bioremens charcoal acne scrub
pure nerium acne therapy
clearasil stubborn acne control 5in1 weekly scrub
nas purifying cleanser
nu skin clear action
one-step corn remover clear
clearasildaily clear hydra-blast pads
gel corn remover
blackhead clearing scrub
oxy volcanic clay acne wash
salicylic acid cream
salicylic acid serum
neutrogena skinclearing mineral powder-honey 85
nelly devuyst salicylic acid complex bioacne
maybelline dream pure bb beauty balm
yes to tomatoes acne control gel cleanser
skin pharmacy advanced acne therapy overnight salicylic acid
atrix system 1
txl active wart remover pads
clear cell cleanser
smooth frizz anti-dandruff conditioner
classic care apricot scrubblemish control
dermaclear mask
terrasil psoriasis therapymaximum strength
rayasal
blemish serum
vichy laboratoires normaderm acne control daily moisturizer
acne toner
renewalanti-dandruff
acne control superclean body washaha bha formula
ishancare psoriasis relief cream
kroger clarify care acne wash
clarifying liquid peel
verrustat medicated plantar pads
garnier clean blackhead eliminating scrub
oxydetox care invisible healing treatment patches
dr deep acpa cleansing foam
back-up plan acne-control body mist
age bright spot fader
kerastase paris k symbiose serum nuit antipelliculaire intensif antidandruff treatment
thera wise natural acne
anti acne exfoliating cleansing pads
some by mi aha bha pha real cica 92% cool calming soothing gel
elf conceler pencil and brush
acne care moisturizer
cvs clarifying body washacne treatment
advanced acne spot treatment
salico
cerave developed with dermatologists psoriasis moisturizing
clearskinblemish clearing spot treatment
corn and callus liquid remover
tula skincare keep it clear acne foam cleanser
soothion psoriasis and seborrheic dermatitis formula
good neighbor pharmacy scalp relief
pharmaskincare acnecare exfoliator
acnefree dermatology inspired care blackhead removing scrub acne treatment
riversol comprehensive acne treatment
narasoo hair tonic
blemish control bar
pharma clear spot treatment
better braids medicated un-braidmedicated
get-back-targeted body acne
clear days aheadfast-acting salicylic acid acne spot treatment
clearskin pore penetratingcooling toner
yourgoodskincalming cleanser
ultra cc radiant foundation broad spectrum spf 17 warm-medium
neovabreakout control
glycylic
clear cell medicated acne masque
unblemish regimen for acne, blemishes and breakouts
bareminerals blemish rescue skin-clearing loose foundationfair ivory 1n
proactiv acne body bar
dr.zium all clear spot
vichy laboratoires normaderm phytoaction daily deep cleansing
cocokind probiotic acne serum
dermoneen
aftaseptic
take control calmingcleanser
proactiv deep cleansing wash
skin clearify spot treatment
killa acne extra strength 2 pack
meijer clarifying body washacne treatment
clearsynergy
skinlycious clear skin essentials starter kit
one-step wart remover
compound w one step plantar foot pads
first aid beauty fab pharma bha acne spot treatment
ped x callus removers, extra thick medicated
clearasilultra rapid action daily wash
zitalon wart removal treatment liquid
clearskinblackhead eliminating daily astringent
clean and clear blackhead eraser scrub
canafarma spot on acne treatment cleanser
egg micro needle soothing
clean and clear advantage acne control moisturizer
triderma psoriasis control face and body cream
af foam sensitive acne pore cleanser
shiseido waso koshirice acne calming treatment
clearasil daily clear
skinpharmacy advanced acne therapy overnight salicylic acid
salicylic wash
wart remover gel
glytone acne back and chest treatment
acne fighting foundation caramel
mesalazine impurity h (ep impurity)
medicated gel cleanser-2% salicylic acid
salicylic acid reagent

Research Excerpts

Overview

Salicylic acid (SA) is an important plant hormone with a critical role in plant defense against pathogen infection. It is a non-steroid anti-inflammatory drug (NSAID) which exerts its activity by inhibiting the enzyme cyclooxygenase (COX). Salicylic Acid is a plant hormone almost exclusively associated with the promotion of immunity.

ExcerptReferenceRelevance
"Salicylic acid is a phenolic phytohormone which controls plant growth and development. "( Fatal attraction of Caenorhabditis elegans to predatory fungi through 6-methyl-salicylic acid.
Brenner-Weiß, G; Bunzel, M; Fischer, R; Hu, X; Keller, J; Kirschhöfer, F; Pop, M; Wernet, N; Yu, X, 2021
)
2.29
"Salicylic acid (SA) is an important plant hormone with a critical role in plant defense against pathogen infection. "( Biosynthesis and Roles of Salicylic Acid in Balancing Stress Response and Growth in Plants.
Chen, Z; Fan, B; Hu, H; Zhong, Q; Zhu, C, 2021
)
2.36
"Salicylic acid (SA) is a natural phenolic compound in plants with many beneficial effects for humans. "( The anxiolytic effect of salicylic acid is mediated via the GABAergic system in the fear potentiated plus maze behavior in rats.
Abbasnejad, M; Esmaeli-Mahani, S; Moghaddam Dizaj Herik, H; Motaghi, S; Sepehri, G, 2022
)
2.47
"Salicylic acid (SA) is a non-steroid anti-inflammatory drug (NSAID) which exerts its activity by inhibiting the enzyme cyclooxygenase (COX)."( Toxicity of two drugs towards the marine filter feeder Mytilus spp, using biochemical and shell integrity parameters.
Campos, JC; Costa, PC; Daniel, D; Nunes, B, 2022
)
1.44
"Salicylic acid (SA) is a plant hormone almost exclusively associated with the promotion of immunity. "( A ménage à trois: salicylic acid, growth inhibition, and immunity.
Hodges, M; Kravets, V; Pokotylo, I; Ruelland, E, 2022
)
2.5
"Salicylic acid is an important pharmaceutic and widely used in plant hormones and personal care products. "( Removal of salicylic acid by electrochemical processes using stainless steel and platinum anodes.
Gökkuş, Ö; Köktaş, İY, 2022
)
2.55
"Salicylic acid (SA) acts as a signaling molecule to perceive and defend against pathogen infections. "( Barley stripe mosaic virus γb protein targets thioredoxin h-type 1 to dampen salicylic acid-mediated defenses.
Cao, Q; Han, C; Jiang, Z; Jin, X; Li, D; Li, Z; Pi, Q; Wang, XB; Yang, M; Yu, J; Zhang, Y, 2022
)
2.39
"Salicylic acid (SA) is a crucial hormone involved in plant immunity. "( Disruption of the primary salicylic acid hydroxylases in rice enhances broad-spectrum resistance against pathogens.
Gao, S; Huang, P; Wang, J; Wang, M; Yao, L; Yu, N; Yu, Q; Zhang, K; Zhang, Y; Zhao, J; Zhao, L, 2022
)
2.46
"Salicylic acid (SA) is a key plant hormone essential for establishing plant resistance to several pathogens and its further affected a special form of induced resistance, the systemic acquired resistance (SAR), which considered as an important aspect of plant innate immunity from the locally induced disease resistance to the whole plant. "( Silica nanoparticles protect rice against biotic and abiotic stresses.
Ding, X; Du, J; Ji, Y; Li, P; Li, Y; Li, Z; Lin, H; Liu, B; Lu, C; Xu, X; Yin, Z; Zhao, H; Zhao, T, 2022
)
2.16
"Salicylic acid (SA) is a key phytohormone regulating plant immunity. "( The Kelch-F-box protein SMALL AND GLOSSY LEAVES 1 (SAGL1) negatively influences salicylic acid biosynthesis in Arabidopsis thaliana by promoting the turn-over of transcription factor SYSTEMIC ACQUIRED RESISTANCE DEFICIENT 1 (SARD1).
Chang, Y; Chen, G; Jiang, K; Mur, LAJ; Ouyang, Y; Roberts, JA; Wang, L; Wang, P; Wang, S; Wang, W; Wang, X; Yang, W; Yu, K; Zhang, J; Zhang, P; Zhang, X; Zhao, B, 2022
)
2.39
"Salicylic acid (SA) is a pivotal hormone required for the development of resistance to many pathogens in plants. "( Key residues for maintaining architecture, assembly of plant hormone SA receptor NPR1.
Ji, C; Li, X; Liu, P; Su, C; Wang, Y; Yan, H; Yang, W, 2022
)
2.16
"Salicylic acid is a key compound in nonsteroidal anti-inflammatory drugs that has been recently used for preventing the risk of hospitalization and death among COVID-19 patients and in preventing colorectal cancer (CRC) by suppressing two key proteins. "( Development and Validation of an HPLC-UV Method for the Quantification of 4'-Hydroxydiclofenac Using Salicylic Acid: Future Applications for Measurement of In Vitro Drug-Drug Interaction in Rat Liver Microsomes.
Barker, J; Salhab, H, 2022
)
2.38
"Salicylic acid (SA) is a phytohormone essential for plant immunity; however, the role of SA in sorghum resistance to anthracnose has not been well explored."( Transcriptome analysis provides insights into the bases of salicylic acid-induced resistance to anthracnose in sorghum.
Li, A; Liu, L; Ma, G; Sun, X; Zhao, S, 2022
)
1.69
"Salicylic acid (SA) is a phenolic phytohormone with critical roles in plant growth regulation and resistance to biotic and abiotic stress. "( Poly(allylamine)-copper(II) coordination complex grafted on core@shell upconversion nanoparticles for ultrafast and sensitive determination of the phytohormone salicylic acid in plant extracts.
Carreño-Vega, O; Ramírez-García, G; Salas, P; Vargas-Zamarripa, M, 2022
)
2.36
"Salicylic acid (SA) is a ubiquitous phenolic phytohormone that induces stomatal closure. "( Negative regulation of salicylic acid-induced stomatal closure by glutathione in Arabidopsis thaliana.
Akter, F; Munemasa, S; Murata, Y; Nakamura, T; Nakamura, Y, 2022
)
2.47
"Salicylic acid (SA) is a phytohormone which works to regulate the abiotic stress response of plants. "( Transcriptomic and alternative splicing analyses provide insights into the roles of exogenous salicylic acid ameliorating waxy maize seedling growth under heat stress.
Guo, J; Hu, Y; Lu, D; Qu, L; Wang, Z, 2022
)
2.38
"Salicylic acid (SA) is a stress hormone synthesized in phenylalanine ammonia-lyase (PAL) and the branching acid pathway. "( Rice β-Glucosidase 4 (Os1βGlu4) Regulates the Hull Pigmentation via Accumulation of Salicylic Acid.
Ali, A; Chen, X; Fang, Y; Liao, Y; Liu, S; Liu, Y; Qiang, R; Shoaib, F; Sun, C; Tian, Y; Wang, J; Wu, T; Wu, X; Xia, D; Xu, P; Xu, Z; Zhang, H; Zhou, H, 2022
)
2.39
"Salicylic acid (SA) is a well-known phytohormone essential for basal immunity and systemic acquired resistance."( Progress in Salicylic Acid-Dependent Signaling for Growth-Defense Trade-Off.
Chan, C, 2022
)
1.82
"Salicylic acid (SA) is a natural inducer of disease resistance in fruit, but its application in the food industry is limited due to low water solubility. "( Control Efficacy of Salicylic Acid Microcapsules against Postharvest Blue Mold in Apple Fruit.
Bian, W; Chen, J; He, S; Song, X; Wang, Y; Yang, X; Ye, L, 2022
)
2.49
"Salicylic acid (SA) is a major plant hormone that mediates the defence pathway against pathogens. "( SlS5H silencing reveals specific pathogen-triggered salicylic acid metabolism in tomato.
Bellés, JM; Campos, L; Hernández, M; Lisón, P; López-Gresa, MP; Miguel, SM; Minguillón, S; Payá, C; Rodrigo, I, 2022
)
2.41
"Salicylic acid (SA) is an essential molecule in biotic and abiotic defense response signal transduction pathways."( Role of Salicylic Acid in Combating Heat Stress in Plants: Insights into Modulation of Vital Processes.
Almalki, WH; Jatav, HS; Parray, JA; Poczai, P; Punia, H; Sangwan, S; Sayyed, RZ; Shameem, N; Sharma, S; Tanwar, H; Yashveer, S, 2022
)
1.88
"Salicylic acid is an NSAID with serious side effects on the GIS. "( Synthesis of New Ester Derivatives of Salicylic Acid and Evaluation of Their COX Inhibitory Potential.
Anıl, B; Bayır, Y; Ercan, Z; Koca, M; Nişancı, B; Özakar, E, 2023
)
2.62
"Salicylic acid (SA) is a phenolic compound produced by all plants that has an important role in diverse processes of plant growth and stress responses. "( Shared and Related Molecular Targets and Actions of Salicylic Acid in Plants and Humans.
Chen, Z; Ding, Y; Fan, B; Zhu, C, 2023
)
2.6
"Salicylic acid (SA) is an important plant hormone and signal required for establishing resistance to diverse pathogens and plant diseases. "( Transcriptional Analysis of Tea Plants (
Gao, L; Li, C; Li, K; Liu, B; Liu, N; Qu, F; Wang, P; Wang, Y; Xia, T; Zhang, X; Zhao, L, 2023
)
2.35
"Salicylic acid (SA) is a key phytohormone regulating plant defenses and stress responses."( Endogenous salicylic acid suppresses de novo root regeneration from leaf explants.
Chen, YS; Ferreira Dias, NC; Hu, L; Ison, M; Mozaffari, K; Ortega, MA; Peper, A; Severns, PM; Teixeira, PJPL; Tran, S; Tsai, CJ; Xu, D; Yang, L; Yao, Y, 2023
)
2.02
"Salicylic acid is a phytohormone that regulates flowering and promotes stress resilience in plants."( Salicylic Acid Treatment and Its Effect on Seed Yield and Seed Molecular Composition of
Abramov, D; Berka, M; Berková, V; Brzobohatý, B; Černý, M; Čičmanec, P; Frejlichová, L; Jan, N; Kameniarová, M; Kopecká, R; Kuzmenko, M; Shejbalová, Š, 2023
)
3.07
"Salicylic acid (SA) is a secondary metabolite."( Salicylic acid promotes terpenoid synthesis in the fungi Sanghuangporus baumii.
Sun, J; Sun, T; Wang, S; Wang, X; Zou, L, 2023
)
3.07
"Salicylic acid (SA) is a central plant hormone mediating immunity, growth, and development. "( Molecular regulation of the salicylic acid hormone pathway in plants under changing environmental conditions.
Castroverde, CDM; Kim, JH; Marchetta, EJR; Rossi, CAM, 2023
)
2.65
"Salicylic acid (SA) is an essential plant hormone that plays critical roles in basal defence and amplification of local immune responses and establishes resistance against various pathogens. "( CRISPR/Cas9-mediated simultaneous mutation of three salicylic acid 5-hydroxylase (OsS5H) genes confers broad-spectrum disease resistance in rice.
Chen, G; Deng, H; Huang, Z; Liu, J; Liu, X; Lu, X; Tang, W; Wang, F; Wang, Y; Xiao, Y; Yao, W; Yin, Z; Yu, Y; Zhang, G; Zhou, JQ, 2023
)
2.6
"Salicylic acid (SA) is a key hormone that regulates plant growth and immunity, and understanding the physiologic processes induced by SA enables the development of highly pathogen-resistant crops. "( Rhodamine-based fluorescent sensors for the rapid and selective off-on detection of salicylic acid and their use in plant cell imaging.
Chen, JY; Ge, MH; Huang, HY; Liu, LW; Liu, ST; Ma, WJ; Niu, W; Tan, S; Tang, AL; Yang, P; Yang, S; Zhou, X, 2023
)
2.58
"Salicylic acid (SA) is an important phytohormone that can mitigate effects against various abiotic stresses in plants, however, its exploration to improve Zn stress tolerance in alfalfa plants is still elusive."( Salicylic acid alleviates Zn-induced inhibition of growth via enhancing antioxidant system and glutathione metabolism in alfalfa.
Duan, X; Guan, C; Li, Q; Yang, Z; Zhao, Y; Zhu, J, 2023
)
3.07
"Salicylic acid (SA) serves as a pivotal plant hormone involved in regulating plant defense mechanisms against biotic stresses, but the extent of its biological significance in relation to peanut resistance is currently lacking. "( Overexpression of the First Peanut-Susceptible Gene,
Ahsan, T; Bai, Y; Liang, B; Liang, C; Lin, Y; Liu, X; Pei, X; Xie, J; Zang, C, 2023
)
2.35
"Salicylic acid (SA) is a phenolic compound capable of enhancing plant growth and development."( LcSABP2, a salicylic acid binding protein 2 gene from Lycium chinense, confers resistance to triclosan stress in Nicotiana tabacum.
Guan, C; Ji, J; Jin, C; Li, Q; Tong, Y; Wang, C; Wang, G, 2019
)
1.63
"Salicylic acid (SA) is an important signaling molecule which confers tolerance to metal toxicities but little is known about the mechanisms of SA-mediated alleviation of Hg stress."( Physiological and molecular mechanisms underlying salicylic acid-mitigated mercury toxicity in lemon balm (Melissa officinalis L.).
Akramian, M; Khadivi, A; Safari, F; Salehi-Arjmand, H, 2019
)
1.49
"Salicylic acid (SA) is a phytohormone that plays important roles in many aspects of plant life, notably in plant defenses against pathogens. "( Salicylic Acid Binding Proteins (SABPs): The Hidden Forefront of Salicylic Acid Signalling.
Kravets, V; Pokotylo, I; Ruelland, E, 2019
)
3.4
"Salicylic acid (SA) is an important signaling hormone in plant immunity. "( Barley isochorismate synthase mutant is phylloquinone-deficient, but has normal basal salicylic acid level.
Glauser, G; Pedersen, C; Qin, Y; Rasmussen, SK; Thordal-Christensen, H; Torp, AM, 2019
)
2.18
"Salicylic acid peel is a cheap and useful option in the treatment of dermatophytic infection."( Efficacy of salicylic acid peel in dermatophytosis.
Madke, B; Saoji, V,
)
1.95
"Salicylic acid (SA) is a significant signaling molecule that induces rice resistance against pathogen invasion. "( Comparative phosphoproteomic analysis of blast resistant and susceptible rice cultivars in response to salicylic acid.
Li, H; Li, Y; Nie, Y; Qin, S; Sun, R; Wang, Z; Zhang, T, 2019
)
2.17
"Salicylic acid (SA) is an endogenous plant signal molecule involved in regulating various plant responses to stress."( Modulation of growth performance and coordinated induction of ascorbate-glutathione and methylglyoxal detoxification systems by salicylic acid mitigates salt toxicity in choysum (Brassica parachinensis L.).
Gu, W; Kamran, M; Lu, Y; Shi, C; Sun, J; Wang, D; Xie, K; Xu, P, 2020
)
1.48
"Salicylic acid (SA) is an important phytohormone mediating both local and systemic defense responses in plants. "( PBS3 and EPS1 Complete Salicylic Acid Biosynthesis from Isochorismate in Arabidopsis.
Bobokalonova, A; Carballo, V; Glinkerman, CM; Pluskal, T; Shen, A; Torrens-Spence, MP; Weng, JK, 2019
)
2.27
"Salicylic acid is an emerging environmental contaminant, usually found at ng/L concentrations in natural waters. "( Exploitation of a short monolithic column for in-line separation and preconcentration: Environmental friendly determination of the emerging pollutant salicylic acid in natural waters.
Rocha, FRP; Sasaki, MK; Souza, PAF, 2020
)
2.2
"Salicylic acid (SA) is a major defense signal in plants, and the perception mechanism as well as downstream signaling activating the immune response are known."( Salicylic Acid Targets Protein Phosphatase 2A to Attenuate Growth in Plants.
Abas, M; Friml, J; Glanc, M; Hajný, J; Lasák, P; Molnár, G; Novák, O; Petrášek, J; Petřík, I; Pospíšil, J; Russinova, E; Tan, S; Verstraeten, I, 2020
)
2.72
"Salicylic acid (SA) is a very simple phenolic compound (a C"( The Role of Salicylic Acid in Plants Exposed to Heavy Metals.
Araniti, F; Bali, AS; Brestic, M; Landi, M; Shahzad, B; Sharma, A; Sidhu, GPS; Skalicky, M; Tripathi, DK, 2020
)
2.38
"Salicylic acid (SA) is a key natural component that mediates local and systemic resistance to pathogens in many dicotyledonous species. "( OsNPR3.3-dependent salicylic acid signaling is involved in recessive gene xa5-mediated immunity to rice bacterial blight.
Jia, Y; Jiang, G; Li, C; Liu, P; Liu, Z; Shi, Y; Wang, Y; Wu, X; Yin, D; Yu, M; Zhai, W; Zhou, Z; Zhu, L, 2020
)
2.33
"Salicylic acid (SA) is an important signaling molecule of the plant immune system. "( Redox-active cysteines in TGACG-BINDING FACTOR 1 (TGA1) do not play a role in salicylic acid or pathogen-induced expression of TGA1-regulated target genes in Arabidopsis thaliana.
Budimir, J; Gatz, C; Nair, A; Thurow, C; Treffon, K, 2021
)
2.29
"Salicylic acid (SA) is a plant hormone essential for effective resistance to viral and non-viral pathogens. "( An update on salicylic acid biosynthesis, its induction and potential exploitation by plant viruses.
Carr, JP; Murphy, AM; Zhou, T, 2020
)
2.37
"Salicylic acid (SA) is a crucial signal molecule and phytohormone, regulating the biotic and abiotic stress responses as well as plant development. "( Exogenous salicylic acid mitigates the accumulation of some pesticides in cucumber seedlings under different cultivation methods.
Gao, Y; Liu, S; Liu, T; Luo, J; Yang, S; Yuan, C; Zhang, R; Zou, N, 2020
)
2.4
"Salicylic acid (SA) is a hormone that mediates systemic acquired resistance in plants. "( Direct Binding of Salicylic Acid to
Burdman, S; Carmi, N; Charkowski, AO; Joshi, JR; Khadka, N; Khazanov, N; Senderowitz, H; Yedidia, I, 2020
)
2.33
"Salicylic acid (SA) is a key plant hormone required for establishing resistance to many pathogens. "( Stories of Salicylic Acid: A Plant Defense Hormone.
Ding, P; Ding, Y, 2020
)
2.39
"Salicylic acid (SA) is a pharmaceutical drug that may exert toxic effects by its own; however, simultaneous exposure of plants to SA and to other substances, often results in the significant changes in the patterns of toxic response/resistance to these other sources of chemical stress. "( Can salicylic acid modulate biochemical, physiological and population alterations in a macrophyte species under chemical stress by diclofenac?
Alkimin, GD; Barata, C; Nunes, B; Soares, AMVM, 2020
)
2.56
"Salicylic acid (SA) acts as a signaling molecule, plays pivotal roles in the overall growth and development of plants under various environmental stresses."( Salicylic acid restrains arsenic induced oxidative burst in two varieties of Artemisia annua L. by modulating antioxidant defence system and artemisinin production.
Aftab, T; Jahan, A; Khan, MMA; Nabi, A; Naeem, M; Sadiq, Y, 2020
)
2.72
"Salicylic acid (SA) is an important signaling molecule involved in plant defense. "( Phospholipid Signaling Is a Component of the Salicylic Acid Response in Plant Cell Suspension Cultures.
Hernández-Sotomayor, SMT; Muñoz-Sánchez, A; Nic-Can, GI; Rodas-Junco, BA, 2020
)
2.26
"Salicylic acid (SA) is a plant hormone that is critical for resistance to pathogens"( Structural basis of salicylic acid perception by Arabidopsis NPR proteins.
Dong, X; Guttman, M; Hinds, TR; Li, H; Liu, L; Rusnac, DV; Shi, H; Wang, W; Withers, J; Yan, S; Zheng, N; Zwack, PJ, 2020
)
2.32
"Salicylic acid (SA) is a well-known priming agent that is widely used to protect plants against stressing agents, including heavy metals as Pb. "( OPDA and ABA accumulation in Pb-stressed Zygophyllum fabago can be primed by salicylic acid and coincides with organ-specific differences in accumulation of phenolics.
Alba, JM; Calderón, AA; Ferrer, MA; Kant, MR; López-Orenes, A, 2020
)
2.23
"Salicylic acid (SA) is a signaling molecule that can induce plant resistance to certain herbivores. "( Physiological responses of plants and mites to salicylic acid improve the efficacy of spirodiclofen for controlling Tetranychus urticae (Acari: Tetranychidae) on greenhouse tomatoes.
Allahyari, H; Homayoonzadeh, M; Michaud, JP; Moeini, P; Talebi, K; Torabi, E, 2020
)
2.26
"Salicylic acid (SA) is a signaling molecule that plays an important role in against Cd toxicity."( Salicylic acid application alleviates cadmium accumulation in brown rice by modulating its shoot to grain translocation in rice.
Bao, H; Chen, Z; Ding, Y; Huang, L; Tan, H; Wang, F; Zhang, Y; Zhu, C, 2021
)
2.79
"Salicylic acid (SA) is an important signal molecule, regulating oxidative stress response in plants. "( Exogenous salicylic acid alleviates the accumulation of pesticides and mitigates pesticide-induced oxidative stress in cucumber plants (Cucumis sativus L.).
An, Q; Li, H; Li, T; Liu, S; Liu, T; Pan, C; Yang, S; Zhang, L; Zou, N, 2021
)
2.47
"Salicylic acid (SA) is an interesting messenger in plant metabolism that modulates multiple pathways, including the antioxidant defence pathway, and stimulates anatomical structures essential to carbon dioxide fixation during the photosynthetic process. "( Exogenous salicylic acid alleviates the negative impacts on production components, biomass and gas exchange in tomato plants under water deficit improving redox status and anatomical responses.
Alsahli, AA; Barbosa, MAM; Lima, EJA; Lobato, AKDS; Silva, BRSD, 2021
)
2.47
"Salicylic acid (SA) is an essential plant defense hormone that promotes immunity against biotrophic and semibiotrophic pathogens. "( Salicylic Acid: Biosynthesis and Signaling.
Li, X; Peng, Y; Yang, J; Zhang, Y, 2021
)
3.51
"Salicylic acid (SA) is a plant hormone involved in a series of growth, development, and stress responses in plants. "( CoNPR1 and CoNPR3.1 are involved in SA- and MeSA- mediated growth of the pollen tube in Camellia oleifera.
Liu, Y; Lu, M; Tan, X; Yang, J; Zhou, J, 2021
)
2.06
"Salicylic acid (SA) is an important plant hormone regulating defense against biotrophic pathogens."( The glycosyltransferase UGT76B1 modulates N-hydroxy-pipecolic acid homeostasis and plant immunity.
Feussner, I; Feussner, K; Herrfurth, C; Huang, W; Mohnike, L; Rekhter, D; Tian, H; Zhang, Y, 2021
)
1.34
"Salicylic acid (SA) is a vital hormone for adaptive responses to biotic and abiotic stresses, which facilitates growth-immunity trade-offs in plants. "( Genetic architecture of the metabolic pathway of salicylic acid biosynthesis in Populus.
Du, Q; El-Kassaby, YA; Fang, Y; Lu, W; Quan, M; Si, J; Wang, D; Xiao, L; Zhang, D, 2021
)
2.32
"Salicylic acid (SA) is a plant hormone that plays a critical role in plant defense."( Application of exogenous salicylic acid reduces disease severity of Plasmodiophora brassicae in pakchoi (Brassica campestris ssp. chinensis Makino).
Gao, L; Li, X; Xi, D; Zhang, Z; Zhu, H; Zhu, Y, 2021
)
1.65
"Salicylic acid (SA) is an important regulator of genes involved in plant defense and pathogen-triggered systemic acquired resistance (SAR). "( Transcriptome analysis reveals key defense-related genes upon SA induction in Cocos nucifera L.
Narváez-Cab, M; Nic-Matos, G; Oropeza, C; Sáenz-Carbonell, L; Silverio-Gómez, C; Vega-Arreguín, J, 2022
)
2.16
"Salicylic acid (SA) acts as a signal molecule to induce resistance in plants against sap-sucking insects."( Salicylic Acid Induced Resistance in Drought-Stressed Pistachio Seedlings Influences Physiological Performance of Agonoscena pistaciae (Hemiptera: Aphalaridae).
Hosseininaveh, V; Maali-Amiri, R; Reyhani Haghighi, S; Stelinski, LL; Talebi, K, 2021
)
2.79
"Salicylic acid (SA) is a well-known plant growth regulator, which participates in many physiological processes of plants under normal and stressful conditions. "( Crosstalk of plant growth regulators protects photosynthetic performance from arsenic damage by modulating defense systems in rice.
AlAjmi, MF; Iqbal, N; Irfan, M; Jahan, B; Khan, MIR; Khan, NA; Rehman, MT; Sehar, Z, 2021
)
2.06
"Salicylic acid (SA) is an important endogenous signal molecule, which by regulating growth and physiological processes improves the plant ability to tolerate salt stress."( Modulation of salt-induced stress impact in Gladiolus grandiflorus L. by exogenous application of salicylic acid.
Ferdosi, MFH; Habib, S; Khan, KA; Shoaib, A, 2021
)
1.56
"Salicylic acid (SA) is an important plant hormone that regulates many aspects of plant growth and development, as well as resistance to (a)biotic stress. "( How does the multifaceted plant hormone salicylic acid combat disease in plants and are similar mechanisms utilized in humans?
Dempsey, DA; Klessig, DF, 2017
)
2.17
"Salicylic acid (SA) is an important plant growth regulator playing a role in the hypersensitive reaction (HR) and the induction of systemic acquired resistance. "( Prolonged dark period modulates the oxidative burst and enzymatic antioxidant systems in the leaves of salicylic acid-treated tomato.
Bela, K; Czékus, Z; Poór, P; Szalai, G; Takács, Z; Tari, I, 2017
)
2.11
"Salicylic acid (SA) is a signaling molecule utilized by plants in response to various stresses. "( Differences in salicylic acid glucose conjugations by UGT74F1 and UGT74F2 from Arabidopsis thaliana.
Choe, JY; Dean, JV; George Thompson, AM; Iancu, CV; Neet, KE, 2017
)
2.25
"Salicylic acid (SA) is a hormone connected with various cellular functions including the fight against invading pathogens. "( Salicylic acid seed priming instigates defense mechanism by inducing PR-Proteins in Solanum melongena L. upon infection with Verticillium dahliae Kleb.
Anup Chandra Pal, M; Mahesh, HM; Melvin, P; Murali, M; Sharada, MS, 2017
)
3.34
"Salicylic acid (SA) is a plant hormone involved in a number of physiological responses including both local and systemic resistance of plants to pathogens. "( Mechanistic differences in the uptake of salicylic acid glucose conjugates by vacuolar membrane-enriched vesicles isolated from Arabidopsis thaliana.
Behrens, C; Choe, JY; Dean, JV; Theccanat, T; Vaca, E, 2017
)
2.16
"Salicylic acid (SA) is a known SAR signal against a broad spectrum of pathogens in plants."( Benzoylsalicylic acid derivatives as defense activators in tobacco and Arabidopsis.
Gudipalli, P; Kamatham, S; Pallu, R; Pasupulati, AK; Singh, SS, 2017
)
1.63
"Salicylic acid is a signal molecule which activates plant defense against plant pathogens such as the soft rot enterobacterium Pectobacterium carotovorum subsp. "( Effect of Salicylic Acid on the Growth and Chemical Responses of Pectobacterium carotovorum subsp. carotovorum.
Ntushelo, K, 2017
)
2.3
"Salicylic acid (SA) is a major defense signal in plants. "( PROHIBITIN3 Forms Complexes with ISOCHORISMATE SYNTHASE1 to Regulate Stress-Induced Salicylic Acid Biosynthesis in Arabidopsis.
Fonseca, A; Gagesch, KR; Greenberg, JT; Herrera-Vásquez, A; Holuigue, L; Jelenska, J; Jiang, SC; Joyce, MB; Marr, SK; Seguel, A; Shakoor, N; Wildermuth, MC, 2018
)
2.15
"Salicylic acid (SA) is a plant defense hormone required for immunity. "( Opposite Roles of Salicylic Acid Receptors NPR1 and NPR3/NPR4 in Transcriptional Regulation of Plant Immunity.
Ao, K; Ding, Y; Li, X; Peng, Y; Sun, T; Zhang, Y, 2018
)
2.26
"Salicylic acid (SA) is a primary pseudoallergen in plant-based foodstuffs."( Which Fruits and Vegetables Should Be Excluded from a Low-Salicylate Diet? An Analysis of Salicylic Acid in Foodstuffs in Taiwan.
Chiang, HL; Ku, KL; Syue, PC; Venter, C; Wu, CH, 2018
)
1.42
"Salicylic acid (SA) is a critical plant hormone that regulates numerous aspects of plant growth and development as well as the activation of defenses against biotic and abiotic stress."( Systemic Acquired Resistance and Salicylic Acid: Past, Present, and Future.
Choi, HW; Dempsey, DA; Klessig, DF, 2018
)
1.48
"Salicylic acid (SA) is an essential hormone for development and induced defense against biotrophic pathogens in plants. "( An E. coli biosensor for screening of cDNA libraries for isochorismate pyruvate lyase-encoding cDNAs.
Linthorst, HJM; Memelink, J; Zhou, Y, 2018
)
1.92
"Salicylic acid (SA) is a vital phytohormone that is intimately involved in coordination of the complex plant defense response to pathogen attack. "( High-Throughput Screening of Chemical Compound Libraries for Modulators of Salicylic Acid Signaling by In Situ Monitoring of Glucuronidase-Based Reporter Gene Expression.
Halder, V; Kombrink, E, 2018
)
2.15
"Salicylic acid (SA) is a potent inducer of defense gene expression in plants, but how SA activates transcription has been controversial. "( The Positives and Negatives of NPR: A Unifying Model for Salicylic Acid Signaling in Plants.
Innes, R, 2018
)
2.17
"Salicylic acid (SA) is a key phytohormone that mediates a broad spectrum of resistance against a diverse range of viruses; however, the downstream pathway of SA governed antiviral immune response remains largely to be explored. "( Plant A20/AN1 protein serves as the important hub to mediate antiviral immunity.
Chang, HH; Chang, JC; Chang, L; Cheng, AP; Chiu, YS; Hsu, DW; Lu, HC; Tzean, Y; Wang, TT; Yeh, HH, 2018
)
1.92
"Salicylic acid (SA) acts as a major signaling molecule in plant immunity and systemic acquired resistance triggered by bacterial or viral pathogens."( Salicylic acid-induced transcriptional reprogramming by the HAC-NPR1-TGA histone acetyltransferase complex in Arabidopsis.
Choi, SM; Jin, H; Kang, MJ; Kwon, DJ; Noh, B; Noh, YS; Yun, SH, 2018
)
2.64
"Salicylic acid (SA) is a class of trace pollutants widely presented in the environment belonged to pharmaceuticals and personal care products. "( Preparation of particle electrodes from manganese slag and its degradation performance for salicylic acid in the three-dimensional electrode reactor (TDE).
Chen, H; Feng, Y; Li, X; Long, Y; Shi, Y; Suo, N; Yu, Y, 2019
)
2.18
"Salicylic acid (SA) is an important phytohormone that is involved in the regulation of plant defence, growth and development. "( AtNPR4 from Arabidopsis thaliana: expression, purification, crystallization and crystallographic analysis.
Jia, Z; Yang, Q; Zhang, M; Zheng, J, 2019
)
1.96
"Salicylic acid (SA) is a key defense hormone associated with wheat resistance against Fusarium head blight, which is a severe disease mainly caused by "( Functional Analysis of
Chen, Q; Deng, M; Gong, X; Guo, ZR; Jiang, QT; Jiang, YF; Kong, L; Lan, XJ; Liu, CH; Luo, CH; Ma, J; Qi, PF; Wang, JR; Wang, Y; Wei, YM; Wu, W; Xu, BJ; Zhang, YZ; Zheng, T; Zheng, YL, 2019
)
1.96
"Salicylic acid (SA) is a common drug, widely used in human medicine due to its analgesic, anti-inflammatory, and antipyretic properties, as well as its activity in terms of preventing platelet aggregation, among other clinical and cosmetic uses."( Acute ecotoxicological effects of salicylic acid on the Polychaeta species Hediste diversicolor: evidences of low to moderate pro-oxidative effects.
Nunes, B, 2019
)
1.51
"Salicylic acid (SA) is an effective elicitor to increase taxol production in Pestalotiopsis microspora. "( Salicylic acid as an effective elicitor for improved taxol production in endophytic fungus Pestalotiopsis microspora.
Chelliah, J; Johnpaul, M; Srinivasan, VPM; Subban, K; Subramani, R, 2019
)
3.4
"Salicylic acid (SA) is a plant hormone and immune signal involved in systemic acquired resistance (SAR)-mediated defense responses."( NPR1 and Redox Rhythmx: Connections, between Circadian Clock and Plant Immunity.
Hou, D; Huang, X; Ma, Y; Ma, Z; Ren, Z; Xu, Z; Zhang, J; Zhou, Y, 2019
)
1.24
"Salicylic acid (SA) is a hormone-like substance, able to enhance the efficiency of the antioxidant (AOX) system in plants and their tolerance to oxidative stress."( Salicylic acid alleviates glyphosate-induced oxidative stress in Hordeum vulgare L.
Fidalgo, F; Soares, C; Spormann, S, 2019
)
2.68
"Salicylic acid is a ubiquitous phytohormone at low levels in most plants, yet are concentrated defense compounds in Populus, likely acting as a selective filter for rhizosphere microbiomes."( Rhizosphere microbiomes diverge among Populus trichocarpa plant-host genotypes and chemotypes, but it depends on soil origin.
Cregger, MA; Engle, NL; Morris, R; Schadt, CW; Tschaplinski, TJ; Veach, AM; Yang, ZK; Yip, DZ, 2019
)
1.24
"Salicylic acid (SA) is a phytohormone regulating immune responses against pathogens. "( Development of a structure-switching aptamer-based nanosensor for salicylic acid detection.
Chen, C; Feng, S; Ji, C; Que, L; Wang, W; Zhou, M, 2019
)
2.19
"Salicylic acid (SA) is an important plant hormone that is traditionally associated with pathogen defense."( Salicylic acid interferes with clathrin-mediated endocytic protein trafficking.
Beck, M; Du, Y; Friml, J; Himschoot, E; Li, H; Robatzek, S; Tejos, R; Vanneste, S, 2013
)
2.55
"Salicylic acid (SA) acts as a signalling molecule in plant defence against biotrophic and hemibiotrophic phytopathogens. "( Salicylic acid: an old hormone up to new tricks.
Boatwright, JL; Pajerowska-Mukhtar, K, 2013
)
3.28
"Salicylic acid (SA) is a key plant defence hormone which plays an important role in local and systemic defence responses against biotrophic pathogens like the smut fungus Ustilago maydis. "( Degradation of the plant defence hormone salicylic acid by the biotrophic fungus Ustilago maydis.
Ajami-Rashidi, Z; Djamei, A; Doehlemann, G; Kahmann, R; Rabe, F, 2013
)
2.1
"Salicylic acid is a topical keratolytic agent used to reduce scaling and hyperkeratosis associated with psoriasis vulgaris. "( A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis.
Akamine, KL; Davis, SA; Edison, BL; Feldman, SR; Green, BA; Gustafson, CJ; Yentzer, BA, 2013
)
1.83
"Salicylic acid (SA) is a small phenolic molecule with hormonal properties, and is an essential component of the immune response. "( The Arabidopsis oligopeptidases TOP1 and TOP2 are salicylic acid targets that modulate SA-mediated signaling and the immune response.
Moreau, M; Noutsos, C; Popescu, G; Popescu, S; Tian, M; Westlake, T; Zampogna, G, 2013
)
2.09
"Salicylic acid is a classic nonsteroidal anti-inflammatory drug. "( Salicylic acid induces mitochondrial injury by inhibiting ferrochelatase heme biosynthesis activity.
Ando, H; Gupta, V; Handa, H; Ishii, R; Kaneko, Y; Liu, S; Nureki, O; Sakamoto, S; Tateno, S; Yamaguchi, Y; Yugami, M, 2013
)
3.28
"Salicylic acid (SA) is a prominent signaling molecule during biotic and abiotic stresses in plants biosynthesized via cinnamate and isochorismate pathways. "( Isolation and characterization of isochorismate synthase and cinnamate 4-hydroxylase during salinity stress, wounding, and salicylic acid treatment in Carthamus tinctorius.
Dehghan, S; Fischer, R; Kavousi, HR; Rahnamaeian, M; Sadeghi, M; Vilcinskas, A; Wenzel, U, 2013
)
2.04
"Salicylic acid (SA) is an important plant hormone that regulates responses to biotic and abiotic stresses."( In situ detection of salicylic acid binding sites in plant tissues.
Cao, YJ; Deng, DY; Hu, XG; Lin, BX; Liu, FF; Liu, JW; Wu, JZ; Yu, Y, 2015
)
1.46
"Salicylic acid (SA) is an elicitor to induce the biosynthesis of secondary metabolites in plant cells. "( Hydrogen peroxide is involved in salicylic acid-elicited rosmarinic acid production in Salvia miltiorrhiza cell cultures.
Dong, J; Guo, H; Hao, W; Hu, G; Yao, Y; Zhang, J, 2014
)
2.13
"Salicylic acid (SA) is an important plant hormone, and its exogenous application can induce tolerance to multiple environmental stresses in plants. "( Endogenous salicylic acid accumulation is required for chilling tolerance in cucumber (Cucumis sativus L.) seedlings.
Dong, CJ; Li, L; Liu, XY; Shang, QM; Zhang, ZG, 2014
)
2.23
"Salicylic acid is an important signalling molecule in plant-microbe defence and symbiosis. "( Characterisation of SalRAB a salicylic acid inducible positively regulated efflux system of Rhizobium leguminosarum bv viciae 3841.
Karunakaran, R; Poole, PS; Tett, AJ, 2014
)
2.14
"Salicylic acid (SA) acts as a potential non-enzymatic antioxidant and a plant growth regulator, which plays a major role in regulating various plant physiological mechanisms. "( Salicylic acid alters antioxidant and phenolics metabolism in Catharanthus roseus grown under salinity stress.
Mariam, A; Misra, N; Misra, R; Yusuf, K; Yusuf, L, 2014
)
3.29
"Salicylic acid (SA) is a key plant hormone that mediates host responses against microbial pathogens. "( Salicylic acid signaling in disease resistance.
Kumar, D, 2014
)
3.29
"Salicylic acid seems to be a negative regulator during later syncytium and female development."( Role of stress-related hormones in plant defence during early infection of the cyst nematode Heterodera schachtii in Arabidopsis.
Dobrev, P; Grundler, FM; Hofmann, J; Kammerhofer, N; Radakovic, Z; Regis, JM; Siddique, S; Vankova, R; Wieczorek, K, 2015
)
1.14
"Salicylic acid (SA) is a widely used active in anti-acne face wash products. "( Salicylic acid deposition from wash-off products: comparison of in vivo and porcine deposition models.
Davies, MA, 2015
)
3.3
"Salicylic acid (SA), is a plant hormone with multifunction that is involved in plant growth, development and the acquisition of stress tolerance. "( Synergistic effect of antioxidant system and osmolyte in hydrogen sulfide and salicylic acid crosstalk-induced heat tolerance in maize (Zea mays L.) seedlings.
Li, ZG, 2015
)
2.09
"Salicylic acid is an excellent keratolytic agent."( Trichloroacetic Acid Versus Salicylic Acid in the Treatment of Acne Vulgaris in Dark-Skinned Patients.
Abdel Meguid, AM; Elaziz Ahmed Attallah, DA; Omar, H, 2015
)
1.43
"Salicylic acid (SA) is a ubiquitous plant phenolic compound that has been used in many plant species to alleviate Cd toxicity by regulating plant growth, reducing Cd uptake and distribution in plants, protecting membrane integrity and stability, scavenging reactive oxygen species and enhancing antioxidant defense system, improving photosynthetic capacity."( Role of salicylic acid in resistance to cadmium stress in plants.
Ding, Y; Liu, Z; Wang, F; Ye, Y; Zhu, C, 2016
)
1.59
"Salicylic acid (SA) is an important signal molecule for modulating plant responses to stress."( Does Salicylic Acid (SA) Improve Tolerance to Salt Stress in Plants? A Study of SA Effects On Tomato Plant Growth, Water Dynamics, Photosynthesis, and Biochemical Parameters.
Ben Ahmed, H; Chalh, A; Gharbi, E; Lutts, S; Manaa, A; Mimouni, H; Vandoorne, B; Wasti, S, 2016
)
1.67
"Salicylic acid (SA) is a plant hormone, which influences several physiological processes, and is a critical modulator of multiple levels of immunity in plants. "( Newly Identified Targets of Aspirin and Its Primary Metabolite, Salicylic Acid.
Klessig, DF, 2016
)
2.12
"Salicylic acid (SA) serves as a critical signaling molecule in plant defense. "( Two Redundant Receptor-Like Cytoplasmic Kinases Function Downstream of Pattern Recognition Receptors to Regulate Activation of SA Biosynthesis.
Cheng, YT; Kong, Q; Li, M; Ma, J; Qu, N; Sun, T; Wu, D; Zhang, Q; Zhang, Y; Zhang, Z, 2016
)
1.88
"Salicylic acid (SA) is an important signalling molecule that is synthesized by plants and induces the expression of resistance genes. "( HC-Pro viral suppressor from tobacco vein banding mosaic virus interferes with DNA methylation and activates the salicylic acid pathway.
Jin, T; Liu, Y; Meng, D; Xu, Y; Yang, L; Zhou, X, 2016
)
2.09
"Salicylic acid (SA) is an important phytohormone that plays vital regulatory roles in plant growth, development, and stress responses. "( Quantitative Proteomic Profiling of Early and Late Responses to Salicylic Acid in Cucumber Leaves.
Cao, N; Dong, CJ; Li, L; Shang, QM, 2016
)
2.12
"Salicylic acid (SA) peel is a well-established peeling agent for acne."( Jessner's solution vs. 30% salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris.
Amrani, A; Dayal, S; Jain, VK; Sahu, P, 2017
)
1.47
"Salicylic acid acts as a signal to activate defense responses in plants, limiting the spread of the pathogen and preventing access to nutrients."( Global gene expression profiles suggest an important role for nutrient acquisition in early pathogenesis in a plant model of Pseudomonas aeruginosa infection.
Badri, D; Schweizer, HP; Stull, VJ; Trunck, LA; Vivanco, J; Weir, TL, 2008
)
1.07
"Salicylic acid (SA) is a primary factor responsible for exerting diverse immune responses in plants and is synthesized in response to attack by a wide range of pathogens. "( BAH1/NLA, a RING-type ubiquitin E3 ligase, regulates the accumulation of salicylic acid and immune responses to Pseudomonas syringae DC3000.
Iba, K; Yaeno, T, 2008
)
2.02
"Salicylic acid (SA) is an important regulator of plant resistance to biotrophic and hemi-biotrophic pathogens. "( An important role of a BAHD acyl transferase-like protein in plant innate immunity.
Chen, Z; Dudareva, N; Fan, B; Qualley, A; Zheng, Z, 2009
)
1.8
"Salicylic acid (SA) is a critical mediator of plant innate immunity. "( Temporal global expression data reveal known and novel salicylate-impacted processes and regulators mediating powdery mildew growth and reproduction on Arabidopsis.
Ausubel, FM; Burgess, DG; Chandran, D; Denoux, C; Dewdney, J; Hather, G; Speed, TP; Tai, YC; Wildermuth, MC, 2009
)
1.8
"Salicylic acid (SA) is a stress-induced hormone involved in the activation of defense genes. "( Early genomic responses to salicylic acid in Arabidopsis.
Alvarez, ME; Blanco, F; Cecchini, NM; Holuigue, L; Jordana, X; Salinas, P; Van Hummelen, P, 2009
)
2.09
"Salicylic acid (SA) is a keratolytic agent used in topical products with antimicrobial actions."( Preparation and evaluation of microemulsion systems containing salicylic acid.
Badawi, AA; El-Mancy, SM; Nour, SA; Sakran, WS, 2009
)
1.31
"Salicylic acid (SA) is an important signal molecule in plants. "( Biosynthesis of salicylic acid in plants.
Chen, Z; Fan, B; Huang, J; Lai, Z; Zheng, Z, 2009
)
2.14
"Salicylic acid is a widely used nonsteroidal anti-inflammatory drug (NSAID). "( Salicylic acid-induced hepatotoxicity triggered by oxidative stress.
Doi, H; Horie, T, 2010
)
3.25
"Salicylic acid (SA) is a biological substance that acts as a phytohormone and plays an important role in signal transduction in plants. "( Electrocatalytic oxidation of phytohormone salicylic acid at copper nanoparticles-modified gold electrode and its detection in oilseed rape infected with fungal pathogen Sclerotinia sclerotiorum.
Chen, H; Dong, XY; Huang, JY; Liu, SY; Wang, Z; Wei, F; Xu, Q; Yang, Q; Yu, JH; Zhao, YD, 2010
)
2.07
"Salicylic acid (SA) is an essential hormone for plant defence and development. "( Resistance and biomass in Arabidopsis: a new model for salicylic acid perception.
Canet, JV; Dobón, A; Ibáñez, F; Perales, L; Tornero, P, 2010
)
2.05
"Salicylic acid (SA) is a potential endogenous plant hormone that plays an important role in plant growth and development. "( Modulation of salt (NaCl)-induced effects on oil composition and fatty acid profile of sunflower (Helianthus annuus L.) by exogenous application of salicylic acid.
Ashraf, M; Noreen, S, 2010
)
2
"Salicylic acid (SA) is a defense hormone required for both local and systemic acquired resistance (SAR) in plants. "( Control of salicylic acid synthesis and systemic acquired resistance by two members of a plant-specific family of transcription factors.
Cheng, YT; Ding, P; Gao, M; He, J; Li, X; Li, Y; Wang, D; Xu, F; Xu, S; Zhang, Y; Zhu, Z, 2010
)
2.19
"Salicylic acid is a frequent pollutant in several industrial wastewaters. "( Wet oxidation of salicylic acid solutions.
Collado, S; Diaz, M; Garrido, L; Laca, A, 2010
)
2.14
"Salicylic acid is a nonsteroidal antiinflammatory drug, some of the pharmacological properties of which arise from its interaction with the lipid bilayer component of the plasma membrane."( Interaction of salicylate and a terpenoid plant extract with model membranes: reconciling experiments and simulations.
Khandelia, H; Mouritsen, OG; Witzke, S, 2010
)
1.08
"Salicylic acid (SA) is an important signal involved in the activation of plant defence responses against abiotic and biotic stress. "( Salicylic acid and its location in response to biotic and abiotic stress.
Abou-Mansour, E; Fragnière, C; L'Haridon, F; Métraux, JP; Serrano, M, 2011
)
3.25
"Salicylic acid (SA) is a phytohormone required for a full resistance against some pathogens in Arabidopsis, and NPR1 (Non-Expressor of Pathogenesis Related Genes 1) is the only gene with a strong effect on resistance induced by SA which has been described. "( Quantitative genetic analysis of salicylic acid perception in Arabidopsis.
Canet, JV; Dobón, A; Perales, L; Tornero, P, 2011
)
2.09
"Salicylic acid (SA) is a critical signal for activation of both local and systemic resistance responses. "( The higher expression levels of dehydroascorbate reductase and glutathione reductase in salicylic acid-deficient plants may contribute to their alleviated symptom infected with RNA viruses.
Lin, HH; Wang, SD; Xi, DH; Yuan, S; Zhu, F, 2011
)
2.03
"Salicylic acid (SA) is a naturally produced compound and has been implicated to play important roles in defense of plants against diverse biotic and abiotic stresses. "( Impact of salicylic acid on the antioxidant enzyme system and hydrogen peroxide production in Cucumis sativus under chilling stress.
Chen, JF; Jiang, B; Lou, LN; Lu, MH; Yang, M; Zhang, WP,
)
1.98
"Salicylic acid (SA) is a phenolic phytohormone with important roles in plant development, transpiration, endogenous signaling and defense against pathogens. "( Salicylic acid may indirectly influence the photosynthetic electron transport.
Hideg, E; Janda, K; Janda, T; Kovács, L; Szalai, G, 2012
)
3.26
"Salicylic acid (SA) is a plant immune signal produced after pathogen challenge to induce systemic acquired resistance. "( NPR3 and NPR4 are receptors for the immune signal salicylic acid in plants.
Dong, X; Fu, ZQ; Mohan, R; Oka, N; Ruble, J; Saleh, A; Spoel, SH; Tada, Y; Wang, W; Yan, S; Zheng, N, 2012
)
2.07
"Salicylic acid (SA) is an essential hormone in plant immunity, but its receptor has remained elusive for decades. "( The Arabidopsis NPR1 protein is a receptor for the plant defense hormone salicylic acid.
Boyle, P; Brindle, ID; Chu, JY; De Luca, V; Després, C; Wang, Y; Wu, Y; Zhang, D, 2012
)
2.05
"Salicylic acid (SA) is a small phenolic molecule that not only is the active ingredient in the multi-functional drug aspirin, but also serves as a plant hormone that affects diverse processes during growth, development, responses to abiotic stresses and disease resistance. "( The combined use of photoaffinity labeling and surface plasmon resonance-based technology identifies multiple salicylic acid-binding proteins.
Friso, G; Klessig, DF; Liu, PP; Tian, M; van Wijk, KJ; von Dahl, CC, 2012
)
2.03
"Salicylic acid is an important regulator of induced plant resistance to pathogens. "( Recent breakthroughs in the study of salicylic acid biosynthesis.
Métraux, JP, 2002
)
2.03
"Salicylic acid is a metabolite of various analgesics."( Investigation of capillary electrophoresis-laser induced fluorescence as a tool in the characterization of sewage effluent for fluorescent acids: determination of salicylic acid.
Brumley, WC; Farley, JW; Flaherty, S; Street, G; Wark, S, 2002
)
1.23
"Salicylic acid (SA) is an essential trigger of plant disease resistance."( Chemical inactivation of the cinnamate 4-hydroxylase allows for the accumulation of salicylic acid in elicited cells.
Alworth, WL; Nikov, GN; Schoch, GA; Werck-Reichhart, D, 2002
)
1.26
"Salicylic acid is a messenger molecule in the activation of defense responses in plants. "( Characterization of salicylic acid-induced genes in Chinese cabbage.
Cha, JS; Cho, TJ; Kim, HY; Min, HJ; Oh, KJ; Park, YS; Ryang, SH, 2003
)
2.09
"Salicylic acid (SA) is an important regulator of plant defense responses, and a variety of Arabidopsis mutants impaired in resistance against bacterial and fungal pathogens show defects in SA accumulation, perception, or signal transduction. "( Arabidopsis local resistance to Botrytis cinerea involves salicylic acid and camalexin and requires EDS4 and PAD2, but not SID2, EDS5 or PAD4.
Ausubel, FM; De Lorenzo, G; Ferrari, S; Plotnikova, JM, 2003
)
2.01
"Salicylic acid is an important signal molecule in plant defense. "( The salicylic acid loop in plant defense.
Shah, J, 2003
)
2.32
"Salicylic acid (SA) is a critical hormone for signaling innate immunity in plants. "( High-affinity salicylic acid-binding protein 2 is required for plant innate immunity and has salicylic acid-stimulated lipase activity.
Klessig, DF; Kumar, D, 2003
)
2.12
"Salicylic acid (SA) is a key signal for the activation of defense genes in response to stress. "( NPR1-independent activation of immediate early salicylic acid-responsive genes in Arabidopsis.
Blanco, F; Holuigue, L; Jordana, X; Letelier, I; Uquillas, C, 2004
)
2.02
"Salicylic acid is a kind of active metabolite of aspirin in vivo. "( [Study on relative bioavailability of aspirin in afenca tablet].
He, L; Jiang, X; Li, S; Lin, S; Yang, J; Zhou, J, 2003
)
1.76
"Salicylic acid peels are an effective and safe therapy for acne vulgaris in Asian patients."( Salicylic acid peels for the treatment of acne vulgaris in Asian patients.
Kim, IH; Lee, HS, 2003
)
3.2
"Salicylic acid (SA) is a key endogenous signal that mediates defense gene expression and disease resistance in many dicotyledonous species. "( Endogenous salicylic acid protects rice plants from oxidative damage caused by aging as well as biotic and abiotic stress.
Mei, C; Qi, M; Yang, Y, 2004
)
2.16
"Salicylic acid (SA) is an important signaling compound in plants and is involved in various defense responses. "( Quantification of free and total salicylic acid in plants by solid-phase extraction and isocratic high-performance anion-exchange chromatography.
Jonak, C; Petutschnig, E; Rozhon, W; Wrzaczek, M, 2005
)
2.05
"Salicylic acid (SA) is a phenolic metabolite produced by plants and is known to play an important role in several physiological processes, such as the induction of plant defense responses against pathogen attack. "( Down regulation of virulence factors of Pseudomonas aeruginosa by salicylic acid attenuates its virulence on Arabidopsis thaliana and Caenorhabditis elegans.
Bais, HP; Dayakar, BV; Najarro, EH; Prithiviraj, B; Schweizer, HP; Suresh, B; Vivanco, JM; Weir, T, 2005
)
2.01
"Salicylic acid is a well-tolerated and potential new treatment for cylindromatosis."( An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.
Bernards, R; Brummelkamp, TR; Dirac, AM; Mooi, WJ; Neering, H; Nijman, SM; Oosterkamp, HM, 2006
)
2.02
"Salicylic acid (SA) is a plant signalling molecule needed for the induction of defence responses upon attack by a variety of pathogens. "( Chromatin immunoprecipitation analysis of the tobacco PR-1a- and the truncated CaMV 35S promoter reveals differences in salicylic acid-dependent TGA factor binding and histone acetylation.
Butterbrodt, T; Gatz, C; Thurow, C, 2006
)
1.98
"Salicylic acid (SA) is a phytohormone best known for its role in plant defense. "( Arabidopsis isochorismate synthase functional in pathogen-induced salicylate biosynthesis exhibits properties consistent with a role in diverse stress responses.
Inada, N; Inoue, K; Marr, SK; Strawn, MA; Wildermuth, MC; Zubieta, C, 2007
)
1.78
"Salicylic acid (SA) is an important signaling molecule in local and systemic plant resistance. "( Efflux pump gene expression in Erwinia chrysanthemi is induced by exposure to phenolic acids.
Barabote, RD; Birch, PR; Hedley, PE; Liu, H; Malouf, J; Payton, P; Pritchard, L; Ravirala, RS; Reverchon, S; San Francisco, MJ; Tatum, O; Toth, IK; Wheeler, DM, 2007
)
1.78
"Salicylic acid (SA) is a plant signaling molecule that mediates the induction of defense responses upon attack by a variety of pathogens. "( SA-inducible Arabidopsis glutaredoxin interacts with TGA factors and suppresses JA-responsive PDF1.2 transcription.
Abdallat, AA; Fode, B; Gatz, C; Ndamukong, I; Thurow, C; Weigel, R; Zander, M, 2007
)
1.78
"Salicylic acid (SA) is a natural phenolic compound known as the active principle of aspirin. "( Circulating salicylic acid is related to fruit and vegetable consumption in healthy subjects.
Battezzati, A; Bertoli, S; Fiorillo, G; Spadafranca, A; Testolin, G, 2007
)
2.16
"Salicylic acid (SA) is a key signal molecule in regulating plant defense against pathogens."( The plant signal salicylic acid shuts down expression of the vir regulon and activates quormone-quenching genes in Agrobacterium.
Banta, LM; Binns, AN; Edlind, MP; Kerr, K; Liu, P; Nester, EW; Ronzone, E; Saenkham, P; Wise, AA; Yuan, ZC, 2007
)
1.4
"Salicylic acid (SA) is an important signal involved in the activation of defence responses against abiotic and biotic stress. "( Salicylic acid production in response to biotic and abiotic stress depends on isochorismate in Nicotiana benthamiana.
Abou-Mansour, E; Buchala, A; Catinot, J; Métraux, JP, 2008
)
3.23
"Salicylic acid (SA) is an important mediator of plant defense response. "( Characterization and biological function of the ISOCHORISMATE SYNTHASE2 gene of Arabidopsis.
Buchala, A; Catinot, J; Doermann, P; Garcion, C; Lamodière, E; Lohmann, A; Métraux, JP, 2008
)
1.79
"Salicylic acid (SA) acts as an endogenous signal for the induction of systemic acquired resistance (SAR) in plants infected by pathogens. "( Ortho-anisic acid as internal standard for the simultaneous quantitation of salicylic acid and its putative biosynthetic precursors in cucumber leaves.
Métraux, JP; Meuwly, P, 1993
)
1.96
"Salicylic acid (SA) is a key defense molecule in higher plants that is required for resistance to diverse pathogens. "( Positive and negative regulation of salicylic acid-dependent cell death and pathogen resistance in Arabidopsis lsd6 and ssi1 mutants.
Greenberg, JT, 2000
)
2.02
"Salicylic acid (SA) is a key endogenous component of local and systemic disease resistance in plants. "( Free and conjugated benzoic acid in tobacco plants and cell cultures. Induced accumulation upon elicitation of defense responses and role as salicylic acid precursors.
Atanassova, R; Chong, J; Fritig, B; Pierrel, MA; Saindrenan, P; Werck-Reichhart, D, 2001
)
1.95
"Salicylic acid (SA) is a key regulator for the induction of systemic acquired resistance (SAR), and NPR1 is a critical mediator for the biological effects of SA. "( Trans-dominant suppression of plant TGA factors reveals their negative and positive roles in plant defense responses.
Lam, E; Miao, ZH; Pontier, D, 2001
)
1.75
"Salicylic acid is a chemical signal in plants infected by pathogens and it is responsible for the anti-inflammatory action of aspirin. "( Salicylic acid in soups prepared from organically and non-organically grown vegetables.
Baxter, GJ; Graham, AB; Lawrence, JR; Paterson, JR; Wiles, D, 2001
)
3.2
"Salicylic acid (SA) is a signalling compound in plants which is able to induce systemic acquired resistance. "( Method for the extraction of the volatile compound salicylic acid from tobacco leaf material.
Bol, JF; Brouwer, N; Delbianco, F; Linthorst, HJ; Verberne, MC; Verpoorte, R,
)
1.83

Effects

Salicylic acid (SA) has a central role in activating plant resistance to pathogens. 5 to 10% has a pronounced keratolytic effect. Salicylic Acid transport has an important role in long-distance signalling.

Salicylic acid (SA) has been implicated in determining the outcome of interactions between many plants and their pathogens. It has been shown to ameliorate the adverse effects of environmental stress on plants. It is frequently used as a facial chemical peeling agent (FCPA) in various cosmetics for facial rejuvenation.

ExcerptReferenceRelevance
"Salicylic acid transport has an important role in long-distance signalling, but methyl salicylate has also been suggested as a phloem-based mobile signal, which can be demethylated to form salicylic acid, inducing the de-novo synthesis of salicylic acid in distal tissue."( The role of methyl salicylate in plant growth under stress conditions.
Gondor, OK; Janda, T; Pál, M; Szalai, G, 2022
)
1.44
"Salicylic acid (SA) has a long history of safe use as ingredient in topical cosmetic products. "( A kinetic-based safety assessment of consumer exposure to salicylic acid from cosmetic products demonstrates no evidence of a health risk from developmental toxicity.
Boisleve, F; Bury, D; Eichenbaum, G; Girard, S; Labib, R; Leal, M; Naciff, J; Wong, J, 2018
)
2.17
"Salicylic acid (SA) has a central role in activating plant resistance to pathogens. "( How does SA signaling link the Flg22 responses?
Kwon, SY; Yi, SY, 2014
)
1.85
"Salicylic acid (SA) has a central role in defense against pathogen attack. "( Phosphatidylinositol 4-kinase activation is an early response to salicylic acid in Arabidopsis suspension cells.
Burketová, L; Flemr, M; Krinke, O; Renou, JP; Ruelland, E; Taconnat, L; Valentová, O; Vergnolle, C; Zachowski, A, 2007
)
2.02
"Salicylic acid 5 to 10% has a pronounced keratolytic effect."( Psoriasis of the scalp. Diagnosis and management.
Franssen, ME; van de Kerkhof, PC, 2001
)
1.03
"Salicylic acid (SA) has observationally been shown to decrease colorectal cancer (CRC) risk. "( Salicylic Acid and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study.
Albanes, D; Alwers, E; Amitay, E; Baron, JA; Bermejo, JL; Berndt, SI; Bishop, DT; Brenner, H; Buchanan, DD; Butterworth, A; Campbell, PT; Casey, G; Castellví-Bel, S; Chan, AT; Chang-Claude, J; Drew, DA; Figueiredo, JC; Gallinger, S; Giles, GG; Gruber, SB; Gsur, A; Gunter, MJ; Hampel, H; Harrison, TA; Hoffmeister, M; Hopper, JL; Keku, TO; Kim, HR; Kweon, SS; Li, CI; Li, L; Lin, Y; Lindblom, A; Lindor, NM; Marchand, LL; Moreno, V; Newcomb, PA; Nounu, A; Peters, U; Pharoah, PDP; Platz, EA; Relton, CL; Rennert, G; Richmond, RC; Sakoda, LC; Schafmayer, C; Scherer, D; Schoen, RE; Slattery, ML; Stadler, ZK; Stewart, ID; Surendran, P; Ulrich, CM; van Dujinhoven, FJB; Van Guelpen, B; Vodicka, P; Vodickova, L; Wareham, NJ; Weinstein, SJ; White, E; Williams, AC; Wolk, A; Woods, MO; Wu, AH; Zheng, W, 2021
)
3.51
"Salicylic acid transport has an important role in long-distance signalling, but methyl salicylate has also been suggested as a phloem-based mobile signal, which can be demethylated to form salicylic acid, inducing the de-novo synthesis of salicylic acid in distal tissue."( The role of methyl salicylate in plant growth under stress conditions.
Gondor, OK; Janda, T; Pál, M; Szalai, G, 2022
)
1.44
"Salicylic acid has been used as an anti-acne agent with its comedolytic property and antimicrobial activity. "( Anti-acne activity of carnitine salicylate and magnolol through the regulation of exfoliation, lipogenesis, bacterial growth and inflammation.
Kim, MS; Kwon, KC; Park, SW; Shin, YW; Song, YS; Won, JG, 2023
)
2.35
"Salicylic acid (SA) has been reported to induce resistance in plants against many pathogens."( Pre-treatment of salicylic acid enhances resistance of soybean seedlings to Fusarium solani.
Bawa, G; Du, J; Du, Y; Feng, L; Liu, C; Shang, J; Sun, X; Wang, X; Yan, L; Yang, W; Yu, L, 2019
)
1.57
"Salicylic acid (SA) has long been known to be essential for basal defense and systemic acquired resistance (SAR). "( Biosynthesis and Regulation of Salicylic Acid and N-Hydroxypipecolic Acid in Plant Immunity.
Huang, W; Li, X; Wang, Y; Zhang, Y, 2020
)
2.29
"Salicylic acid (SA) has been reported to play a pivotal role in the regulation of plants biotic and abiotic stress response."( Exogenous salicylic acid ameliorates heat stress-induced damages and improves growth and photosynthetic efficiency in alfalfa (Medicago sativa L.).
Cao, L; Chen, L; Ji, K; Wassie, M; Zhang, Q; Zhang, W, 2020
)
1.68
"Salicylic acid (SAL) has recently been shown to induce biofilm formation in Staphylococcus aureus and to affect the expression of virulence factors. "( Salicylic acid stabilizes Staphylococcus aureus biofilm by impairing the agr quorum-sensing system.
Buzzola, F; Dotto, C; Ehling-Schulz, M; Grunert, T; Ledesma, M; Lombarte Serrat, A; Sordelli, DO; Vay, C, 2021
)
3.51
"Salicylic acid (SA) has a long history of safe use as ingredient in topical cosmetic products. "( A kinetic-based safety assessment of consumer exposure to salicylic acid from cosmetic products demonstrates no evidence of a health risk from developmental toxicity.
Boisleve, F; Bury, D; Eichenbaum, G; Girard, S; Labib, R; Leal, M; Naciff, J; Wong, J, 2018
)
2.17
"Salicylic acid has the great potential for reducing the toxicity of heavy metals without negatively impacting the growth of the plants."( Salicylic acid induces amelioration of chromium toxicity and affects antioxidant enzyme activity in Sorghum bicolor L.
Brar, B; Joshi, UN; Sihag, S, 2019
)
2.68
"Salicylic acid (SA) has emerged as a key plant defense hormone with critical roles in different aspects of plant immunity. "( Salicylic acid: biosynthesis, perception, and contributions to plant immunity.
Li, X; Zhang, Y, 2019
)
3.4
"Salicylic acid (SA) has for a long time been used to treat various skin disorders due to its anti-inflammatory, bacteriostatic, and antifungal properties. "( Exploring the Use of Amine Modified Mesoporous Magnesium Carbonate for the Delivery of Salicylic Acid in Topical Formulations: In Vitro Cytotoxicity and Drug Release Studies.
Cheung, O; Ferraz, N; Strømme, M; Vall, M; Zardán Gómez de la Torre, T, 2019
)
2.18
"Salicylic acid (SA) has been reported to ameliorate various stresses in plants. "( Salicylic acid restrains nickel toxicity, improves antioxidant defence system and enhances the production of anticancer alkaloids in Catharanthus roseus (L.).
Aftab, T; Idrees, M; Khan, MM; Naeem, M, 2013
)
3.28
"Salicylic acid (SA) has been implicated in determining the outcome of interactions between many plants and their pathogens. "( Changes in leaf proteome profile of Arabidopsis thaliana in response to salicylic acid.
Chattopadhyay, S; Datta, R; Sinha, R, 2013
)
2.06
"Salicylic acid (SA) has long been implicated in plant responses to oxidative stress. "( Constitutively elevated salicylic acid levels alter photosynthesis and oxidative state but not growth in transgenic populus.
Anino, EO; Babst, BA; Chen, HY; Frost, CJ; Guo, W; Harding, SA; Nyamdari, B; Tsai, CJ; Wilson, MC; Xue, LJ; Yuan, Y, 2013
)
2.14
"Salicylic acid (SA) has been used in pharmaceutical and cosmetic preparations for many years. "( Percutaneous absorption of salicylic acid--in vitro and in vivo studies.
Hadgraft, J; Lane, ME; Mateus, R; Moore, DJ, 2014
)
2.14
"Salicylic acid (SA) has been shown to ameliorate the adverse effects of environmental stress on plants."( Salicylic acid alleviates the adverse effects of salt stress in Torreya grandis cv. Merrillii seedlings by activating photosynthesis and enhancing antioxidant systems.
Du, X; Hu, Y; Li, T; Shen, C; Tang, H; Wu, J, 2014
)
2.57
"Salicylic acid (SA) has a central role in activating plant resistance to pathogens. "( How does SA signaling link the Flg22 responses?
Kwon, SY; Yi, SY, 2014
)
1.85
"Salicylic acid (SA) has been frequently used as a facial chemical peeling agent (FCPA) in various cosmetics for facial rejuvenation and dermatological treatments in the clinic. "( Synergistic efficacy of salicylic acid with a penetration enhancer on human skin monitored by OCT and diffuse reflectance spectroscopy.
Dai, C; Fan, S; Lv, J; Nie, L; Zhao, Q, 2016
)
2.18
"Salicylic acid has been proved to: (1) reduce bacterial adhesion up to 68.1 ± 5.6%; (2) affect biofilm structural development, reducing viable biomass by 97.0 ± 0.7% and extracellular proteins and polysaccharides by 83.9 ± 2.5% and 49.5 ± 5.5% respectively; and (3) promote biofilm detachment 3.4 ± 0.6-fold."( The response of Escherichia coli biofilm to salicylic acid.
Cappitelli, F; Cattò, C; Dell'Orto, S; Forlani, F; Gelain, A; Grazioso, G; Marzano, V; Villa, F; Villa, S; Vitali, A, 2017
)
1.44
"Salicylic acid (SA) has been characterized as an activator of pathogen-triggered resistance of plants. "( Genome-wide analyses of the transcriptomes of salicylic acid-deficient versus wild-type plants uncover Pathogen and Circadian Controlled 1 (PCC1) as a regulator of flowering time in Arabidopsis.
León, J; Martínez, C; Mir, R; Segarra, S, 2010
)
2.06
"Salicylic acid has the best evidence to support its effectiveness, but it is slow to work and requires frequent application for up to 12 weeks."( Treatment of nongenital cutaneous warts.
Mulhem, E; Pinelis, S, 2011
)
1.09
"Salicylic acid has strong comedolytic effects because of its lipophilic nature."( Salicylic acid peels versus Jessner's solution for acne vulgaris: a comparative study.
Bae, BG; Chung, KY; Lee, JH; Lee, KH; Lee, SH; Lee, SJ; Lee, YS; Park, CO; Shin, H, 2013
)
2.55
"Salicylic acid has been used widely in the treatment of dry skin conditions and also helps reduce acne symptoms. "( Preparation, optimization, characterization, and stability studies of salicylic acid liposomes.
Bhalerao, SS; Raje Harshal, A, 2003
)
2
"Salicylic acid peels have been introduced as a useful modality in acne treatment. "( Salicylic acid peels for the treatment of acne vulgaris in Asian patients.
Kim, IH; Lee, HS, 2003
)
3.2
"Salicylic acid (SA) has been proposed to antagonize jasmonic acid (JA) biosynthesis and signaling. "( The outcomes of concentration-specific interactions between salicylate and jasmonate signaling include synergy, antagonism, and oxidative stress leading to cell death.
Atzorn, R; Kenton, P; Miersch, O; Mur, LA; Wasternack, C, 2006
)
1.78
"Salicylic acid peel has effectiveness for both of acne and postinflammatory hyperpigmentation that are common in patients with skin of color."( Whitening effect of salicylic acid peels in Asian patients.
Ahn, HH; Kim, IH, 2006
)
1.38
"Salicylic acid has been reported to have anti-inflammatory properties."( Salicylic acid protects the skin from UV damage.
Gan, D; Goyarts, E; Maes, D; Mammone, T,
)
2.3
"Salicylic acid (SA) has a central role in defense against pathogen attack. "( Phosphatidylinositol 4-kinase activation is an early response to salicylic acid in Arabidopsis suspension cells.
Burketová, L; Flemr, M; Krinke, O; Renou, JP; Ruelland, E; Taconnat, L; Valentová, O; Vergnolle, C; Zachowski, A, 2007
)
2.02
"Salicylic acid (SA) has been proposed to play a role in the induction of pathogenesis-related (PR) proteins and systemic acquired resistance (SAR) in tobacco. "( Interconversion of the salicylic acid signal and its glucoside in tobacco.
Grynkiewicz, G; Hennig, J; Indulski, J; Klessig, DF; Malamy, J, 1993
)
2.04
"Salicylic acid 5 to 10% has a pronounced keratolytic effect."( Psoriasis of the scalp. Diagnosis and management.
Franssen, ME; van de Kerkhof, PC, 2001
)
1.03
"Salicylic acid has keratolytic properties and aids in the removal of scales."( A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis
Goode, K; Squire, RA, 2002
)
1.23
"Salicylic acid has been widely used in the topical treatment of psoriasis. "( Topical salicylic acid interferes with UVB therapy for psoriasis.
Kristensen, B; Kristensen, O, 1991
)
2.16
"Salicylic acid has been shown to decrease gastric mucosal lesions induced by indomethacin in the rat. "( Salicylic acid blocks indomethacin-induced cyclooxygenase inhibition and lesion formation in rat gastric mucosa.
Elashoff, J; Guth, PH; Hansen, D; Kauffman, GL; Ligumsky, M; Paulsen, G, 1985
)
3.15

Actions

Salicylic acid (SA) plays an important role in the active oxygen metabolism and the photosynthesis of the plant. It plays a central role in defense against pathogen attack, as well as in germination, flowering, senescence, and the acquisition of thermotolerance. Salicylic Acid did not produce significant changes in any of these biomarkers.

ExcerptReferenceRelevance
"Salicylic acid (SA) plays an important role for plant immunity, especially resistance against biotrophic pathogens. "( HISTONE DEACETYLASE 6 suppresses salicylic acid biosynthesis to repress autoimmunity.
Chen, J; He, L; Jin, Y; Shi, H; Wang, Y; Wu, Z; Yang, W, 2021
)
2.35
"Salicylic acid (SA) plays an important role in plant immune response, including resistance to pathogens and systemic acquired resistance. "( Brassinosteroids enhance salicylic acid-mediated immune responses by inhibiting BIN2 phosphorylation of clade I TGA transcription factors in Arabidopsis.
Kim, JM; Kim, SK; Kim, TW; Kim, YW; Roh, J; Youn, JH, 2022
)
2.47
"Salicylic acid (SA) plays a key role in plant resistance to pathogens. "( Hypersensitivity-Related Genes HSR201 and HSR203J Are Regulated by Calmodulin-Binding Protein 60-Type Transcription Factors and Required for Pathogen Signal-Induced Salicylic Acid Synthesis.
Katou, S; Komori, H; Takagi, K; Tasaki, K, 2022
)
2.36
"Salicylic acid (SA) plays a critical role in allergic reactions of plants to pathogens and acquired systemic resistance. "( Effects of Salicylic Acid Concentration and Post-Treatment Time on the Direct and Systemic Chemical Defense Responses in Maize (
Du, T; Feng, Y; Shu, Y; Tan, F; Wang, J; Wang, X, 2022
)
2.55
"Salicylic acid (SA) plays a pivotal role in plant response to biotic and abiotic stress. "( The origin and evolution of salicylic acid signaling and biosynthesis in plants.
Chen, Z; Jia, X; Wang, L; Xu, L; Yi, K; Zhang, Y; Zhao, H, 2023
)
2.65
"Salicylic acid (SA) plays important roles in different aspects of plant development, including root growth, where auxin is also a major player by means of its asymmetric distribution. "( Salicylic acid inhibits rice endocytic protein trafficking mediated by OsPIN3t and clathrin to affect root growth.
Cao, Y; Du, Y; Friml, J; Fu, Q; Han, L; He, X; Huang, H; Huang, W; Jiang, L; Li, K; Liu, C; Lu, X; Luo, C; Wu, L; Yang, J; Yao, B; Zhang, X; Zhang, Z; Zhao, J; Zhao, S; Zhao, Y; Zhou, X; Zhu, H; Zhu, R; Zhu, Z, 2023
)
3.8
"Salicylic acid (SA) plays a central role in plant responses to environmental stresses. "( Biochemical study of the effect of stress conditions on the mandelonitrile-associated salicylic acid biosynthesis in peach.
Bernal-Vicente, A; Diaz-Vivancos, P; Hernández, JA; Petri, C, 2020
)
2.22
"Salicylic acid (SA) plays important roles in the stress response of plants."( Salicylic acid application alleviates the adverse effects of triclosan stress in tobacco plants through the improvement of plant photosynthesis and enhancing antioxidant system.
Guan, C; Ji, J; Jin, C; Li, Q; Wang, C; Wang, G; Wu, H; Zhang, Y, 2020
)
2.72
"Salicylic acid (SA) plays an important role in the response of plants to abiotic stresses. "( Enhancement of endogenous SA accumulation improves poor-nutrition stress tolerance in transgenic tobacco plants overexpressing a SA-binding protein gene.
Guan, C; Ji, J; Jin, C; Li, Q; Li, X; Wang, G, 2020
)
2
"Salicylic acid (SA) plays crucial roles in plant development and mediates plant responses to biotic and abiotic stress."( Application of exogenous salicylic acid reduces Cd toxicity and Cd accumulation in rice.
Bao, H; Cai, C; Chen, Z; Ding, Y; Huang, L; Tan, H; Wang, F; Zhu, C, 2021
)
1.65
"Salicylic acid (SA) plays a crucial role in plant immunity. "( Salicylic acid promotes quiescent center cell division through ROS accumulation and down-regulation of PLT1, PLT2, and WOX5.
Chen, D; Liu, R; Rong, D; Wang, Z; Wu, S; Xiao, Y; Yamamuro, C, 2021
)
3.51
"Salicylic acid plays an important role in the plant immune response, and its degradation is therefore important for plant-pathogenic fungi. "( Discovery and Functional Analysis of a Salicylic Acid Hydroxylase from Aspergillus niger.
de Vries, RP; Dilokpimol, A; Hildén, KS; Lubbers, RJM; Mäkelä, MR; Visser, J, 2021
)
2.33
"Salicylic acid (SA) plays pivotal role in plant defense against biotrophic and hemibiotrophic pathogens. "( More stories to tell: NONEXPRESSOR OF PATHOGENESIS-RELATED GENES1, a salicylic acid receptor.
Chen, H; Chen, J; Freeman, A; Kong, M; Liu, F; Zhang, J, 2021
)
2.3
"Salicylic acid (SA) plays a crucial role in plant innate immunity. "( Modulation of Plant Salicylic Acid-Associated Immune Responses via Glycosylation of Dihydroxybenzoic Acids.
Chen, L; Hou, BK; Huang, XX; Li, YJ; Liu, Q; Zhu, GQ, 2018
)
2.25
"The salicylic acid (SA) plays a critical role during the establishment of systemic acquired resistance (SAR) in uninfected plant tissues after localised exposure to a pathogen. "( Salicylic acid in Populus tomentosa is a remote signalling molecule induced by Botryosphaeria dothidea infection.
Dong, HX; Li, YX; Liu, ZY; Ma, J; Zhang, W; Zhang, XY, 2018
)
2.48
"Salicylic acid (SA) plays a key role in the signal transduction pathways of various stress responses, demonstrating the protective effect of SA against abiotic stress factors."( Salicylic acid induces amelioration of chromium toxicity and affects antioxidant enzyme activity in Sorghum bicolor L.
Brar, B; Joshi, UN; Sihag, S, 2019
)
2.68
"Salicylic acid induced rapid increase in NADPH-oxidase activity in histochemical assay with nitroblue tetrazolium but the reaction was not observed in presence of 1-butanol and NADPH-oxidase inhibitor diphenylene iodide (DPI)."( Involvement of phospholipase D and NADPH-oxidase in salicylic acid signaling cascade.
Iakovenko, O; Kalachova, T; Kravets, V; Kretinin, S, 2013
)
1.36
"Salicylic acid (SA) plays a key role in plant resistance to pathogens. "( Transcriptome analysis of WIPK/SIPK-suppressed plants reveals induction by wounding of disease resistance-related genes prior to the accumulation of salicylic acid.
Asakura, N; Katou, S; Kojima, T; Mitsuhara, I; Seo, S, 2013
)
2.03
"Salicylic acid plays a critical role in activating plant defence responses after pathogen attack. "( Overexpression of a soybean salicylic acid methyltransferase gene confers resistance to soybean cyst nematode.
Arelli, PR; Chen, F; Lin, J; Liu, W; Mazarei, M; Pantalone, VR; Stewart, CN; Zhao, N; Zhu, JJ; Zhuang, X, 2013
)
2.13
"Salicylic acid plays a crucial role in plant tissues and has a suppression effect on some fungi."( Effects of salicylic acid on Aspergillus flavus infection and aflatoxin B₁ accumulation in pistachio (Pistacia vera L.) fruit.
Alizadeh-Salteh, S; Mohammadi, N; Panahirad, S; Safaie, N; Zaare-Nahandi, F, 2014
)
1.51
"Salicylic acid plays the role of a stabilizer, and gives a pathway to control the three-dimensional water matrix structure."( Thermodynamics of sodium dodecyl sulphate-salicylic acid based micellar systems and their potential use in fruits postharvest.
Briz-Cid, N; Cid, A; Mejuto, JC; Morales, J; Rial-Otero, R; Simal-Gándara, J, 2014
)
1.39
"Salicylic acid (SA) plays a central role in plant innate immunity. "( Perception of the plant immune signal salicylic acid.
Dong, X; Yan, S, 2014
)
2.12
"Salicylic acid (SA) plays a critical role in plant defense against pathogen invasion. "( Salicylic acid binding of mitochondrial alpha-ketoglutarate dehydrogenase E2 affects mitochondrial oxidative phosphorylation and electron transport chain components and plays a role in basal defense against tobacco mosaic virus in tomato.
Klessig, DF; Li, X; Liao, Y; Shi, K; Tian, M; Wang, Y; Xia, X; Yu, J; Zhang, H; Zhou, J; Zhou, Y, 2015
)
3.3
"Salicylic acid (SA) plays an important role in various aspects of plant development and responses to stresses. "( TCP transcription factors are critical for the coordinated regulation of isochorismate synthase 1 expression in Arabidopsis thaliana.
Dong, X; Gao, J; Kuai, B; Ren, G; Wang, X; Zhou, X; Zhu, Z, 2015
)
1.86
"Salicylic acid (SA) promotes plant defense responses against toxic metal stresses. "( Exogenous salicylic acid protects phospholipids against cadmium stress in flax (Linum usitatissimum L.).
Belkadhi, A; Chaïbi, W; De Haro, A; Djebali, W; Obregon, S, 2015
)
2.26
"Salicylic acid (SA) plays important roles in the induction of systemic acquired resistance (SAR) in plants. "( Development of Inhibitors of Salicylic Acid Signaling.
Asami, T; Jiang, K; Kurimoto, T; Miyazaki, S; Nakajima, M; Nakamura, H; Seo, EK, 2015
)
2.15
"Salicylic acid (SA) plays a significant role in plants responding to biotic and abiotic stresses, but the involved regulatory factors and their signaling mechanisms are largely unknown."( Transcriptome Sequencing in Response to Salicylic Acid in Salvia miltiorrhiza.
Dong, J; Liang, Z; Liu, H; Qi, Y; Wang, J; Zhang, X, 2016
)
1.42
"Salicylic acid (SA) plays many roles in plant physiology. "( Role of salicylic acid in plant abiotic stress.
Lin, HH; Yuan, S,
)
2.01
"Salicylic acid (SA) plays a central role in defense against pathogen attack, as well as in germination, flowering, senescence, and the acquisition of thermotolerance. "( Phospholipase D activation is an early component of the salicylic acid signaling pathway in Arabidopsis cell suspensions.
Burketová, L; Collin, S; Flemr, M; Krinke, O; Renou, JP; Ruelland, E; Taconnat, L; Valentová, O; Vergnolle, C; Yu, A; Zachowski, A, 2009
)
2.04
"Salicylic acid did not produce significant changes in any of these biomarkers."( The effects of topically applied glycolic acid and salicylic acid on ultraviolet radiation-induced erythema, DNA damage and sunburn cell formation in human skin.
Barton, C; Beer, JZ; Coelho, SG; Hearing, VJ; Kaidbey, K; Kornhauser, A; Miller, SA; Takahashi, K; Wei, RR; Yamaguchi, Y, 2009
)
1.33
"Salicylic acid plays an important role in the active oxygen metabolism and the photosynthesis of the plant. "( [Effects of exogenous salicylic acid on photosynthesis in Arabidopsis leaves based on fluorescence spectra and delayed fluorescence technique].
Chen, WL; Chen, ZQ; Yang, CW, 2009
)
2.11
"Salicylic acid (SA) plays multiple roles in regulating plant adaptive responses to biotic and environmental stresses."( Salicylic acid reduces napropamide toxicity by preventing its accumulation in rapeseed (Brassica napus L.).
Cui, J; Wu, GL; Yang, H; Zhang, R; Zhu, HM, 2010
)
2.52
"Salicylic acid (SA) plays a key role in plant defense response to biotic stress, but information is scarce concerning the application of SA to enhancing Xac resistance."( Exogenous treatment with salicylic acid attenuates occurrence of citrus canker in susceptible navel orange (Citrus sinensis Osbeck).
Liu, JH; Wang, Y, 2012
)
1.4
"Salicylic acid (SA) plays a key role in plant disease resistance and hypersensitive cell death but is also implicated in hardening responses to abiotic stressors. "( Salicylic acid alleviates the cadmium toxicity in barley seedlings.
Dietz, KJ; Finkemeier, I; Georgi, M; Metwally, A, 2003
)
3.2
"Salicylic acid (SA) plays a crucial role in stress resistance in plants by modifying the expression of a battery of genes. "( Identification of NPR1-dependent and independent genes early induced by salicylic acid treatment in Arabidopsis.
Blanco, F; Dominguez, C; Frey, N; Garretón, V; Holuigue, L; Jordana, X; Pérez-Acle, T; Van der Straeten, D, 2005
)
2
"Salicylic acid (SA) plays a central role in resistance and defense induction in response to pathogen attack, but its role in the activation of the hypersensitive response (HR), a form of programmed cell death associated with resistance of plants, remains to be elucidated. "( An essential role for salicylic acid in AtMYB30-mediated control of the hypersensitive cell death program in Arabidopsis.
Raffaele, S; Rivas, S; Roby, D, 2006
)
2.09
"Salicylic acid (SA) plays important roles in plants, most notably in the induction of systemic acquired resistance (SAR) against pathogens. "( Quantitative in situ assay of salicylic acid in tobacco leaves using a genetically modified biosensor strain of Acinetobacter sp. ADP1.
Carr, JP; Huang, L; Huang, WE; Li, Y; Naylor, M; Preston, GM; Singer, AC; Wang, H; Whiteley, AS, 2006
)
2.07
"Salicylic acid (SA) plays a central role in plant disease resistance, and emerging evidence indicates that auxin, an essential plant hormone in regulating plant growth and development, is involved in plant disease susceptibility. "( Dual regulation role of GH3.5 in salicylic acid and auxin signaling during Arabidopsis-Pseudomonas syringae interaction.
He, Z; Li, Q; Li, Z; Staswick, PE; Wang, M; Zhang, Z; Zhu, Y, 2007
)
2.06
"Salicylic acid (SA) plays a key role in the establishment of resistance to microbial pathogens in many plants. "( Salicylic acid is a modulator of tobacco and mammalian catalases.
Durner, J; Klessig, DF, 1996
)
3.18
"Salicylic acid (SA) plays an important signaling role in the resistance of many plants to pathogen invasion. "( Characterization of a salicylic acid-insensitive mutant (sai1) of Arabidopsis thaliana, identified in a selective screen utilizing the SA-inducible expression of the tms2 gene.
Klessig, DF; Shah, J; Tsui, F, 1997
)
2.05
"Salicylic acid (SA) can inhibit the facilitated transport of inorganic sulfate in the kidney, placenta, and erythrocytes. "( Salicylic acid induces changes in the physical properties of model and native kidney membranes.
Balasubramanian, SV; Morris, ME; Straubinger, RM, 1997
)
3.18
"Salicylic acid (SA) plays an important role in plant disease resistance. "( Purification, cloning, and expression of a pathogen inducible UDP-glucose:Salicylic acid glucosyltransferase from tobacco.
Lee, HI; Raskin, I, 1999
)
1.98
"Salicylic acid (SA) plays a critical signaling role in the activation of plant defense responses after pathogen attack. "( Nitric oxide and salicylic acid signaling in plant defense.
Durner, J; Kachroo, P; Klessig, DF; Kumar, D; Lam, E; Navarre, DA; Noad, R; Pontier, D; Shah, J; Silva, H; Trifa, Y; Wendehenne, D; Zhang, S; Zhou, JM, 2000
)
2.09
"Salicylic acid (SA) plays a key role in activating defenses and cell death during plant-pathogen interactions. "( A role for salicylic acid and NPR1 in regulating cell growth in Arabidopsis.
Greenberg, JT; Lu, H; Rate, DN; Vanacker, H, 2001
)
2.14
"Salicylic acid may produce its analgesic action mainly via a central mechanism."( Two modes of analgesic action of aspirin, and the site of analgesic action of salicylic acid.
Aihara, H; Higuchi, S; Otomo, S; Shioiri, Y; Tanaka, N, 1986
)
1.22

Treatment

Salicylic acid (SA) treatments can attenuate the negative effects of salt on growth. Treatment causes almost tenfold increase in UGT74W1 expression in roots, while leaves and stem showed decrease in expression.

ExcerptReferenceRelevance
"Salicylic acid treatment mediated production of defensive enzymes in plants, including superoxide dismutase (SOD), ascorbate peroxidase (APX), catalase (CAT), glutathione reductase (GR), guaiacol peroxidase (GPX) and polyphenol oxidase (PPO), as well as that of other metabolites such as phenol, malondialdehyde (MDA), H2O2, free amino acids, and pigments via phenylpropanoid pathways under conditions of drought."( Salicylic Acid Induced Resistance in Drought-Stressed Pistachio Seedlings Influences Physiological Performance of Agonoscena pistaciae (Hemiptera: Aphalaridae).
Hosseininaveh, V; Maali-Amiri, R; Reyhani Haghighi, S; Stelinski, LL; Talebi, K, 2021
)
2.79
"Salicylic acid (SA) treatments can attenuate the negative effects of salt on growth."( Preferentially enhancing anti-cancer isothiocyanates over glucosinolates in broccoli sprouts: How NaCl and salicylic acid affect their formation.
Babalar, M; Esfandiari, A; Hunter, DA; Matich, AJ; McKenzie, MJ; Saei, A, 2017
)
1.39
"Salicylic acid (SA)-treatment has been reported to improve plant tolerance to various abiotic stresses. "( Exogenous salicylic acid improves freezing tolerance of spinach (Spinacia oleracea L.) leaves.
Arora, R; Min, K; Shin, H, 2018
)
2.33
"Salicylic acid treatment at all concentrations considerably improved the anthocyanin content in the berries and, compared with untreated berries, the accumulation of malvidin-3-O-β glucoside was higher in SA-treated fruits."( Pre-véraison treatment of salicylic acid to enhance anthocyanin content of grape (Vitis vinifera L.) berries.
Gohari, G; Oraei, M; Panahirad, S; Zaare-Nahandi, F, 2019
)
1.54
"Salicylic acid treatment causes almost tenfold increase in UGT74W1 expression in roots, while leaves and stem showed decrease in expression."( Molecular cloning and characterization of genistein 4'-O-glucoside specific glycosyltransferase from Bacopa monniera.
Khan, BM; Santosh Kumar, RJ; Singh, S; Vishwakarma, RK, 2014
)
1.12
"The salicylic acid treatment revealed that StMKK6 is regulated by the hormone that is in agreement with the salicylic acid-regulated domains found in the StMKK6 promoter."( Involvement of potato (Solanum tuberosum L.) MKK6 in response to potato virus Y.
Baebler, S; Bedina-Zavec, A; Coll, A; Dobnik, D; Gruden, K; Lazar, A; Zel, J, 2014
)
0.88
"Salicylic acid (SA) treatment has been widely used to maintain fruit quality during postharvest storage. "( Biochemical and proteomic analysis of grape berries (Vitis labruscana) during cold storage upon postharvest salicylic acid treatment.
Cai, H; Li, H; Pan, J; Wang, Y; Wu, Z; Yuan, X, 2014
)
2.06
"Salicylic acid (SA) treatment selectively reduced the cytosine DNA methylation of stilbene synthase ( STS ) genes and stimulated resveratrol production in cell cultures of Vitis amurensis. "( Salicylic acid induces alterations in the methylation pattern of the VaSTS1, VaSTS2, and VaSTS10 genes in Vitis amurensis Rupr. cell cultures.
Karetin, YA; Kiselev, KV; Tyunin, AP, 2015
)
3.3
"Salicylic acid treatment significantly increased the levels of actein and deoxyactein in the rhizome of Black cohosh, suggesting that the synthesis of triterpene glycosides is controlled in part by salicylic acid."( Salicylic Acid Treatment Increases the Levels of Triterpene Glycosides in Black Cohosh (Actaea Racemosa) Rhizomes.
De Capite, A; Lancaster, T; Puthoff, D, 2016
)
2.6
"Salicylic acid treatment significantly reduced the clinical score of eyes and bacterial load in eyes during microbial keratitis but had no effect on numbers of infiltrating neutrophils."( Effect of Salicylic Acid on the Membrane Proteome and Virulence of Pseudomonas aeruginosa.
Bandara, M; Hume, E; Sankaridurg, P; Willcox, M; Zhu, H, 2016
)
1.56
"The salicylic acid-treated tomato plants challenged with Fol exhibited significantly reduced vascular browning and leaf yellowing wilting."( Salicylic acid-induced resistance to Fusarium oxysporum f. sp. lycopersici in tomato.
Mallick, N; Mandal, S; Mitra, A, 2009
)
2.28
"Salicylic acid treatment and wounding enhanced the expression further by the chimeric promoter."( Development of insect resistant transgenic cotton lines expressing cry1EC gene from an insect bite and wound inducible promoter.
Kumar, M; Shukla, AK; Singh, H; Tuli, R, 2009
)
1.07
"Salicylic acid pretreatment completely reversed the effects of PMA and TNFalpha on both Akt and IRS1."( Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor alpha (TNFalpha)-induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells.
Dallas-Yang, Q; Jiang, G; Liu, F; Moller, DE; Zhang, BB, 2003
)
2.48
"Salicylic acid treatment resulted in moderately increased expression of phenylalanine ammonia lyase (PAL), NPR1, PR1 and HSP70 genes that participate in resistance to pathogens in plants."( Salicylic acid-, but not cytokinin-induced, resistance to WClMV is associated with increased expression of SA-dependent resistance genes in Phaseolus vulgaris.
Gális, I; Jameson, PE; Smith, JL, 2004
)
2.49
"Salicylic acid (SA) treatment enhanced the phosphorylation of recombinant TGA2 in vitro; it also enhanced phosphorylation of a TGA2-GFP fusion protein in vivo."( Salicylic acid-inducible Arabidopsis CK2-like activity phosphorylates TGA2.
Kang, HG; Klessig, DF, 2005
)
2.49
"Salicylic acid (SA) treatment can induce expression of NHL25 and NHL3."( NHL25 and NHL3, two NDR1/HIN1-1ike genes in Arabidopsis thaliana with potential role(s) in plant defense.
Dangl, JL; Lee, J; Nass, N; Nürnberger, T; Parker, J; Scheel, D; Tornero, P; Varet, A, 2002
)
1.04
"M71 treated with salicylic acid (SA)."( De novo transcriptome assembly and characterization of the 10-hydroxycamptothecin-producing Xylaria sp. M71 following salicylic acid treatment.
Ding, X; Liu, F; Liu, K; Zhang, Y, 2017
)
0.99
"Treatment with salicylic acid 33% was performed once a month, for a total of four times."( Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement.
De Vita, V; Fabbrocini, G; Marasca, C; Monfrecola, G; Palmisano, F, 2013
)
2.17
"Pretreatment with salicylic acid/betamethasone and calcipotriol/betamethasone before BF-200 ALA application did not increase PpIX fluorescence from 1 to 5 h compared to no pretreatment, and both were significantly inferior to curettage (P < 0.0017 and 0.0024, respectively)."( Short-term chemical pretreatment cannot replace curettage in photodynamic therapy.
Nissen, CV; Philipsen, PA; Wiegell, SR; Wulf, HC, 2016
)
0.76
"and treated by salicylic acid were isolated by the methods of gel-filtration, affinity chromatography and isoelectric focusing, their biochemical properties were studied."( [Isolation and properties of lectins from cell walls of wheat seedlings infected by Fusarium graminearum and treated by salicylic acid].
Adamovskaia, VG; Molodchenkova, OO; Sagaĭdak, TV; Tsiselskaia, LĬ,
)
0.68
"Treatment with salicylic acid up-regulates the PR-1g gene, encoding a basic protein of the PR-1 family, in PR-1-deficient tobacco, indicating that PR-1 expression may repress that of PR-1g."( Silencing of acidic pathogenesis-related PR-1 genes increases extracellular beta-(1->3)-glucanase activity at the onset of tobacco defence reactions.
Galiana, E; Marais, A; Ponchet, M; Rivière, MP; Willats, W, 2008
)
0.69
"Pretreatment with salicylic acid (SA), an inducer of plant disease resistance, enhanced the capacity of parsley cells for the induction of a rapid K(+)/pH response and the subsequent coumarin (phytoalexin) secretion. "( Pretreatment with salicylic acid primes parsley cells for enhanced ion transport following elicitation.
Conrath, U; Fuchs, A; Katz, V, 2002
)
0.98

Toxicity

Salicylic acid (SA) has a long history of safe use as ingredient in topical cosmetic products. The present study investigated the effect of salicylic Acid (SA), sodium hydrosulfide (NaHS) and concomitant application of SA and NaHs seed priming.

ExcerptReferenceRelevance
" Toxic effects of either metabolite were not evident beyond 24 h, and toxicity of 2,5-DIOH was significantly greater in comparison to 2,3-DIOH."( Comparative acute nephrotoxicity of salicylic acid, 2,3-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid in young and middle aged Fischer 344 rats.
Birnbaum, LS; Blair, PC; Clark, AM; McMahon, TF; Stefanski, SA; Wilson, RE, 1991
)
0.56
"Cardiac side effects from aspirin are uncommon; however, severe acid-base imbalance, pulmonary edema, ventricular ectopic activity and cardiopulmonary arrest have been reported in patients with toxic serum salicylate concentrations."( Cardiac conduction abnormalities and atrial arrhythmias associated with salicylate toxicity.
Alpert, MA; Beach, CL; Flaker, GC; Mukerji, V; Weber, RD,
)
0.13
" The LD50 of SA with LPS was about one third of that of SA alone."( [Studies on the pharmacological bases of fetal toxicity of drugs (VII). Enhancement effect of bacterial pyrogen on the fetal toxicity of salicylic acid].
Itami, T; Kanoh, S, 1984
)
0.47
" To evaluate the role of direct toxic action of drugs on hepatocytes, the effects of salicylate, chloroquine, prednisolone and indomethacin on LDH leakage from cultured rat hepatocytes were studied."( Hepatotoxic effects of anti-rheumatic drugs in cultured rat hepatocytes.
Akesson, A; Akesson, B, 1984
)
0.27
" The results of the possible toxic effects of these aromatic compounds showed that at their effective concentrations they were non-toxic to 1-day-old chicks."( Inhibition of aflatoxin production in groundnut with benzoic acid derivatives and possible toxic effect of their aromatic residues.
Offonry, S; Uraih, N, 1981
)
0.26
" We used a tertiary referral clinic population to estimate safe exposure doses for epidemiological studies."( Aspirin, salicylate, sulfite and tartrazine induced bronchoconstriction. Safe doses and case definition in epidemiological studies.
Buckley, CE; Corder, EH, 1995
)
0.29
"In plants potentially toxic compounds are ultimately deposited in the large central vacuole."( A herbicide antidote (safener) induces the activity of both the herbicide detoxifying enzyme and of a vacuolar transporter for the detoxified herbicide.
Amrhein, N; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E; Tommasini, R, 1994
)
0.29
" The free acid compounds were less toxic than their corresponding salts."( Comparative cytotoxicity of 5-aminosalicylic acid (mesalazine) and related compounds in different cell lines.
Dierickx, PJ; Janssen, L; Noble, E, 1997
)
0.57
" Preincubation of Hep G2 cells with low, nontoxic concentrations of menadione increased the viability of the cells against toxic doses of menadione or H2O2."( Menadione cytotoxicity to Hep G2 cells and protection by activation of nuclear factor-kappaB.
Cederbaum, AI; Chen, Q, 1997
)
0.3
"The results of this study suggest that superficial salicylic acid peels are both safe and efficacious for treatment of acne vulgaris, oily skin, textural changes, melasma, and post-inflammatory hyperpigmentation in patients with skin types V and VI."( The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups.
Grimes, PE, 1999
)
0.85
"We compared the gastric toxic effect of aspirin (ASA) in both normal and diabetic rats, with that of NCX-4016, a derivative of ASA with nitric oxide (NO) releasing moiety."( Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats.
Fujita, A; Takeuchi, K; Tashima, K; Umeda, M, 2000
)
0.31
"rad;OH concentration in embryonic tissues after COC exposure and toxic interactions of COC and NaSAL can also occur at an earlier stage of development."( Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis.
Sparber, SB; Venturini, L, 2001
)
0.31
" We conclude that these drugs are toxic to renal inner medullary collecting duct cells under the conditions of high osmolality normally present in the inner medulla, that combinations of the drugs are more toxic than are the drugs individually, and that the toxicity includes induction of proliferation of these cells that are otherwise quiescent in the presence of high osmolality."( Toxicity of acetaminophen, salicylic acid, and caffeine for first-passage rat renal inner medullary collecting duct cells.
Burg, MB; Cai, Q; Dmitrieva, NI; Ferguson, D; Michea, LF; Rocha, G, 2003
)
0.62
"The digitized, controlled, scalp-cooling system represents an effective and safe device that should be clinically evaluated in a randomized trial and in studies using other chemotherapy regimens to determine optimal temperatures and durations of cooling for maximal efficacy."( Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients.
Bjurberg, M; Gustavsson, A; Ridderheim, M, 2003
)
0.32
" Reported and theoretical adverse effects from systemic exposure are detailed."( Topical acne drugs: review of clinical properties, systemic exposure, and safety.
Akhavan, A; Bershad, S, 2003
)
0.32
"Freely circulating, protein unbound, active inhaled corticosteroid (ICS) can cause systemic adverse effects."( Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
Chen, K; David, M; Guo, Z; Huang, Y; King, SP; Luo, Y; Nave, R; Rohatagi, S; Schemm, C; Shen, L,
)
0.13
"Chemical peeling with salicylic acid is a well tolerated and safe treatment modality in many superficial facial dermatoses."( Tolerance and safety of superficial chemical peeling with salicylic acid in various facial dermatoses.
Bari, AU; Iqbal, Z; Rahman, SB,
)
0.69
"To quantify the incidence of seizures and adverse events during standard electroencephalography (EEG)."( Seizures and adverse events during routine scalp electroencephalography: a clinical and EEG analysis of 1000 records.
Angus-Leppan, H, 2007
)
0.34
"A retrospective random sample of 1000 of a total of 3391 reports of standard scalp EEG recordings during 2002 at Kings College Hospital were studied, and adverse events during standard EEG were recorded."( Seizures and adverse events during routine scalp electroencephalography: a clinical and EEG analysis of 1000 records.
Angus-Leppan, H, 2007
)
0.34
" Sixty of the adverse events were seizures."( Seizures and adverse events during routine scalp electroencephalography: a clinical and EEG analysis of 1000 records.
Angus-Leppan, H, 2007
)
0.34
" IPM was also well tolerated, with minimal adverse events."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.13
"Data suggest that IPM is a safe and effective therapy for the treatment of head lice in children and adults."( North American efficacy and safety of a novel pediculicide rinse, isopropyl myristate 50% (Resultz).
Goodman, JJ; Kaul, N; Palma, KG; Silagy, SS; Toole, J,
)
0.13
" The aim of this study was to clarify the spatial dimensions of a high-positioned foramina to allow for the safe performance of this maneuver."( Course of the bony canal associated with high-positioned supraorbital foramina: an anatomic study to facilitate safe mobilization of the supraorbital nerve.
Fujii, K; Oka, H; Osawa, S; Shimizu, S; Utsuki, S, 2008
)
0.35
"Effective and safe products are needed for long-term management of scalp psoriasis."( A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH, 2008
)
0.35
" Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2."( A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH, 2008
)
0.35
" Treatment had no significant adverse effects."( Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin.
Alam, M; Boone, SL; Helenowski, I; Joshi, SS; Kundu, RV; Rademaker, A; West, DP; White, L; Yoo, S, 2009
)
0.59
"Salicylic acid peels are safe in this population."( Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin.
Alam, M; Boone, SL; Helenowski, I; Joshi, SS; Kundu, RV; Rademaker, A; West, DP; White, L; Yoo, S, 2009
)
2.03
"We, the Food and Drug Administration (FDA), are issuing this final rule to include benzoyl peroxide as a generally recognized as safe and effective (GRASE) active ingredient in over-the-counter (OTC) topical acne drug products."( Classification of benzoyl peroxide as safe and effective and revision of labeling to drug facts format; topical acne drug products for over-the-counter human use; final rule.
, 2010
)
0.36
" In contrast to ThU SA was considered safe for drought-stress alleviation in crop plant agriculture."( Screening the bio-safety of wheat produced from pretreated grains to enhance tolerance against drought using physiological and spectroscopic methods.
Abdelkader, AF; Abo-Aly, MM; Attia, MS; Bakir, EM; Hassanein, RA, 2010
)
0.36
" It appears from our initial experience that it may be performed in a safe and reproducible manner without a drain and on an outpatient basis."( Robotic facelift thyroidectomy: II. Clinical feasibility and safety.
Seybt, MW; Singer, MC; Terris, DJ, 2011
)
0.37
" These results illustrate the ameliorating effect of SA under stress conditions and reveal that SA is more effective in alleviating the toxic effects of insecticides at higher concentrations than that at lower concentrations."( Exogenous application of salicylic acid to alleviate the toxic effects of insecticides in Vicia faba L.
Singh, A; Singh, AK; Srivastava, AK, 2013
)
0.69
" On the other hand, highest side effect for Group D is irritation 29(96."( Safety in use of cryotherapy and topical salicylic acid with lactic acid combination in treating verruca vulgaris.
Ahamed, RS; Alam, M; Khondker, L; Sultana, R, 2012
)
0.64
" Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports."( Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation.
Bell, M; Meinking, TL; Mertz-Rivera, K; Villar, ME, 2013
)
0.39
"5% concentration of this ivermectin lotion formulation shows promise as a safe and effective treatment for head lice infestation and the associated signs of pruritus."( Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation.
Bell, M; Meinking, TL; Mertz-Rivera, K; Villar, ME, 2013
)
0.39
" However, the IAA or SA treatment attenuated the adverse effects of Cd on these attributes."( Exogenous treatment with indole-3-acetic acid and salicylic acid alleviates cadmium toxicity in wheat seedlings.
Agami, RA; Mohamed, GF, 2013
)
0.64
" In addition, the cells exposed to both compounds, Al and SA, showed evident morphological signals of recovery from the toxic state produced in the presence of Al."( Effect of salicylic acid on the attenuation of aluminum toxicity in Coffea arabica L. suspension cells: A possible protein phosphorylation signaling pathway.
Cab-Guillén, Y; Chan-May, A; Hernández-Sotomayor, SM; Muñoz-Sanchez, JA, 2013
)
0.79
" We propose a safe and effective means of dissecting the OA."( A safe and effective technique for harvesting the occipital artery for posterior fossa bypass surgery: a cadaveric study.
Bernardo, A; Burrell, JC; Evins, AI; Fukuda, H; Stieg, PE,
)
0.13
"This segmentation provided a safe and effective procedure for harvesting the OA, in which dissection of the transitional segment is a critical step."( A safe and effective technique for harvesting the occipital artery for posterior fossa bypass surgery: a cadaveric study.
Bernardo, A; Burrell, JC; Evins, AI; Fukuda, H; Stieg, PE,
)
0.13
"5 mM), alleviated the toxic effects of Cd by increasing the growth parameters, photosynthetic pigments, GSH and FAME content and decreasing proline and MDA content respectively."( Amelioration of Cd toxicity by pretreatment of salicylic acid in Cicer arietinum L. seedlings.
Canakci, S; Dursun, B, 2013
)
0.65
" Salicylic acid (SA) has been shown to ameliorate the adverse effects of environmental stress on plants."( Salicylic acid alleviates the adverse effects of salt stress in Torreya grandis cv. Merrillii seedlings by activating photosynthesis and enhancing antioxidant systems.
Du, X; Hu, Y; Li, T; Shen, C; Tang, H; Wu, J, 2014
)
2.76
" Sixteen patients (52%) experienced a total of 20 adverse events; 19 were considered unrelated to study treatment, 14 were mild, and none were serious or lesional or perilesional on the scalp."( Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.
Eichenfield, LF; Ganslandt, C; Kurvits, M; Schlessinger, J,
)
0.13
"Scalp block with a mixture of lidocaine and ropivacaine seems to provide effective and safe anesthetic management in patients undergoing awake craniotomy."( Efficacy and Safety of a Lidocaine and Ropivacaine Mixture for Scalp Nerve Block and Local Infiltration Anesthesia in Patients Undergoing Awake Craniotomy.
Chaki, T; Hatakeyama, Y; Hayase, T; Ishioka, Y; Janicki, PK; Kaneuchi-Yamashita, M; Kohri, N; Sugino, S; Yamakage, M, 2016
)
0.43
"We found the use of VAC therapy applied directly to the dura or cortical brain as a safe and effective technique for short-term wound temporization in the setting of indeterminate oncologic margins or active infection."( Vacuum-assisted closure therapy to the brain: a safe method for wound temporization in composite scalp and calvarial defects.
Blackburn, S; Mast, B; Murad, G; Prince, N; Sapountzis, S; Shaw, C; Singhal, D; Werning, J, 2015
)
0.42
" Selenium, a micronutrient, is essential for both humans and animals but is toxic at higher doses."( Alleviation of selenium toxicity in Brassica juncea L.: salicylic acid-mediated modulation in toxicity indicators, stress modulators, and sulfur-related gene transcripts.
Gupta, M; Gupta, S, 2016
)
0.68
" Information related to treatment with CPS and adverse effects was abstracted from medical records."( Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts.
Álvarez Castro, C; Becerro de Bengoa Vallejo, R; García Sánchez, MM; López López, D; Losa Iglesias, ME; Romero Morales, C; Vilar Fernández, JM, 2016
)
0.68
" Unfortunately, chlorhexidine solutions are toxic to the cornea and middle ear, and they pose a splash risk to both the patient and health care personnel."( Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic.
Steinsapir, KD; Woodward, JA, 2017
)
0.46
" Povidone-iodine is a safe and effective alternative."( Chlorhexidine Keratitis: Safety of Chlorhexidine as a Facial Antiseptic.
Steinsapir, KD; Woodward, JA, 2017
)
0.46
" Anatomical observations of leaf and root revealed that herbicide affected internal structures, while SA played a vital role in protection from toxic effects."( Salicylic acid mediates antioxidant defense system and ABA pathway related gene expression in Oryza sativa against quinclorac toxicity.
Ali, B; Gill, RA; Islam, F; Lv, M; Wang, J; Yan, G; Yang, C; Zhou, W, 2016
)
1.88
" In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA."( Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years.
Jun, M; Lee, NR; Lee, WS, 2017
)
0.46
" Mostly mild or moderate treatment-emergent adverse events were reported by 79 of 91 patients; the most common were nasopharyngitis, eczema, seborrheic dermatitis, urticaria and injection site reactions."( Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Aoki, T; Cameron, GS; Ishii, T; Morisaki, Y; Nakagawa, H; Nakajo, K; Osuntokun, OO; Saeki, H, 2017
)
0.46
"More than 75% of patients with cancer cite alopecia as the most feared side effect of treatment, with as many as 10% considering treatment refusal."( Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia
.
Fischer-Cartlidge, E; Ross, M, 2017
)
0.46
" Few patients discontinue cooling early because of adverse experiences."( Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia
.
Fischer-Cartlidge, E; Ross, M, 2017
)
0.46
"There is little information about how hair diameter differences within the safe donor area."( Hair diameter evaluation in different regions of the safe donor area in Asian populations.
Kim, NR; Manonukul, K; Park, JH; Park, JM, 2017
)
0.46
" The safe donor area was defined as the area contained within 28 cm from the horizontal plane of the upper border of the hair rim to the vertical line of the bilateral external acoustic meatus."( Hair diameter evaluation in different regions of the safe donor area in Asian populations.
Kim, NR; Manonukul, K; Park, JH; Park, JM, 2017
)
0.46
"Our results suggest that safe donor areas between zones 4 and 7 could be useful for specific hair transplantation surgeries requiring thinner hair, such as eyebrows, eyelashes, and female hairline correction surgery, whereas hair from zones 1-3 could be more useful for those requiring thicker hair, such as male and female pattern hair loss."( Hair diameter evaluation in different regions of the safe donor area in Asian populations.
Kim, NR; Manonukul, K; Park, JH; Park, JM, 2017
)
0.46
" Superficial chemical peeling is a skin-wounding procedure which might cause some potentially undesirable adverse events."( Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris.
Al-Khateeb, A; Al-Talib, H; Hameed, A; Murugaiah, C,
)
0.13
" Adverse events were predominantly mild or moderate."( Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
Berman, B; Bukhalo, M; Hanke, CW; Pariser, DM; Siegel, D; Skov, T; Swanson, N; Villumsen, J; Weiss, JS, 2017
)
0.46
"Transgenic mustard plants ( Brassica juncea ) expressing non-allergenic and biologically safe RiD peptide show higher tolerance against Lipaphis erysimi."( Overexpression of biologically safe Rorippa indica defensin enhances aphid tolerance in Brassica juncea.
Jana, K; Sarkar, P; Sikdar, SR, 2017
)
0.46
"Salicylic acid (SA) has a long history of safe use as ingredient in topical cosmetic products."( A kinetic-based safety assessment of consumer exposure to salicylic acid from cosmetic products demonstrates no evidence of a health risk from developmental toxicity.
Boisleve, F; Bury, D; Eichenbaum, G; Girard, S; Labib, R; Leal, M; Naciff, J; Wong, J, 2018
)
2.17
"3%) were the most commonly occurring adverse effects with cantharidin treatment."( Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018
)
0.48
" Common adverse effects included erythema, irritation, and desquamation."( Efficacy and safety of 308-nm excimer lamp in the treatment of scalp psoriasis: a retrospective study.
Pakornphadungsit, K; Phusuphitchayanan, P; Rattanakaemakorn, P; Suchonwanit, P; Thadanipon, K, 2019
)
0.51
"The 308-nm excimer light appears to be an effective and safe modality that requires short treatment time."( Efficacy and safety of 308-nm excimer lamp in the treatment of scalp psoriasis: a retrospective study.
Pakornphadungsit, K; Phusuphitchayanan, P; Rattanakaemakorn, P; Suchonwanit, P; Thadanipon, K, 2019
)
0.51
" To uncover the toxic alleviation effects of SA on potato plants to cadmium (Cd) stress, the morphological, physiological, and biochemical indexes including antioxidant defense system were assayed in potato plants under 200 μM Cd stress in 1/2 Hoagland solution with foliar application of 600 μM SA concentration (10 ml/plant)."( Foliar application of salicylic acid alleviate the cadmium toxicity by modulation the reactive oxygen species in potato.
Guan, C; Ji, J; Li, Q; Wang, G; Wang, Y, 2019
)
0.83
"This study suggests that salicylic acid when applied through pre-treatment of seeds or through a foliar spray can be used to ameliorate the toxic effects of chromium (VI)."( Salicylic acid induces amelioration of chromium toxicity and affects antioxidant enzyme activity in Sorghum bicolor L.
Brar, B; Joshi, UN; Sihag, S, 2019
)
2.26
" Adverse events were evaluated."( A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019
)
0.51
" Pretreatment with appropriate levels of SA showed a mitigating effect on Cd damage, whereas an excessive dose of exogenous SA aggravated the toxic effects of Cd."( Salicylic Acid Signals Plant Defence against Cadmium Toxicity.
Fu, Q; Guo, B; Li, N; Liang, Y; Liu, C, 2019
)
1.96
"Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer therapy."( Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines.
Bagnardi, V; Bianco, N; Campennì, G; Cancello, G; Cardillo, A; Colleoni, M; Dellapasqua, S; Iorfida, M; Masiero, M; Mazza, M; Mazzocco, K; Montagna, E; Munzone, E; Pagan, E; Palazzo, A; Pettini, G; Pravettoni, G; Sangalli, C; Tramacere, A; Veronesi, P, 2019
)
0.51
"Mercury (Hg) is one of the most toxic heavy metals with strong negative effects on the plant growth and functions."( Physiological and molecular mechanisms underlying salicylic acid-mitigated mercury toxicity in lemon balm (Melissa officinalis L.).
Akramian, M; Khadivi, A; Safari, F; Salehi-Arjmand, H, 2019
)
0.77
" Adverse effects of both the agents were also noted at each visit."( Comparative study of efficacy and safety of 45% mandelic acid versus 30% salicylic acid peels in mild-to-moderate acne vulgaris.
Dayal, S; Kalra, KD; Sahu, P, 2020
)
0.79
" However, adverse effects were lesser with MA peels."( Comparative study of efficacy and safety of 45% mandelic acid versus 30% salicylic acid peels in mild-to-moderate acne vulgaris.
Dayal, S; Kalra, KD; Sahu, P, 2020
)
0.79
" Safety response criteria included adverse drug reactions [ADRs; any adverse event (AE) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AEs (a secondary response criterion)."( Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.
Eichenfield, LF; Kurvits, M; Liljedahl, M; Marcoux, D, 2020
)
0.56
" The sludge utilization for fertilizers on agricultural land would pose the risk of causing adverse effects on plant growth and yield by TCS."( Salicylic acid application alleviates the adverse effects of triclosan stress in tobacco plants through the improvement of plant photosynthesis and enhancing antioxidant system.
Guan, C; Ji, J; Jin, C; Li, Q; Wang, C; Wang, G; Wu, H; Zhang, Y, 2020
)
2
" Photosynthetic index and gene expression analyses demonstrated that SA could alleviate adverse effects of Al toxicity by increasing light capture efficiency, promoting electron transport in the photosynthetic electron transport chain and thylakoid lumen deacidification, and promoting synthesis of aenosine triphosphate (ATP) and nicotinamide adenine dinucleotide phosphate (NADPH)."( Protective roles of salicylic acid in maintaining integrity and functions of photosynthetic photosystems for alfalfa (Medicago sativa L.) tolerance to aluminum toxicity.
An, Y; Cheng, X; Fang, T; Huang, B; Zhao, E; Zheng, B; Zhou, P, 2020
)
0.88
"In the present study, impact of salicylic acid (SA), sodium hydrosulfide (NaHS) and concomitant application of SA and NaHs seed priming was investigated in alleviation of the lead stress adverse effects on growth parameters, total chlorophyll content, dicarbonyl stress, and lead-induced iron deficiency in maize."( Pre- sowing seed treatment with salicylic acid and sodium hydrosulfide confers Pb toxicity tolerance in maize (Zea mays L.).
Jamei, R; Rahmani, F; Zanganeh, R, 2020
)
1.13
"04)The most common adverse events reported during the scalp cooling sessions were chills (7%), and chills with headaches (6%)."( Safety and efficacy of scalp cooling system in preventing chemotherapy induced alopecia - A single center prospective study.
Baby, V; Joseph, S; Kate, S; Nagarkar, R; Pathan, D; Patil, R; Ramesh, YV; Vyavhare, R, 2021
)
0.62
" However, exogenously applied SA relieved the adverse effects caused by B toxicity and led to an increase in growth parameters under B stress and non-stress conditions."( Salicylic acid-mediated alleviation of soil boron toxicity in Mentha arvensis and Cymbopogon flexuosus: Growth, antioxidant responses, essential oil contents and components.
Aftab, T; Choudhary, S; Khan, MMA; Mukarram, M; Naeem, M; Wani, KI; Zehra, A, 2021
)
2.06
" Thus, we evaluated the beneficial roles of alone or/and combine applications of SA and Si in mitigating the toxic effects of Cr in the leaves and roots of rice (Oryza sativa) seedlings."( Salicylic acid underpins silicon in ameliorating chromium toxicity in rice by modulating antioxidant defense, ion homeostasis and cellular ultrastructure.
Azhar, W; Hamid, Y; Hussain, S; Khan, AR; Salam, A; Shah, AM; Sheteiwy, MS; Ulhassan, Z; Yang, S; Zhou, W, 2021
)
2.06
" The main adverse effects in ALA-PDT treatment were mild edema and tolerable pain, and no adverse effect was observed in red-light treatment."( Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety.
Cao, Z; Hu, W; Liu, X; Wang, P; Wang, X; Zhang, G; Zhang, L; Zhang, Y; Zhou, Z, 2021
)
0.62
" The adverse effects of ALA-PDT were mild, which indicated safety and tolerability of this treatment."( Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety.
Cao, Z; Hu, W; Liu, X; Wang, P; Wang, X; Zhang, G; Zhang, L; Zhang, Y; Zhou, Z, 2021
)
0.62
"Infiltration of ropivacaine and Diprospan can achieve satisfactory postoperative pain relief after craniotomy; it is a simple, easy, and safe technique, worth clinical promotion."( Postoperative Analgesic Efficacy and Safety of Ropivacaine Plus Diprospan for Preemptive Scalp Infiltration in Patients Undergoing Craniotomy: A Prospective Randomized Controlled Trial.
Han, X; Ji, N; Luo, F; Ren, T; Wang, Y, 2022
)
0.72
" Patient satisfaction was evaluated by questionnaire, and adverse effects were documented."( Efficacy and safety of a thermal fractional skin rejuvenation system (Tixel) for the treatment of facial and/or scalp actinic keratoses.
Agmon, Y; Chorny, I; Friedland, R; Hodak, E; Klein, I; Lapidoth, M; Leshem, YA; Levi, A; Mimouni, D; Oren-Shabtai, M; Sloutsky, N; Snast, I, 2022
)
0.72
" No apparent adverse events were observed throughout treatment duration."( Safety and efficacy of Trimax-360 serum in healthy adult subjects with mild to moderate alopecia of scalp.
Chew, SK; Gajjar, T; Sethi, S, 2022
)
0.72
"The results of this open label study suggest that 98 days treatment with botanical-based Trimax-360 Serum is safe and effective in significantly improving the rate of hair growth."( Safety and efficacy of Trimax-360 serum in healthy adult subjects with mild to moderate alopecia of scalp.
Chew, SK; Gajjar, T; Sethi, S, 2022
)
0.72
" Most adverse effects were mild and moderate, and scalp cooling did not increase the risk of scalp metastases."( Effectiveness, Safety, and Tolerance of Scalp Cooling for Chemotherapy-Induced Alopecia.
Huang, J; Liu, WQ; Ning, N; Yang, KL; Zhang, XY, 2022
)
0.72
" Regarding safety, all subjects in both the scalp cooling and hair loss observation groups experienced adverse events; only 1 subject in each group experienced a severe adverse event due to chemotherapy and majority of the subjects in both groups experienced minor adverse events."( [Efficacy and Safety of Scalp Cooling Device RV21-01 for Suppression of Chemotherapy-Induced Alopecia in Breast Cancer Patients].
Fukuma, E; Kato, M; Nomizu, T; Ueo, H, 2023
)
0.91
" No adverse reaction was reported in either group."( Efficacy and safety of a facial serum and a mask containing salicylic acid and lipohydroxy acid in acne management: A randomized controlled trial.
He, X; Li, S; Niu, YG; Steel, A; Wang, HT; Zhang, XS; Zhang, Z, 2023
)
1.15
" Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal."( Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population.
Armesto-Santos, S; Ballescá-López, F; Botella-Estrada, R; Carrascosa, JM; de la Cueva-Dovao, P; Herranz-Pinto, P; Hospital-Gil, M; Llamas-Velasco, M; López-Estebaranz, JL; Magdaleno-Tapial, J; Martínez-Lorenzo, E; Ribera-Pibernat, M; Rivera, R; Romero-Mate, A; Ruíz-Villaverde, R; Sahuquillo-Torralba, A; Salgado-Boquete, L; Velasco-Pastor, M; Vilarrasa-Rull, E; Yanguas-Bayona, JI, 2023
)
0.91
" No adverse events were reported."( Effectiveness and safety of scalp acupuncture for treating migraine: A systematic review and meta-analysis.
Heo, I; Hwang, EH; Hwang, MS; Kim, CY; Park, SY; Shin, BC, 2023
)
0.91
" Use of Azospirillum brasilense and salicylic acid significantly increased mung bean seedling growth (49%) and contributed to reducing the toxic effect of Cr stress (34% and 14% in plant height, respectively) due to their beneficial properties in promoting plant growth."( Alleviation of chromium toxicity in mung bean (Vigna radiata L.) using salicylic acid and Azospirillum brasilense.
Ali, HH; Awan, TH; Elshikh, MS; Hameed, A; Ikram, K; Ilyas, M; Iqbal, R; Khan, WUD; Mustafa, AEMA; Rizwan, M; Zaheer, MS, 2023
)
1.42
" This strategy has the ability to reduce oxidative stress brought on by chromium, enhancing plant resistance to adverse circumstances."( Alleviation of chromium toxicity in mung bean (Vigna radiata L.) using salicylic acid and Azospirillum brasilense.
Ali, HH; Awan, TH; Elshikh, MS; Hameed, A; Ikram, K; Ilyas, M; Iqbal, R; Khan, WUD; Mustafa, AEMA; Rizwan, M; Zaheer, MS, 2023
)
1.14

Pharmacokinetics

The plasma concentrations of aspirin (ASA), salicylic acid (SA) and gentisic acid (GA) were determined by LC-MS/MS method. The pharmacokinetic parameters were calculated by noncompartmental analysis. Blood samples were obtained at scheduled timepoints before and up to 24 hours after each dose.

ExcerptReferenceRelevance
" The results show that antacid affected the relative bioavailability of aspirin since the mean peak concentration (Cmax) of aspirin was significantly higher when antacid was given."( The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers.
Chaiyos, N; Itthipanichpong, C; Sirivongs, P; Wittayalertpunya, S, 1992
)
0.28
" As a consequence, the biological half-life was eight to ten times longer than in the ruminants studied previously."( Pharmacokinetics and elimination of salicylic acid in rabbits.
Barker, SA; Davis, LE; Hsieh, LC; Koritz, GD; Malbrough, MS; Neff-Davis, CA; Short, CR, 1991
)
0.56
"The pharmacokinetic profile of this new preparation fits that proposed by others to produce a selective inhibition of thromboxane synthesis by platelets."( [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology].
Artaza, MA; Castel, JM; Laporte, JR, 1991
)
0.58
"The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers."( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects.
Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989
)
0.78
" In this study, pharmacokinetic interactions between arbaprostil and aspirin were examined in humans after chronic doses of both drugs."( Pharmacokinetic interactions between arbaprostil and aspirin in humans.
Cox, JW; Euler, AR; Gee, WL; Hsyu, PH; Pullen, RH,
)
0.13
" The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng."( Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.
Bochner, F; Lloyd, JV; Morris, PM; Siebert, DM; Williams, DB, 1988
)
0.27
" Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%)."( Nonlinear pharmacokinetics of aspirin in rats.
Levy, G; Wientjes, MG, 1988
)
0.27
" At the end of each 2-week dosage period, plasma and urine were collected over a dosage interval for the estimation of various pharmacokinetic parameters."( Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.
Bochner, F; Cleland, LG; Graham, GG; Imhoff, DM; Polverino, A; Rolan, PE; Tregenza, RA, 1987
)
0.27
" Pharmacokinetic studies in four volunteers showed that the plasma protein binding and renal clearance of acetazolamide were significantly reduced during chronic salicylate dosing."( Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.
Brandt, JL; Chapron, DJ; Feig, PU; Gomolin, IH; Kramer, PA; Sweeney, KR, 1986
)
0.27
" It is important in pharmacokinetic studies to measure plasma levels of both acetylsalicylic acid and salicylic acid."( Determinants of the pharmacokinetics of antithrombotic drugs.
Marks, GS, 1983
)
0.49
" Most of the pharmacokinetic parameters derived from these profiles were not significantly different between young subjects, elderly subjects and subjects with alcoholic liver disease."( Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.
Brooks, PM; Roberts, MS; Rumble, RH; Thomas, D; Wanwimolruk, S, 1983
)
0.27
" Before one can extrapolate between species, however, the pharmacokinetic model must be predictable within the species for which it was developed."( Correlating pharmacokinetics and teratogenic endpoints.
Kimmel, CA; Young, JF,
)
0.13
"74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg."( Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model.
Eppler, J; Fraga, C; Giesbrecht, E; Ito, S; Johnson, D; Rais, A; Verjee, Z; Wiggins, T, 1995
)
0.29
" The results of the pharmacokinetic analyses from blood and urinary data indicated no significant differences in the disposition of ASA between CuD and CuS rats."( Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin.
Bacolod, M; Dawson, C; Gonzales, C; Kishore, V; Lopez-Anaya, A, 1994
)
0.29
" Individual pharmacokinetic parameters were estimated by compartmental modeling (ASA and SA) and by model-independent methods (SUA)."( Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.
Dubovská, D; Gajdos, M; Krivosíková, Z; Piotrovskij, VK; Spustová, V; Trnovec, T,
)
0.43
"The time course of salicylic acid at a dermal application site and in local underlying tissues below the site in rats was examined using a physiologically based pharmacokinetic model assuming first-order diffusional mass transfer between the dermis and underlying tissues."( Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application.
Roberts, MS; Singh, P, 1993
)
0.87
" Blood samples for pharmacokinetic determinations of ASA and its metabolite, salicylic acid (SA) and platelet aggregation studies were obtained at scheduled timepoints before and up to 24 hours after each dose."( Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers.
Benedek, IH; Joshi, AS; King, SY; Kornhauser, DM; Pieniaszek, HJ, 1995
)
0.52
" Pharmacokinetic characteristics (AUC, Cmax, tmax, t1/2, MRT) were taken or calculated on the basis of plasma concentration/time profiles."( Lack of influence of glycine on the single dose pharmacokinetics of acetylsalicylic acid in man.
Bias-Imhoff, U; Riechers, AM; Schulz, HU; Schurer, M; Schwantes, U, 1996
)
0.52
" The concentration-depth profiles for solutes in underlying tissues with variable blood flows were described by a compartment-in-series pharmacokinetic model in which each tissue's blood flows to and from a central compartment were incorporated."( Effects of vasoconstriction on dermal pharmacokinetics and local tissue distribution of compounds.
Roberts, MS; Singh, P, 1994
)
0.29
" Thus, not only drug monitoring but also pharmacokinetic investigations from blood plasma have become possible without further sample pretreatment."( Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE).
Kunkel, A; Wätzig, H, 1999
)
0.3
" Renal excretion rate, elimination half-life and total bioavailability of salicylates were calculated."( Pharmacokinetics of salicin after oral administration of a standardised willow bark extract.
Heide, L; Kötter, I; Schmid, B, 2001
)
0.31
" The plasma and urine results demonstrated no pharmacokinetic interaction between oseltamivir and aspirin."( Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.
Barrett, J; Dorr, A; Liu, B; Oo, C; Ward, P, 2002
)
0.31
" The aim of this open, randomized, three-factorial (three-treatment, three-period, six-sequence) Latin Square clinical study was to investigate if there were any pharmacokinetic interactions between ASA and PSE when given as fixed combination of 500 mg ASA/30 mg PSE."( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.55
" The supplementary evaluation for the non-normalized original parameters AUC and Cmax also revealed bioequivalence."( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.55
"The maximum plasma concentration, half-life time, area under the curve and the amount of salicylates excreted were statistically different between the JRA and the RF groups, as well as between the RF group and the controls, however, there were no significant differences between the JRA group and the controls."( Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases.
Carbajal Rodríguez, L; Flores Pérez, J; Juárez Olguín, H; Lares Asseff, I; Loredo Abdalá, A, 2004
)
0.59
" However, due to ample variability of pharmacokinetic parameters it is recommended that dose schemes are individualized on the type of autoimmune disease considered."( Comparative pharmacokinetics of acetyl salicylic acid and its metabolites in children suffering from autoimmune diseases.
Carbajal Rodríguez, L; Flores Pérez, J; Juárez Olguín, H; Lares Asseff, I; Loredo Abdalá, A, 2004
)
0.59
" In the routine practice of therapeutic drug monitoring (TDM) and pharmacokinetic studies, drug concentration determined by intermittent blood sampling is used as a surrogate for calculating the drug concentration in the peripheral compartment tissues."( Electroporation and transcutaneous extraction (ETE) for pharmacokinetic studies of drugs.
Hui, SW; Murthy, SN; Sen, A; Zhao, YL, 2005
)
0.33
" Consistent with the prediction that reduced GHB brain concentrations could translate to decreased pharmacodynamic effects, a pilot study in rats showed that the pronounced GHB sedative/hypnotic effects (24."( Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.
Bhattacharya, I; Boje, KM, 2006
)
0.33
"AZD5438 is a novel, orally bioavailable, cyclin-dependent kinase (CDK) inhibitor demonstrating preclinical pharmacodynamic (PD) effects on CDK substrates and active growth inhibition of human tumour xenografts."( A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Amakye, D; Byth, K; Camidge, DR; Forder, C; Growcott, J; Hughes, A; Pemberton, M; Swaisland, H; Wilkinson, R; Wilson, D, 2007
)
0.34
" There is, however, limited information on its pharmacokinetic and pharmacodynamic effects in vivo."( Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats.
Choi, CI; Gao, L; Joseph, S; Kopelovich, L; Patlolla, JM; Rao, CV; Rigas, B; Steele, VE, 2008
)
0.35
"A comparative analysis of the concentrations of acetylsalicylic acid (ASA) and its metabolite, salicylic acid (SA), in the blood was performed and the other pharmacokinetic parameters were studied after conventional intragastric and transdermal administration in rabbits."( [Experimental study of the pharmacokinetics of acetylsalicylic acid upon transdermal administration].
Basok, IuB; Polukhina, OS; Salomatina, LA; Sevast'ianov, VI,
)
0.63
" Steady state was achieved by day 14, and the observed half-life of approximately 29 h supports daily dosing of the product."( Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.
Adams, M; Fein, MC; Furst, J; Kulp, J; Levy, S; Meng, TC, 2010
)
0.36
" The plasma concentrations of its metabolites, aspirin (ASA), salicylic acid (SA) and gentisic acid (GA) were determined by LC-MS/MS method and the pharmacokinetic parameters were calculated by noncompartmental analysis."( Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration.
Chen, DM; Huang, LL; Ihsan, A; Wang, X; Yuan, ZH, 2011
)
0.61
" The disposition of SS and SA were evaluated simultaneously using a pharmacokinetic model comprising several transit absorption steps and linear and nonlinear dual elimination pathways for SA."( Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats.
Almon, RR; Cao, Y; DuBois, DC; Jusko, WJ, 2012
)
0.66
"Our animal study indicated that co-administration of DG with warfarin/aspirin can cause significant pharmacokinetic and pharmacodynamic herb-drug interactions in rat."( Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin.
Fung, KP; Lau, BS; Leung, PC; Wang, S; Zhang, Z; Zhou, L; Zuo, Z, 2012
)
0.38
" The developed assay method was applied to an oral pharmacokinetic study in humans."( Low dose aspirin estimation: an application to a human pharmacokinetic study.
Hotha, KK; Kolagatla, PR; Venkateswarlu, V; Vijaya Bharathi, D, 2013
)
0.39
" The aim of this study was to investigate the pharmacokinetic and pharmacodynamic interactions between warfarin and aspirin in beagles after single and multiple doses."( Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs.
Hu, T; Huang, J; Huang, X; Li, J; Li, L; Pappoe, F; Shen, C; Tang, H; Zhang, P; Zhang, W, 2016
)
0.43

Compound-Compound Interactions

Study investigated the effects of intense pulsed light (IPL) combined with 30% supramolecular salicylic acid on facial seborrheic dermatitis.

ExcerptReferenceRelevance
"15 patients with superficial basaliomas or premalignant epithelial neoplastic disorders (actinic keratosis, leukoplakia, Bowen's disease) were treated locally over three weeks with retinoic acid (RA) alone or in combination with 5-fluorouracil (5-FU)."( [Vitamin A acid for the topical management of epithelial neoplasms. Combination with 5-fluorouracil].
Kurka, M; Orfanos, CE; Pullmann, H, 1978
)
0.26
"In a randomized controlled trial, 58 subjects were treated for Pediculus humanus var capitis with either pyrethrins combined with piperonyl butoxide (RID, Pfizer Inc, New York) or 1% permethrin (NIX, Burroughs Wellcome Co, Research Triangle Park, NC); 31 subjects received RID and 27 subjects received NIX."( Pyrethrins combined with piperonyl butoxide (RID) vs 1% permethrin (NIX) in the treatment of head lice.
Carson, DS; Tribble, PW; Weart, CW, 1988
)
0.27
" Subjects were initially given a single dose of aspirin alone or in combination with sucralfate for 2 days."( Evaluation of a potential drug interaction between sucralfate and aspirin.
Chang, CW; Lau, AH; Schlesinger, PK, 1986
)
0.27
"The effect of a saline cathartic combined with activated charcoal or activated charcoal alone on aspirin bioavailability was characterized in six healthy volunteers."( Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal.
Anderson, WH; Czajka, PA; Mowry, JB; Sketris, IS; Stafford, DT, 1982
)
0.26
" Since anti-platelet therapy with ASA is often combined with dipyridamol, the influence of this drug was also examined."( Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol.
Brantmark, B; Melander, A; Wåhlin-Boll, E, 1982
)
0.57
"The extensive horizontal scalp reduction technique with its difficulties and known limitations in relocation of flap and horizontal reduction was performed twice in combination with a Juri flap technique as treatment of wide scar alopecia resulting from a thermal burn."( Post-thermal burn alopecia and its treatment using extensive horizontal scalp reduction in combination with a Juri flap.
Felman, G, 1994
)
0.29
" Here we describe a rapid and sensitive HPLC method using ultraviolet absorbance (UV) and electrochemical detection (EC) to detect SA (UV), its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids (DHBA) and catechol in combination with catechol- and indoleamines and related metabolites (EC) in one isocratic run."( Detection of salicylate and its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissu
Gramsbergen, JB; Sloot, WN, 1995
)
0.29
"Twelve patients with post-burn contracture were treated using artificial dermis combined with thin split-skin grafting during the period January 1994 to April 1996."( Reconstruction of burn deformity using artificial dermis combined with thin split-skin grafting.
Negishi, N; Nozaki, M; Sasaki, K; Soejima, K; Takeuchi, M, 1997
)
0.3
"We describe a new non-anastomotic bypass procedure using dural pedicle insertion over the brain surface combined with encephalogaleomyosynangiosis and preservation of the superficial temporal artery (STA)."( Non-anastomotic bypass surgery for childhood moyamoya disease using dural pedicle insertion over the brain surface combined with encephalogaleomyosynangiosis.
Shirane, R; Yoshida, YK; Yoshimoto, T, 1999
)
0.3
"Hydroquinone 4% cream with 2% glycolic acid is safe and effective in improving photodamage on the neck and upper chest when used alone or in combination with salicylic acid peels."( Efficacy of hydroquinone cream (USP 4%) used alone or in combination with salicylic acid peels in improving photodamage on the neck and upper chest.
Gladstone, HB; Jeffers, M; Moy, RL; Nguyen, SL; Ottomeyer, T; Williams, R; Wortzman, M, 2000
)
0.73
"To observe the short-term effect of patients with poly-infarctional vascular dementia (PIVD) treated by CT positioning scalp circum-needling (SCN) combined with Chinese herbal medicine."( [Observation on efficacy of CT positioning scalp circum-needling combined with Chinese herbal medicine in treating poly-infarctional vascular dementia].
Lun, X; Rong, L; Yang, WH, 2003
)
0.32
"Scalp acupuncture combined with body acupuncture has a better clinical therapeutic effect than that of simple scalp acupuncture for the patient of stroke."( [Observation on therapeutic effect of scalp acupuncture combined with body acupuncture on stroke].
Wang, BQ; Zhou, P; Zhu, YP, 2005
)
0.33
"To probe into effect of scalp acupuncture combined with sports therapy on movement function of limbs in the patient of poststroke hemiplegia."( [Clinical study on scalp acupuncture combined with sports therapy for rehabilitation of poststroke hemiplegia].
Mu, JP; Zhao, DG, 2005
)
0.33
"Scalp acupuncture combined with sports therapy can promote recovery of the movement function of limbs in the patient of poststroke hemiplegia."( [Clinical study on scalp acupuncture combined with sports therapy for rehabilitation of poststroke hemiplegia].
Mu, JP; Zhao, DG, 2005
)
0.33
" Group A (n = 33) were treated by scalp acupuncture combined with consciousness-restoring resuscitation method, group B (n = 60) by scalp acupuncture combined with traditional acupuncture, and group C (n = 27) by traditional acupuncture."( [Observation on clinical therapeutic effect of scalp acupuncture combined with body acupuncture on apoplectic hemiplegia].
Bao, F; Sun, H; Wang, DH; Wang, FQ; Zhang, YX, 2006
)
0.33
"Scalp acupuncture combined with consciousness-restoring resuscitation method and scalp acupuncture combined with traditional acupuncture have a similar therapeutic effect on apoplectic hemiplegia, which is superior to that of traditional acupuncture."( [Observation on clinical therapeutic effect of scalp acupuncture combined with body acupuncture on apoplectic hemiplegia].
Bao, F; Sun, H; Wang, DH; Wang, FQ; Zhang, YX, 2006
)
0.33
"To observe the therapeutic effect of cluster-needle stimulation of scalp-points combined with rehabilitation training for apoplectic aphemia."( [Clinical treatment of apoplectic aphemia with multi-needle puncture of scalp-points in combination with visual-listening-speech training].
Zhang, HM, 2007
)
0.34
" etc] combined with rehabilitation (Acup+ Rehab) group."( [Clinical treatment of apoplectic aphemia with multi-needle puncture of scalp-points in combination with visual-listening-speech training].
Zhang, HM, 2007
)
0.34
"The cluster-needle puncture of scalp-points combined with rehabilitation training is an effective therapy for improving apoplectic aphemia."( [Clinical treatment of apoplectic aphemia with multi-needle puncture of scalp-points in combination with visual-listening-speech training].
Zhang, HM, 2007
)
0.34
"To compare therapeutic effects between body acupuncture and scalp acupuncture combined with body acupuncture on atherosclerotic cerebral infarction at acute stage."( [Comparison of therapeutic effects between body acupuncture and scalp acupuncture combined with body acupuncture on atherosclerotic cerebral infarction at acute stage].
Bao, F; Sun, H; Wang, DH; Wang, FQ; Zhang, YX, 2008
)
0.35
" They were treated respectively by scalp acupuncture combined with body acupuncture and simple body acupuncture."( [Comparison of therapeutic effects between body acupuncture and scalp acupuncture combined with body acupuncture on atherosclerotic cerebral infarction at acute stage].
Bao, F; Sun, H; Wang, DH; Wang, FQ; Zhang, YX, 2008
)
0.35
"Acupuncture can improve mind, speech and limb motor function of the patient with atherosclerotic cerebral infarction at acute stage, and the therapeutic effect of scalp combined with body acupuncture is better than that of simple body acupuncture."( [Comparison of therapeutic effects between body acupuncture and scalp acupuncture combined with body acupuncture on atherosclerotic cerebral infarction at acute stage].
Bao, F; Sun, H; Wang, DH; Wang, FQ; Zhang, YX, 2008
)
0.35
" The drug interaction with human serum albumin (HSA) has been an important component in understanding its mechanism of action, especially in drug distribution and in drug-drug interaction on HSA in the case of multi-drug therapy."( A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography.
Chen, L; Huang, M; Meehan, EJ; Yang, F; Zhu, L, 2008
)
0.35
"Adopting single-blind, randomized controlled method, 90 cases of cerebral thrombosis at convalescent period were assigned to 3 groups: a scalp acupuncture group (group A), a rehabilitation therapy group (group B) and a scalp acupuncture combined with rehabilitation therapy group (group C)."( [Effects of scalp acupuncture combined with rehabilitation therapy on motor function in the hemiplegic patient of cerebral thrombosis at convalescent period].
Huang, GF; Zhang, HX; Zhang, TF, 2008
)
0.35
"We report a new simple method of cranial reconstruction using an autologous split calvarial bone, combined with free graft of temporal loose areolar tissue."( [A cranial reconstruction using an autologous split calvarial bone combined with a free graft of temporal loose areolar tissue].
Houkin, K; Kamoshima, Y; Oyama, A; Shimoda, Y; Terasaka, S; Warabi, T, 2012
)
0.38
" The in vivo antithrombotic property of ibudilast (CAS 50847-11-5), a phosphodiesterase 4 (PDE4) inhibitor, was evaluated in a photochemically-induced guinea pig carotid artery thrombosis model in combination with low-dose ASA."( Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury.
Hoshina, K; Manita, S; Matsuzawa, S; Miyata, Y; Ooie, T; Sasahara, T; Sueyoshi, S; Yasue, T, 2012
)
0.38
" Using on-line HPLC purification combined with SAXS measurements, the most likely apo and ATP-bound protein conformations in solution were determined."( Determination of the GH3.12 protein conformation through HPLC-integrated SAXS measurements combined with X-ray crystallography.
Brown, E; Jez, JM; Kapp, U; Marcellin, R; Round, A; Westfall, CS; Zubieta, C, 2013
)
0.39
"To compare the therapeutic differences among scalp acupuncture combined with auricular point sticking, body acupuncture and western medication for treatment of vascular dementia (VD)."( [Effects of scalp acupuncture combined with auricular point sticking on cognitive behavior ability in patients with vascular dementia].
Ding, DM; Huang, HY; Li, SK; Ma, L; Wu, XH; Zhang, ZL, 2014
)
0.4
"The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets."( [Effects of scalp acupuncture combined with auricular point sticking on cognitive behavior ability in patients with vascular dementia].
Ding, DM; Huang, HY; Li, SK; Ma, L; Wu, XH; Zhang, ZL, 2014
)
0.4
"Imiquimod 5% cream as a monotherapy or in combination with SA can be used safely in children with warts and is equally effective and more effective than cryotherapy in plantar warts."( Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: A randomized study.
Antoniou, C; Katsarou, A; Kontochristopoulos, G; Kouris, A; Lagogiani, I; Stefanaki, C, 2016
)
0.43
"To evaluate efficacy and tolerability of a twice-daily, three-product skincare regimen using AHA-RC in combination with BHA for patients with acne."( Novel retinoid ester in combination with salicylic acid for the treatment of acne.
Draelos, Z; Lewis, J; McHugh, L; Pellegrino, A; Popescu, L, 2016
)
0.7
"To investigate the therapeutic effect of scalp expanded flap combined with JPL hair removal for large area scar on forehead."( [Scalp expanded flap combined with IPL hair removal for large area scar on forehead].
Hongwei, Y; Hua, L; Hui, G; Li, C; Li, Z; Peng, W; Xia, Y, 2015
)
0.42
" 2012, 9 cases with large area scar on forehead received treatment of adjacent scalp expanded flap combined with JPL hair removal."( [Scalp expanded flap combined with IPL hair removal for large area scar on forehead].
Hongwei, Y; Hua, L; Hui, G; Li, C; Li, Z; Peng, W; Xia, Y, 2015
)
0.42
"5% 5-fluorouracil solution in combination with 10% salicylic acid (low-dose 5-FU/SA) are mostly related to lesions appearing on the head and face."( Low-dose 5-fluorouracil in combination with salicylic acid for the treatment of actinic keratoses on the hands and/or forearms - results of a non-interventional study.
Hadshiew, I; Melzer, A; Prechtl, A; Reinhold, U, 2017
)
0.97
"SA peel combined with vitamin C mesotherapy is a safe and effective alternative for the treatment of melasma with no significant side effects and minimal downtime."( Salicylic acid peeling combined with vitamin C mesotherapy versus salicylic acid peeling alone in the treatment of mixed type melasma: A comparative study.
Balevi, A; Özdemir, M; Ustuner, P, 2017
)
1.9
" The SA and Put were applied alone as well as in combination with plant growth promoting rhizobacteria (PGPR)."( Effects of exogenously applied salicylic acid and putrescine alone and in combination with rhizobacteria on the phytoremediation of heavy metals and chickpea growth in sandy soil.
Bano, A; Khan, N, 2018
)
0.77
"To assess treatment methods, interim results, and complications of absolute ethanol embolization combined with surgical resection of scalp arteriovenous malformations (AVMs)."( Absolute Ethanol Embolization Combined with Surgical Resection of Scalp Arteriovenous Malformations: Interim Results.
Fan, X; Han, Y; Su, L; Wang, Z, 2018
)
0.48
"On the basic therapy, to assess the clinical effects of dynamic scalp acupuncture, scalp acupuncture combined with proprioceptive neuromuscular facilitation (PNF) therapy and simple PNF therapy for upper limb motor impairment in ischemic post-stroke spastic hemiplegia."( [Dynamic scalp acupuncture combined with PNF therapy for upper limb motor impairment in ischemic stroke spastic hemiplegia].
Chen, W; Chu, L; Han, Z; Ling, J; Lu, J; Qi, L; Wang, H; Wang, Z; Xu, W; Zhou, Y, 2018
)
0.48
"To investigate the feasibility and therapeutic effect of frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi."( [Frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi].
Chen, C; Li, B; Li, W; Sun, Z, 2017
)
0.46
"From January 2013 to December 2015,6 cases with congenital facial giant nevi were treated with expanded frontal and scalp skin flap combined with laser hair removal in the department of plastic surgery, An Zhen Hospital, Capital Medical University."( [Frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi].
Chen, C; Li, B; Li, W; Sun, Z, 2017
)
0.46
"To observe the clinical effect of scalp acupuncture combined with cognitive training on cognitive disorder after cerebral injury."( Clinical observation of 60 cases of treating cognitive disorder after cerebral injury in combination with scalp acupuncture and cognitive training.
Chen, J; Du, J; He, M; Liu, L; Yin, J, 2018
)
0.48
" To compare the efficacy and safety of fractional Er:Glass laser used in combination with topical 5% minoxidil versus 5% minoxidil alone for the treatment of male AGA, 30 men with AGA were randomized to 24 weeks of split-scalp treatment using fractional Er:Glass laser and 5% minoxidil on one side (combined therapy) or 5% minoxidil alone on the other side (monotherapy)."( A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Khunkhet, S; Rojhirunsakool, S; Suchonwanit, P, 2019
)
0.51
" This study investigated the effect of scalp electroacupuncture combined with Memantine in VaD."( The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study.
Gao, J; Han, X; Huang, L; Mao, E; Wu, G; Yue, A; Zhou, B, 2020
)
0.56
"To explore the effect of dynamic scalp acupuncture combined with task-oriented mirror therapy (TOMT) for upper limb motor function and activity ability of daily living in patients with hemiplegia after ischemic stroke."( [Clinical observation of dynamic scalp acupuncture combined with task-oriented mirror therapy for upper limbs function impairment in patients with hemiplegia after ischemic stroke].
Ge, S; Huang, LH; Meng, ZX; Yin, ZL; Zhang, MJ, 2020
)
0.56
"The dynamic scalp acupuncture combined with TOMT treatment can effectively improve the upper limb function and the activities ability of daily living in patients with hemiplegia after ischemic stroke, which is better than TOMT after scalp acupuncture and simple TOMT treatment."( [Clinical observation of dynamic scalp acupuncture combined with task-oriented mirror therapy for upper limbs function impairment in patients with hemiplegia after ischemic stroke].
Ge, S; Huang, LH; Meng, ZX; Yin, ZL; Zhang, MJ, 2020
)
0.56
"In this study, we investigated the effects of intense pulsed light (IPL) combined with 30% supramolecular salicylic acid on facial seborrheic dermatitis."( Clinical study on treatment of facial seborrheic dermatitis with intense pulsed light combined with 30% supramolecular salicylic acid.
Gu, RL; Wang, SQ, 2020
)
0.98
"IPL combined with 30% supramolecular salicylic acid was effective in the treatment of facial seborrheic dermatitis and provided a quicker result with no adverse reactions."( Clinical study on treatment of facial seborrheic dermatitis with intense pulsed light combined with 30% supramolecular salicylic acid.
Gu, RL; Wang, SQ, 2020
)
1.04
"After ethics committee approval and informed consent, 56 adult patients were enrolled, and randomly assigned to receive a selective scalp block combined with incision line infiltration preoperatively or postoperatively."( Preoperative Versus Postoperative Scalp Block Combined With Incision Line Infiltration for Pain Control After Supratentorial Craniotomy.
Bilotta, F; Kulikov, A; Lubnin, A; Pugliese, F; Sergi, PG; Tere, V, 2021
)
0.62
" Patients assigned to receive a scalp block combined with incision line infiltration preoperatively needed less intraoperative opioids than those assigned to postoperative scalp block."( Preoperative Versus Postoperative Scalp Block Combined With Incision Line Infiltration for Pain Control After Supratentorial Craniotomy.
Bilotta, F; Kulikov, A; Lubnin, A; Pugliese, F; Sergi, PG; Tere, V, 2021
)
0.62
" This article introduces an approach to reconstruct total facial injuries with a prefabricated expanded thoracic flap combined with an expanded scalp flap (called combined flaps), which not only solves the limitations of blood supply and expanded volume but also reduces patchwork scars."( Prefabricated Expanded Flap Combined With Expanded Scalp Flap for Total Face Resurfacing.
Char, S; Liu, Y; Shi, Y; Sun, H; Tan, X; Wang, X; Yang, C; Yao, J; Yao, P, 2021
)
0.62
"To observe the improvement of stroke patients' ability to participate in daily activities by using Scalp acupuncture therapy combined with exercise."( Scalp acupuncture therapy combined with exercise can improve the ability of stroke patients to participate in daily activities.
Hu, X; Li, B; Wang, X, 2021
)
0.62
"The scores of Barthel index of all groups were higher than those before treatment, and the scalp acupuncture for 2 h combined with rehabilitation training group had the highest score."( Scalp acupuncture therapy combined with exercise can improve the ability of stroke patients to participate in daily activities.
Hu, X; Li, B; Wang, X, 2021
)
0.62
"Scalp acupuncture therapy combined with exercise therapy can significantly improve the ability of stroke patients to participate in daily activities; 2 h of scalp acupuncture combined with exercise therapy had the most significant effect."( Scalp acupuncture therapy combined with exercise can improve the ability of stroke patients to participate in daily activities.
Hu, X; Li, B; Wang, X, 2021
)
0.62
"To compare the efficacy of scalp acupuncture combined with lower-limb intelligent feedback training and lower-limb intelligent feedback training alone for lower-limb motor dysfunction after stroke."( [Scalp acupuncture combined with lower-limb intelligent feedback training for lower-limb motor dysfunction after stroke: a randomized controlled trial].
Li, QF; Liang, WR; Pan, XH; Wang, YL; Zhang, CX; Zhang, SH; Zhou, MC, 2021
)
0.62
" In addition, the patients in the observation group were treated with scalp acupuncture combined with lower-limb intelligent feedback training."( [Scalp acupuncture combined with lower-limb intelligent feedback training for lower-limb motor dysfunction after stroke: a randomized controlled trial].
Li, QF; Liang, WR; Pan, XH; Wang, YL; Zhang, CX; Zhang, SH; Zhou, MC, 2021
)
0.62
"The scalp acupuncture combined with lower-limb intelligent feedback training could reduce the muscle tension of lower limbs, promote the separation movement mode of lower limbs, improve the plantar pressure distribution, and improve the balance ability and walking ability in stroke patients, and the curative effect is better than lower-limb intelligent feedback training alone."( [Scalp acupuncture combined with lower-limb intelligent feedback training for lower-limb motor dysfunction after stroke: a randomized controlled trial].
Li, QF; Liang, WR; Pan, XH; Wang, YL; Zhang, CX; Zhang, SH; Zhou, MC, 2021
)
0.62
" This prospective open-label observational single-arm study examined efficacy and safety of simulated daylight (SDL)-PDT using the IndoorLux® system in combination with 5-aminolevulinic acid gel (BF-200 ALA)."( No room for pain: A prospective study showing effective and nearly pain-free treatment of actinic keratosis with simulated daylight photodynamic therapy (SDL-PDT) using the IndoorLux® System in combination with BF-200 ALA (Ameluz®).
Bai-Habelski, JC; Medrano, K; Palacio, A; Reinhold, U, 2022
)
0.72
"This study introduces fluocinolone acetonide (FA) microemulsion in combination with ablative fractional lasering as a new effective treatment for scalp psoriasis."( Fluocinolone Acetonide Microemulsion in Combination with a Fractional Laser for the Treatment of Scalp Psoriasis.
Muangsiri, W; Vejjabhinanta, V; Werawatganone, P, 2022
)
0.72
" We assessed the time-dependent biological impact induced by environmental concentrations of caffeine alone (CAF; 5 ng/L to 10 µg/L) and its combination with salicylic acid (CAF+SA; 5 ng/L+0."( Comparison of cellular mechanisms induced by pharmaceutical exposure to caffeine and its combination with salicylic acid in mussel Mytilus galloprovincialis.
Afsa, S; Ben Mansour, H; Billè, B; Cappello, T; De Marco, G; Galati, M; Parrino, V, 2022
)
1.13
" In this study, we present an alternative technique to reconstruct the aesthetic units using an expanded scalp flap combined with laser hair removal."( Expanded scalp flap combined with laser hair removal to reconstruct facial defects around the hairline.
Chu, F; Ding, J; Liu, S; Ma, X; Tang, Y; Yu, Z, 2022
)
0.72
"The expanded scalp flap combined with laser hair removal is a feasible and effective technique to reconstruct both sides of the hairline simultaneously from a single donor site with a good colour match and a similar texture and thickness."( Expanded scalp flap combined with laser hair removal to reconstruct facial defects around the hairline.
Chu, F; Ding, J; Liu, S; Ma, X; Tang, Y; Yu, Z, 2022
)
0.72
"Honey combined with silver may be an effective method for the treatment of chronic scalp wounds."( Honey combined with silver ion dressing in complicated chronic wound of the scalp: a case report.
Li, ZP; Lin, JQ; Liu, HY; Yang, LL; Yang, X; Zeng, XH; Zhang, Y, 2022
)
0.72
"This study aimed to analyze the effect of traditional Chinese medicine-based rehabilitation nursing combined with scalp acupuncture (TCMRN + SA) on negative emotions and the quality of life of patients with stroke."( Effect of traditional Chinese medicine-based rehabilitation nursing combined with scalp acupuncture on negative emotions and quality of life of patients with stroke: A randomized controlled trial.
Cai, J; Li, J; Sun, Q; Xie, J, 2022
)
0.72
"To determine the efficacy of supramolecular salicylic acid combined with doxycycline on acne, totally 70 patients with acne treated in our dermatology department from May 2020 to May 2021 were enrolled and randomized (1:1) into control or experimental groups using the random number table method."( Efficacy of supramolecular salicylic acid in combination with doxycycline in the treatment of acne.
Liu, Y; Long, T; Meng, Z; Shang, W; Yang, J, 2023
)
1.47
" Given the limitations of existing evidence, we conducted a systematic evaluation to assess the effectiveness of SA in combination with conventional therapy (CT) for intervening in PSD."( Efficacy of scalp acupuncture combined with conventional therapy in the intervention of post-stroke depression: A systematic review and meta-analysis.
Chen, J; Cheng, H; Kong, X; Li, J; Liu, D; Liu, P; Ou, X; Pan, Z; Zhong, D, 2023
)
0.91
"A total of 11 articles were included, and a meta-analysis was conducted to evaluate the effectiveness of SA combined with CT for treating PSD."( Efficacy of scalp acupuncture combined with conventional therapy in the intervention of post-stroke depression: A systematic review and meta-analysis.
Chen, J; Cheng, H; Kong, X; Li, J; Liu, D; Liu, P; Ou, X; Pan, Z; Zhong, D, 2023
)
0.91
"While the effectiveness of SA combined with CT in treating PSD still requires further validation through rigorous randomized double-blind trials, this study provides a comprehensive collection of studies that meet the criteria for SA combined with CT in PSD treatment."( Efficacy of scalp acupuncture combined with conventional therapy in the intervention of post-stroke depression: A systematic review and meta-analysis.
Chen, J; Cheng, H; Kong, X; Li, J; Liu, D; Liu, P; Ou, X; Pan, Z; Zhong, D, 2023
)
0.91
"This study aimed to assess the efficacy of Jiao's scalp acupuncture in combination with Xiangshao granules on chronic tension-type headache (CTTH) with concomitant nonalcoholic fatty liver disease (NAFLD) in climacteric women."( Efficacy of Jiao's scalp acupuncture in combination with Xiangshao granules on chronic tension-type headache with concomitant nonalcoholic fatty liver disease in climacteric women.
Hu, WJ; Pei, F; Zhao, YL, 2023
)
0.91
"Jiao's scalp acupuncture, in combination with Xiangshao granules, was superior in treating CTTH in climacteric women compared with either acupuncture or medication."( Efficacy of Jiao's scalp acupuncture in combination with Xiangshao granules on chronic tension-type headache with concomitant nonalcoholic fatty liver disease in climacteric women.
Hu, WJ; Pei, F; Zhao, YL, 2023
)
0.91
"To evaluate the safety and efficacy of FUE when combined with an expanded scalp flap for facial organ reconstruction."( Hair follicle extraction combined with an expanded scalp flap for facial organ reconstruction.
Fan, Z; Gan, Y; Hu, Z; Le, D; Liu, B; Mao, X; Miao, Y; Qu, Q; Sun, P; Zhang, J, 2023
)
0.91
" CHG can be combined with salicylic acid to exhibit synergistic antiviral activity at lower concentrations and reduce the time required for inactivation."( Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic acid.
Arefian, E; Jamshidinia, N; Mohammadipanah, F; Saadatpour, F, 2023
)
1.41

Bioavailability

Salicylic acid is more sensitive to systemic anaphylaxis than that of poorly absorbed drugs. The relative bioavailability of salicylic Acid was 105.

ExcerptReferenceRelevance
"The effect of antacid on aspirin pharmacokinetics and bioavailability was determined in 10 healthy adult male and female volunteers, aged 20-45 years old."( The effect of antacid on aspirin pharmacokinetics in healthy Thai volunteers.
Chaiyos, N; Itthipanichpong, C; Sirivongs, P; Wittayalertpunya, S, 1992
)
0.28
"Bioavailability studies have been performed with ten healthy volunteers on different dosage forms of acetylsalicylic acid (ASA) in order to assess the bioavailability of two different ASA gums compared with commercial ASA tablets."( Bioavailability of two formulations of acetylsalicylic acid gums.
Bianchi, A; Bonina, FP; Bousquet, E; Ciampini, N; Montenegro, L; Tirendi, S, 1992
)
0.76
" We found that salicylic acid absorption from this solution was delayed but complete whereas the absorption of atenolol, cimetidine, frusemide and hydrochlorothiazide was four- to five-fold lower than expected from oral bioavailability studies."( Absorption of polar drugs following caecal instillation in healthy volunteers.
Kim, M; Riley, SA; Rowland, M; Sutcliffe, F; Turnberg, LA, 1992
)
0.64
" Salicylate is well absorbed across normal and diseased skin."( Refractory hypoglycemia secondary to topical salicylate intoxication.
Arnold-Capell, PA; Curry, SC; Raschke, R; Richeson, R, 1991
)
0.28
" The absorption rate was independent of the amount of un-ionized drug, which varied with the pH of the solution."( In situ perfusion system for oral mucosal absorption in dogs.
Mizobe, M; Noda, K; Samejima, M; Suzuki, T; Yamahara, H, 1990
)
0.28
" Apart from the potential advantages in terms of improved gastric tolerability, the increased rate of absorption of aspirin solutions is therapeutically useful whenever a rapid onset of action is required."( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects.
Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989
)
0.6
" At low etidronate concentrations and short exposure times, the salicylic acid absorption rate was significantly increased compared with saline controls."( Dose-dependent effect of calcium and magnesium etidronate on salicylic acid absorption in the rat.
Dittert, LW; Shrewsbury, RP; Wurster, DE, 1985
)
0.75
"Rectal bioavailability of Ara-C (serum AUC 4 h: 65 micrograms h-1 ml-1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 micrograms h-1 ml-1)."( Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C.
Engle, KK; Higuchi, T; Liversidge, GG; Nishihata, T, 1986
)
0.27
" The rate of absorption of ASA was faster and its peak plasma concentration was higher after the ingestion of CT."( The absorption of acetylsalicylic acid from an enteric-coated formulation and the inhibition of thromboxane formation.
Anttila, M; Kahela, P; Uotila, P, 1988
)
0.58
" From the above results, it was concluded that this in situ experimental model of rectal absorption has advantages in that it can be used directly to measure the rectal absorption rate and to determine ratios of easily metabolized and poorly absorbed drugs."( An in situ experimental model in rabbits for the study of rectal absorption.
Hiura, M; Kasama, T; Mayuzumi, K; Minato, M; Minohara, K; Nakai, M; Ohshiro, K; Sakaguchi, Y, 1986
)
0.27
" The method described can be used to assess the bioavailability of keratolytic agents incorporated in topical formulations."( In vivo measurement of the keratolytic effect of salicylic acid in three ointment formulations.
Nook, TH, 1987
)
0.53
" Furthermore, the luminal stirring increased the absorption rate constant for salicylic acid."( Studies on drug absorption from oral cavity. II. Influence of the unstirred water layer on absorption from hamster cheek pouch in vitro and in vivo.
Hamada, C; Hisaichi, S; Kimura, T; Kurosaki, Y; Nakayama, T, 1987
)
0.5
"The bioavailability and pharmacokinetics of acetylsalicylic acid were studied in 6 volunteers, under a cross-over design, using plain compressed aspirin, two buffered preparations and an enteric-coated tablet."( Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
Cerletti, C; de Gaetano, G; Dejana, E; Galletti, F; Latini, R; Marzot, M; Urso, R, 1986
)
0.52
"The bioavailability of enteric coated and plain aspirin tablets was studied in four beagle dogs."( Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets.
Amidon, GL; Fleisher, D; Lui, CY; Oberle, R, 1986
)
0.27
" Total urinary recovery, and recovery of salicyluric acid and the two SA glucuronides were not different, thus confirming the equivalent bioavailability and metabolite profile of the 2 ASA formulations."( Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets.
Montgomery, PR; Sitar, DS,
)
0.61
" The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application."( [The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate].
Altmayer, P; Cattarius-Korb, S; Krüger, B; Lang, E; Mutschler, E; Sörgel, F; Spahn, H, 1985
)
0.77
" This suggests that the intestinal absorption of rapidly absorbed drugs, including salicylic acid, is more sensitive to systemic anaphylaxis than that of poorly absorbed drugs."( Effect of systemic anaphylaxis on the absorption of salicylic acid from the rat small intestine.
Kimura, T; Nakamura, J; Sezaki, H; Takada, S; Yamamoto, A, 1984
)
0.74
"The 3 acetylsalicylic acid preparations showed at normal patients at the same elimination phase no significant differences concerning the bioavailability (comparison of the area under the concentration-time-curve)."( [Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin].
Berlet, G; Chemnitius, KH; Schröber, R; Traeger, A; Zaumseil, J, 1984
)
0.65
" A significantly faster absorption rate was observed with the sodium bicarbonate-citrate buffer, when compared with the potassium bicarbonate-citrate buffer and the unbuffered tablets, which were equivalent."( Comparative aspirin absorption kinetics after administration of sodium- and potassium-containing buffered solutions.
Mason, WD, 1984
)
0.27
" During the absorption phase isofezolac plasma levels were slightly decreased in association with isofezolac-aspirin, but bioavailability of isofezolac was not modified."( The effect of antacid and aspirin on the bioavailability of isofezolac in man.
Flouvat, B; Henry, JF; Rocher, I, 1984
)
0.27
" This method has been applied to human bioavailability studies and the data are presented."( Improved method for the determination of aspirin and its metabolites in biological fluids by high-performance liquid chromatography: applications to human and animal studies.
Beach, CA; Bianchine, JR; Gerber, N; Kershaw, RA; Mays, DC; Sharp, DE, 1984
)
0.27
" Phenylalanine and phenylalanylglycine, both poorly absorbed across the rectal membrane when administered alone, did not enhance the rectal absorption of either antibiotic."( The effects of salicylate on the rectal absorption of phenylalanine and some peptides, and the effects of these peptides on the rectal absorption of cefoxitin and cefmetazole.
Higuchi, T; Lee, CS; Nishihata, T; Rytting, JH; Yamamoto, M, 1984
)
0.27
"The effect of a saline cathartic combined with activated charcoal or activated charcoal alone on aspirin bioavailability was characterized in six healthy volunteers."( Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal.
Anderson, WH; Czajka, PA; Mowry, JB; Sketris, IS; Stafford, DT, 1982
)
0.26
" In order to compare the bioavailability of unchanged ASA from rapid- and slow-release formulations, the single-dose concentration profiles of ASA and SA were studied in healthy volunteers following intake of two different rapid-release (conventional and effervescent tablets) and three different slow-release (microencapsulated ASA in tablets and in capsules, and enteric-coated tablets) formulations of ASA, and of one slow-release formulation of sodium salicylate."( Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol.
Brantmark, B; Melander, A; Wåhlin-Boll, E, 1982
)
0.57
"kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively."( Effect of interstitial cystitis on drug absorption from urinary bladder.
Au, JL; Buffington, CA; Gao, X, 1994
)
0.29
"An optical whole-cell biosensor based on a genetically engineered bioluminescent catabolic reporter bacterium was developed for continuous on-line monitoring of naphthalene and salicylate bioavailability and microbial catabolic activity potential in waste streams."( Optical biosensor for environmental on-line monitoring of naphthalene and salicylate bioavailability with an immobilized bioluminescent catabolic reporter bacterium.
Bienkowski, PR; Heitzer, A; Malachowsky, K; Sayler, GS; Thonnard, JE; White, DC, 1994
)
0.29
" Insulin rectal bioavailability was quantitated through the measurement of its hypoglycaemic effect and of its serum levels."( Effect of sodium salicylate on insulin rectal absorption in humans.
el-Ahmady, O; el-Damacy, H; el-Kabbany, N; el-Shattawy, H; Gamal-el-Deen, S; Hosny, E, 1994
)
0.29
" Their lymphatic bioavailability (central lymph), their biotransformation and urinary excretion in rats were also studied."( Effect of plasma binding of ortho- and para-I-benzoates on their distribution in blood and into lymph, biotransformation and excretion in rat urine.
Gallová, S; Kvĕtina, J; Lamka, J; Láznícek, M; Rudisar, L,
)
0.13
" Neither differences in bioavailability of ASA nor the formation of SA seems to contribute to the aspirin-elicited reactions."( Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects.
Anderson, P; Andersson, R; Boréus, LO; Dahlén, B; Zetterström, O, 1994
)
0.66
" Thus, the rate of transport of drug into blood circulation after oral administration may significantly differ from the true rate of absorption through the gut membrane."( First-pass accumulation of salicylic acid in gut tissue after absorption in anesthetized rat.
Chiou, WL; Choi, YM; Chung, SM, 1995
)
0.59
" Estimates of the absorption rate constant from the dermis and the elimination rate constant from the perfused limb were made by the simultaneous fitting of absorption and efflux data with a one-compartmental pharmacokinetic model."( The effect of protein binding on the deep tissue penetration and efflux of dermally applied salicylic acid, lidocaine and diazepam in the perfused rat hindlimb.
Cross, SE; Roberts, MS; Wu, Z, 1996
)
0.51
" fruit extract incorporated in a traditional meal on the bioavailability of aspirin tablets 600 mg dose was studied in 6 healthy volunteers."( Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers.
Aguye, IA; Mustapha, A; Yakasai, IA,
)
0.13
"The objective of the present work was to determine the relative bioavailability of salicylic acid (SA) after repeated (14-day) topical application to subjects who presented normal, acnegenic, or photodamaged facial skin."( Percutaneous absorption of salicylic acid after repeated (14-day) in vivo administration to normal, acnegenic or aged human skin.
Davis, DA; Kraus, AL; Odio, MR; Olerich, M; Thompson, GA, 1997
)
0.82
" These results demonstrate that salicylic acid is well absorbed by healthy skin."( Percutaneous absorption of salicylic acid in man after topical administration of three different formulations.
Gabard, B; Rufli, T; Schwarb, FP; Surber, C, 1999
)
0.88
" Salicylate is well absorbed by normal and diseased skin."( [Acute salicylate intoxication after trancutaneous absorption].
D'Orlando, L; Mercante, WP; Pertoldi, F,
)
0.13
" The greatest topical bioavailability was observed for the alcoholic solution containing glycerol (SA)."( Distribution of salicylic acid in human stratum corneum following topical application in vivo: a comparison of six different formulations.
Chuang, S; Hsu, M; Sheu, H; Tsai, J, 1999
)
0.65
" With a single administration of 100 mg/kg of the extract, aspirin blood levels remained unchanged, but salicylic acid bioavailability was reduced in 44% compared with control animals."( Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat.
Castañeda-Hernández, G; Cruz, L; Navarrete, A, 1999
)
0.52
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" It is present in the diet, and the hepatic and duodenal sulphation might limit the bioavailability of this compound."( Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum.
De Santi, C; Mosca, F; Pacifici, GM; Pietrabissa, A; Spisni, R, 2000
)
0.31
" Renal excretion rate, elimination half-life and total bioavailability of salicylates were calculated."( Pharmacokinetics of salicin after oral administration of a standardised willow bark extract.
Heide, L; Kötter, I; Schmid, B, 2001
)
0.31
" Differences in corticosteroid bioavailability could account for differences in efficacy."( Bioavailability of clobetasol propionate in different vehicles.
Feldman, SR; Franz, TJ; Lehman, PA; Spellman, MC,
)
0.13
" Lack of interaction was assessed by determination of pharmacokinetic characteristics and relative bioavailability of both substances and salicylic acid (CAS 69-72-7, SA), administered in combination and as equally single dosed drugs."( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.75
" The purpose of this open, randomized, three-factorial (three-treatment, three-period, six-sequence) Latin Square clinical study was to investigate the relative bioavailability of ASA and PSE as well as the establishment of bioequivalence after single administration of the fixed combination (final formulation for approval) of 500 mg ASA/30 mg PSE*HCl and the preliminary formulation of this combination."( Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.54
" The relative bioavailability of salicylic acid was 105."( [Study on relative bioavailability of aspirin in afenca tablet].
He, L; Jiang, X; Li, S; Lin, S; Yang, J; Zhou, J, 2003
)
0.6
"Phenolic acids such as p-coumaric acid and microbial metabolites of poorly absorbed polyphenols are absorbed by the monocarboxylic acid transporter (MCT)-mediated transport system which is identical to the fluorescein/H(+) cotransport system."( Non-involvement of the human monocarboxylic acid transporter 1 (MCT1) in the transport of phenolic acid.
Konishi, Y; Tohjo, Y; Watanabe, H; Yashiro, T, 2006
)
0.33
"Impairment of nitric oxide bioavailability secondary to increased arginase activity and overproduction of reactive oxygen species (ROS) is thought to be a major cause of vascular complications in sickle cell disease (SCD)."( Cysteine-iron promotes arginase activity by driving the Fenton reaction.
Iyamu, EW; Perdew, H; Woods, GM, 2008
)
0.35
"The present study describes the phenanthrene-degrading activity of Sphingomonas paucimobilis 20006FA and its ability to promote the bioavailability of phenanthrene."( Study of the degradation activity and the strategies to promote the bioavailability of phenanthrene by Sphingomonas paucimobilis strain 20006FA.
Berthe-Corti, L; Coppotelli, BM; Del Panno, MT; Dias, RL; Ibarrolaza, A; Morelli, IS, 2010
)
0.36
"A 3-step acne system has been developed to enhance the bioavailability and follicular penetration of benzoyl peroxide (BPO)."( A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide.
Del Rosso, JQ; Eichenfield, L; Parr, L; Shalita, A; Swinyer, L; Tanghetti, E; Thiboutot, D; Tschen, E, 2009
)
0.35
" The EPs also play an important role in specific absorption rate calculation, a major concern in high-field MRI, as well as in nonmedical areas such as wireless telecommunications."( Imaging electric properties of biological tissues by RF field mapping in MRI.
He, B; Zhang, X; Zhu, S, 2010
)
0.36
" Biosurfactants can increase soil-sorbed PAHs desorption, solubilisation, and dissolution into the aqueous phase, which increases the bioavailability of PAHs for microbial metabolism."( The role of salicylate and biosurfactant in inducing phenanthrene degradation in batch soil slurries.
Elliot, R; Gottfried, A; Singhal, N; Swift, S, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
" Food products with good bioavailability of iron and calcium should be recommended for women of childbearing age in all age groups."( A comparison of levels of select minerals in scalp hair samples with estimated dietary intakes of these minerals in women of reproductive age.
Suliburska, J, 2011
)
0.37
" Recent results with the bicyclic salicylic acid pharmacophores indicate that the new chemistry platform may provide a potential solution to overcome the bioavailability issue that has plagued the PTP drug discovery field for many years."( Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors.
He, R; He, Y; Liu, S; Yu, ZH; Zeng, LF; Zhang, ZY, 2012
)
0.93
" Furthermore, the bepotastine salicylate-loaded tablet was prepared by the wet granulation method, and the dissolution and bioavailability in beagle dogs were evaluated compared to the bepotastine besilate-loaded commercial product."( Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs.
Cho, KH; Choi, HG, 2013
)
0.39
" These findings suggest that cigarette smoke-induced modifications of HSA may affect the binding, transport and bioavailability of specific ligands in smokers."( Cigarette smoke induces alterations in the drug-binding properties of human serum albumin.
Clerici, M; Colombo, G; Colombo, R; Dalle-Donne, I; Gagliano, N; Giustarini, D; Milzani, A; Portinaro, N; Rossi, R; Secundo, F, 2014
)
0.4
" The bioavailability of salicylic acid differs depending on the vehicle used and pH of transcellular fluids."( A review of toxicity from topical salicylic acid preparations.
Levitt, J; Madan, RK, 2014
)
0.99
" It is important to understand the bioavailability of aspirin and its major metabolite, salicylic acid, since dosage and route of administration can vary for treating differing diseases, and the major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent."( Bioavailability of aspirin in rats comparing the drug's uptake into gastrointestinal tissue and vascular and lymphatic systems: implications on aspirin's chemopreventive action.
Dial, EJ; Edler, S; Fang, D; Li-Geng, T; Lichtenberger, LM; Phan, T; Philip, J, 2016
)
0.66
" Further, the dermatokinetic studies also confirmed better permeation and enhanced skin bioavailability of SA to epidermis as well as dermis vis-à-vis the CGF."( Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model.
Devi, N; Jain, A; Katare, OP; Sharma, G; Thakur, K, 2018
)
0.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Bioavailability and the rate of anabolic steroid testosterone metabolism can be affected upon UGT glucuronidation enzyme alteration."( Potential Assessment of UGT2B17 Inhibition by Salicylic Acid in Human Supersomes In Vitro.
Barker, J; Naughton, DP; Salhab, H, 2021
)
0.88
"Information about the chemical constituents of SJHK were collected, and druggable compounds were screened based on oral bioavailability and drug-likeness."( Network pharmacology and molecular docking approaches to elucidate the potential compounds and targets of Saeng-Ji-Hwang-Ko for treatment of type 2 diabetes mellitus.
Ahn, D; Chung, SJ; Jeong, S; Kim, H; Kim, HH; Kim, Y; Ko, M, 2022
)
0.72
"Plant-derived secondary metabolites (polyphenols/terpenes/alkaloids) and microbial exometabolites/membrane components of fermented tropical fruits are known as highly bioavailable biomolecules causing skin and hair improvement effects (wound healing, anti-inflammatory, antioxidant, antidiabetic, antiacne, skin/hair microbiota balancing, hair growth-promoting, and hair loss-inhibiting)."( Biomolecules of Fermented Tropical Fruits and Fermenting Microbes as Regulators of Human Hair Loss, Hair Quality, and Scalp Microbiota.
Chandler, DL; De Luca, C; Ibragimova, G; Kharaeva, Z; Korkina, L; Mayer, W; Trakhtman, I; Weibel, M, 2023
)
0.91

Dosage Studied

Salicylic acid, caffeine and metoprolol were individually dosed to the ligated stomach. The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic Acid (SA) metabolites were studied at three aspirin dosage regimens in patients with rheumatoid arthritis.

ExcerptRelevanceReference
" Thirty received betahistine hydrochloride (SERC) or placebo orally in fixed dosage for six months on a double-blind basis and were followed by ward behavioral and psychometric ratings."( Rheoencephalographic and other studies of betahistine in humans. IV. Prolonged administration with improvement in arteriosclerotic dementia.
Blatchley, RJ; Bohm, M; Fisher, R; Floam, J; Seipel, JH,
)
0.13
" Recombinant human (rHu) EPO (5000 units) in a dosing solution or in a rectal suppository was placed in the rectum of healthy rats and changes in serum EPO levels were monitored by an enzyme-linked immunosorbent assay."( Effects of salicylate and other enhancers on rectal absorption of erythropoietin in rats.
Kawanishi, G; Mizuno, A; Ueda, M, 1992
)
0.28
"To evaluate the efficacy and to determine the minimum effective dosage of four pediculicides against head louse infestation, as well as to select a safe, effective, practical, and cheap agent, 1,657 infested school children in 25 primary schools in Szu-Hu, Kou-Hu, and Ku-Keng Districts of Yunlin County were treated and 1,611 of them were examined."( Evaluation of efficacy of four pediculicides against head louse (Pediculus capitis) infestation.
Chow, CY; Chuang, CH; Chung, WC; Fan, PC; Hsu, HM; Kuo, CL; Lin, CY, 1992
)
0.28
"The lithium content of human hair shows an approximately linear response to extradietary lithium supplementation at dosage levels of up to 2000 micrograms/d."( Lithium in scalp hair of adults, students, and violent criminals. Effects of supplementation and evidence for interactions of lithium with vitamin B12 and with other trace elements.
Flores-Arce, MF; Schrauzer, GN; Shrestha, KP, 1992
)
0.28
"Bioavailability studies have been performed with ten healthy volunteers on different dosage forms of acetylsalicylic acid (ASA) in order to assess the bioavailability of two different ASA gums compared with commercial ASA tablets."( Bioavailability of two formulations of acetylsalicylic acid gums.
Bianchi, A; Bonina, FP; Bousquet, E; Ciampini, N; Montenegro, L; Tirendi, S, 1992
)
0.76
" Cyclosporine A did not produce any side effects because the administered dosage was relatively low."( Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies.
Hori, Y; Irie, M; Nakagawa, T; Nakayama, J; Teshima, H; Urabe, A, 1992
)
0.28
" The results show a dose-response relationship and the assay seems to be specific for alpha-MSH, because other peptides such as ACTH, beta-LPH and beta-endorphins do not compete for binding sites as alpha-MSH does."( Evidence for alpha-MSH binding sites on human scalp hair follicles: preliminary results.
Bos, JD; Ghanem, GE; Lejeune, FJ; Nanninga, PB; Westerhof, W, 1991
)
0.28
" Results of the present study indicates that 1% gamma-BHC emulsion is an effective pediculicide at a dosage of 5 ml or 10 ml."( Chemotherapy of head louse (Pediculus humanus capitis) infestation gamma benzene hexachloride (gamma-BHC) among school children in Szu-Hu District, Yunlin County, Central West Taiwan.
Chan, CH; Chao, D; Fan, PC; Lee, KM; Liu, HY, 1991
)
0.28
" The area under the plasma concentration-time curve of salicylic acid following the administration of salicylic acid to the oral mucosa with a film dosage form and the thickness of stratum corneum of each site were in inverse proportion to each other, suggesting that the stratum corneum layer represents the principle barrier to drug absorption."( Regional variation in oral mucosal drug absorption: permeability and degree of keratinization in hamster oral cavity.
Kimura, T; Kurosaki, Y; Nakayama, T; Nishimura, H; Takatori, T, 1991
)
0.53
"Electron microscopic examination of upper gastrointestinal biopsies with x-ray microanalysis was used to detect electron-dense particles of bismuth in the mucosa of the upper gastrointestinal tract, 30-60 minutes after oral dosing with either tripotassium dicitrato bismuthate [De-Noltab; Brocades (Great Britain) Ltd."( Transmucosal penetration of bismuth particles in the human stomach.
Hudson, M; Lewin, JF; Nwokolo, CU; Pounder, RE, 1992
)
0.28
" So the use of small dosage regimens of selezen to these patients can be proposed."( Blood binding of selezen (imidazole salicylate) in man.
Acuto, GC; Bianchini, C; de Santis, F; Morin, D; Tillement, JP; Zini, R, 1991
)
0.28
" Effects of these treatments on functional integrity of renal tissue was assessed from 0--72 h after dosing by measurement of urinary creatinine, GLU, and PRO, as well as excretion of proximal and distal tubular renal enzymes."( Comparative acute nephrotoxicity of salicylic acid, 2,3-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid in young and middle aged Fischer 344 rats.
Birnbaum, LS; Blair, PC; Clark, AM; McMahon, TF; Stefanski, SA; Wilson, RE, 1991
)
0.56
" Sections of skin from C3H and CF1 mice which were topically dosed with minoxidil (in vivo) showed no minoxidil-immunoreactivity."( Immunohistochemical and autoradiographic findings suggest that minoxidil is not localized in specific cells of vibrissa, pelage, or scalp follicles.
Buhl, AE; Diani, AR; Johnson, GA; Kawabe, TT; Knight, KA; Sawada, GA; Walker, CJ; Zelei, BV, 1990
)
0.28
"The patients reported in our previous paper were followed further, by analyzing hair samples collected monthly for 4 or 5 months, while growing hair continues to reflect the individual dosage history of haloperidol."( Human scalp hair as evidence of individual dosage history of haloperidol: longer-term follow-up study.
Sato, R; Uematsu, T, 1990
)
0.28
"The pharmacokinetic profile of an innovative formulation of soluble aspirin (l-ornithine acetylsalicylate, ldB 1003) was compared with that of conventional tablets and two other soluble dosage forms (d, l-lysine acetylsalicylate and a buffered effervescent formulation of acetylsalicylic acid) after administration of single oral doses in six normal volunteers."( Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects.
Attardo Parrinello, G; Barzaghi, N; Gatti, G; Perucca, E; Vitiello, B, 1989
)
0.78
" The initial dose probably saturates the skin for a period of time longer than the dosing intervals examined."( Absorption of minoxidil after topical application: effect of frequency and site of application.
Della-Coletta, AA; Eller, MG; Szpunar, GJ, 1989
)
0.28
" The volunteers also received 50 mg modified release capsules daily for 6 days to determine the effect on collagen, ADP and arachidonate induced platelet aggregation and thromboxane production, and to compare the pharmacokinetics after repeated dosing with the parameters obtained after the single dose."( Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.
Bochner, F; Lloyd, JV; Morris, PM; Siebert, DM; Williams, DB, 1988
)
0.27
" If decisions to alter salicylate dosage are made with due regard to the drug's saturation kinetics, measurements using either EMIT or ACA should allow the clinician to titrate patients' serum concentrations accurately within the narrow therapeutic range."( Clinical assessment of an enzyme immunoassay (EMIT) for measurement of serum salicylate.
Edwards, C; Hendeles, L, 1988
)
0.27
"Subjects (7 males and 7 females) were dosed with salicylic acid (1 g) and hourly urinary samples were analyzed for its metabolites."( Possible genetic influence on conjugate formation in salicylic acid metabolism.
Emudianughe, TS,
)
0.64
"Steady-state serum salicylic acid (SA) concentrations and the formation rates of salicyluric acid (SU), salicylphenolic glucuronide (SPG), salicylacyl glucuronide (SAG), and gentistic acid (GA), and the excretion rate of unchanged SA were determined in three normal subjects following the administration of a single oral dose of acetylsalicylic acid (ASA) 37 mg kg-1 and during multiple dosing with ASA 56 mg kg-1 day-1."( Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers.
Day, RO; Dromgoole, SH; Furst, DE; Paulus, HE,
)
0.46
"Buffered solid dosage forms containing aspirin, magnesium hydroxide, and aluminum hydroxide are blended with acidic ethanol to extract the aspirin and salicylic acid rapidly."( Determination of aspirin and salicylic acid by reverse-phase liquid chromatography.
Heidemann, DR; Schulenberg, ES; Smith, WH,
)
0.62
" It may lead to erroneous conclusions concerning patient compliance, unwarranted increases in salicylate dosage and resultant toxicity, and delay of appropriate therapeutic maneuvers."( Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis.
Baer, PA; Ikeman, RL; Shore, A, 1987
)
0.27
"The pharmacokinetics of salicyl phenolic glucuronide (SPG) and other salicylic acid (SA) metabolites were studied at three aspirin dosage regimens in eight patients with rheumatoid arthritis."( Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis.
Bochner, F; Cleland, LG; Graham, GG; Imhoff, DM; Polverino, A; Rolan, PE; Tregenza, RA, 1987
)
0.51
" CMT dosing was changed in 37 cases by using the formula: dosing rate = total clearance X concentration."( A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimens.
Blocka, K; Cassell, S; Dromgoole, S; Furst, DE; Harris, ER; Hirschberg, JM; Josephson, N; Paulus, HE; Rupp, PA; Trimble, RB, 1987
)
0.27
" The release of aspirin from its dosage form was detected by monitoring the change in intestinal pH."( Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets.
Amidon, GL; Fleisher, D; Lui, CY; Oberle, R, 1986
)
0.27
" During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight."( Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986
)
0.27
" There are many suggestions given in the literature for the therapy of the primary disease and of the skin, including long term therapy with high dosed rubifacient drugs or steroids."( [Livedo racemosa].
Lindemann, J; Rose, KG, 1986
)
0.27
" The drug dosing schedule was then reversed after 1 week."( Evaluation of a potential drug interaction between sucralfate and aspirin.
Chang, CW; Lau, AH; Schlesinger, PK, 1986
)
0.27
"Two elderly patients, who were chronically receiving aspirin, developed lethargy, incontinence, and confusion after dosing with acetazolamide."( Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.
Brandt, JL; Chapron, DJ; Feig, PU; Gomolin, IH; Kramer, PA; Sweeney, KR, 1986
)
0.27
" Piroxicam was comparable to indomethacin with respect to efficacy and offered better toleration and a simplified dosage regimen."( Piroxicam vs indomethacin: a double blind multicenter comparative study in osteoarthritis. A Canadian Multicenter Study.
, 1985
)
0.27
" Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced."( Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis.
Brown, RS; Goldlust, MB; Griffin, VL; Harrison, LI; Rosa, RM; Shang, SF; Weinblatt, M; Williams, ME, 1986
)
0.27
"A high unit dose (15 grain/975 mg) enteric coated aspirin preparation was studied in normal individuals and patients with arthritis to determine how readily well tolerated, therapeutic (150-300 micrograms/ml) salicylate (SA) levels could be achieved using a twice daily dosing regimen."( Aspirin dosing using 15 grain enteric coated tablets.
Feigal, D; Jang, H; Pollet, S; White, RH; Yim, CW, 1985
)
0.27
" This method, which requires the incorporation of only 10-12 microCi into the dosage form, provided reliable dissolution data after oral administration of [111In]lactose tablets."( In vivo dissolution measurement with indium-111 summation peak ratios.
Brouwer, KR; Jay, M; Woodward, MA, 1985
)
0.27
" The pharmacokinetics of ASA is affected by the dosage form used and the presence of food."( Aspirin: plasma concentration and effects.
Thiessen, JJ, 1983
)
0.27
" The response(s) of a drug is a complicated function of the concentration in the blood plasma, which in turn is some function of the dosage input."( Quantitative relationships between dynamics and kinetics of drugs: a systems dynamics approach.
Burgers, JP; van Rossum, JM, 1984
)
0.27
"The extent to which a controlled release acetylsalicylic acid (ASA) formulation inhibited platelet function has been evaluated in single and chronic dosing studies."( Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies.
Cossum, PA; McLeod, LJ; Roberts, MS; Vial, JH, 1984
)
0.76
" The 24-h area under the salicylate curve (AUC0-24 h) after the final 3000-mg salicylate dose averaged about twice the mean 12-h AUC after the last 1500-mg dose, indicating that the two dosing regimens were equally bioavailable."( Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages.
Kann, J; Levitt, MJ, 1984
)
0.27
" Signs and symptoms were those of an intracranial neoplasm and appeared 5 years after an irradiation dosage of 1890 rets."( Delayed cerebral pseudo-tumoral radionecrosis following scalp-tumour irradiation. Case report and review of literature.
Colin, J; Malhaire, JP; Person, H; Vallee, B, 1984
)
0.27
" Compared with probenecid, thimerosal and mercaptide V yielded dose-response curves of steeper slope and higher maximal effect."( Effects of analogs of salicylate on p-aminohippurate uptake into basal-lateral membranous vesicles.
Bildstein, C; Liu, D; Mamelok, RD; Tse, SS, 1984
)
0.27
" Available pharmacokinetic data can be used to predict plasma ASA and SA levels following different ASA dosing regimen."( Relevance to redesigning aspirin therapeutic regimens.
Thiessen, JJ, 1983
)
0.27
" When steady state was achieved patients were hospitalized, and blood and urine specimens were obtained during three dosing intervals and during the washout period that followed."( Availability of salicylate from salsalate and aspirin.
Cassell, S; Dromgoole, SH; Furst, DE; Paulus, HE, 1983
)
0.27
" With the aid of micro-sampling procedures, and sensitive and rapid analytical techniques, blood, urine and feces samples are obtained from individual animals following dosing and the data are simulated using a hybrid computer to develop a pharmacokinetic model."( Correlating pharmacokinetics and teratogenic endpoints.
Kimmel, CA; Young, JF,
)
0.13
"A simultaneous analysis of aspirin and nonaspirin salicylates in solid pharmaceutical dosage forms is described."( Stabilized normal-phase high-performance liquid chromatographic analysis of aspirin and salicylic acid in solid pharmaceutical dosage forms.
Galante, RN; Grim, WM; Visalli, AJ, 1984
)
0.49
" By contrast, increasing aspirin dosage resulted in decreased clearance and disproportionate increases in unbound SA (CpuSA)."( Disposition of and clinical response to salicylates in patients with rheumatoid disease.
Bochner, F; Cham, B; Graham, G; Günsberg, M; Imhoff, D; Parsons, G, 1984
)
0.27
"After a standard meal, 12 normal volunteers received three aspirin dosage forms in a single-dose, complete crossover study."( Influence of food on aspirin absorption from tablets and buffered solutions.
Mason, WD; Winer, N, 1983
)
0.27
" In view of other more aggressive treatments reported in the literature for this disease, high-dosage prednisone with rapid change to alternate-day dosage is a reasonable initial course of action."( Perifolliculitis capitis: successful control with alternate-day corticosteroids.
Adrian, RM; Arndt, KA, 1980
)
0.26
"Influence of dosing time on pharmacological effects and toxicity of acetylsalicylic acid was investigated in ICR male mice under light-dark (12:12) cycle."( Chronopharmacological study of acetylsalicylic acid in mice.
Ogawa, N; Ohdo, S; Song, JG, 1995
)
0.8
" Further clinical studies are required to establish its role and the optimum dosage regimen of charcoal to be administered."( Multiple-dose activated charcoal: a review of relevant clinical studies.
Bradberry, SM; Vale, JA, 1995
)
0.29
" Predicted plasma salicylate concentration-time curves were constructed for various aspirin dosage regimens."( Plasma salicylate concentrations in immature dogs following aspirin administration: comparison with adult dogs.
Bill, RL; Bowers, LD; Caywood, DD; Cipolle, RJ; Waters, DJ, 1993
)
0.29
" One month later, she repeated the dosage and experienced only spotting."( Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol.
Alencar, AJ; Fonseca, W; Misago, C; Pereira, RM, 1993
)
0.29
" Scalp hair was collected by shaving and vacuuming the dosed area at baseline and at 4-week intervals."( The penetration enhancer SEPA augments stimulation of scalp hair growth by topical minoxidil in the balding stumptail macaque.
Brunden, MN; Diani, AR; Shull, KL; Zaya, MJ, 1995
)
0.29
" Consistent therapy with itraconazole (Sempera) dosed at 3 mg/kg body weight per day over a period of 4 weeks led to a permanent cure."( [Trichophyton soudanense as the pathogen of tinea corporis et capitis].
Bröcker, EB; Ebert, J; Schwinn, A; Wever, S, 1995
)
0.29
" However, little is known about the dose-response relationship for salicylate-related effects on labor and gestation."( Maternal reproductive effects of oral salicylic acid in Sprague-Dawley rats.
Daston, GP; Davis, DP; Kraus, AL; Odio, MR; York, RG, 1996
)
0.57
" Similar, log-linear dose-response curves were found for both ASA and SA, significant in effect at 3 g/kg and higher drug contents and reaching saturation level at 15 or 30 g/kg, respectively, which, 20 min after application, caused a mean pain suppression of 95% using ASA and 80% using SA."( Dose-dependent competitive block by topical acetylsalicylic and salicylic acid of low pH-induced cutaneous pain.
Kreysel, HW; Reeh, PW; Steen, KH, 1996
)
0.53
" However, they are not sensitive enough for the simultaneous determination of ASA and its major metabolites salicylic (SA) and salicyluric (SUA) acids at the low dosage schedules (30-100 mg ASA/d)."( A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications.
Dzúrik, R; Krivosíková, Z; Spustová, V, 1996
)
0.29
" If a dose-response situation exists for the carcinogenic potential of HPV infection, this finding may be relevant to the increased risk of skin cancer in this group of patients."( Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers.
Berkhout, RJ; Bouwes Bavinck, JN; Boxman, IL; Mulder, LH; ter Schegget, J; Vermeer, BJ; Wolkers, MC, 1997
)
0.3
" SN related to inadequate dosage of prednisolone."( Scalp necrosis in giant cell arteritis and review of the literature.
Currey, J, 1997
)
0.3
" The skin surface was not protected during the absorption dosing period."( Percutaneous absorption of salicylic acid, theophylline, 2, 4-dimethylamine, diethyl hexyl phthalic acid, and p-aminobenzoic acid in the isolated perfused porcine skin flap compared to man in vivo.
Maibach, H; Melendres, J; Riviere, JE; Sedik, L; Wester, RC, 1998
)
0.6
" A positive dose-response relationship for the percutaneous penetration of SA in response to increasing SLS pretreatment concentrations and thus the degree of irritant dermatitis was found."( Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function.
Benfeldt, E; Menné, T; Serup, J, 1999
)
0.56
" Microdialysis sampling in anatomical regions remote from the dosed site excluded the possibility that SA levels measured were due to systemic absorption."( Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function.
Benfeldt, E; Serup, J, 1999
)
0.55
" A gentle rise of pH was observed as the dosage of the base increased when arginine and lysine were used, in contrast to the sharp rise of pH observed when sodium hydroxide was used."( Preparation and characterization of acrylic hydrogels neutralized by basic amino acids.
Machida, K; Matsuyama, K; Miyanaga, Y; Ohki, T; Toida, Y; Uchida, T; Wada, K, 2000
)
0.31
"A pattern-fitting procedure for quantitative analysis of crystalline pharmaceuticals in solid dosage forms using X-ray powder diffraction data is described."( Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data.
Momose, Y; Yamamura, S, 2001
)
0.31
" Despite this clear evidence of an effect, the magnitude of the dose-response relationship is much less clear because of probable errors in individual estimates of dose to the thyroid gland."( Thyroid cancer following scalp irradiation: a reanalysis accounting for uncertainty in dosimetry.
Carroll, RJ; Lubin, JH; Ron, E; Schafer, DW; Stovall, M, 2001
)
0.31
" We describe the effectiveness of cyclosporin A in a case of GLPLS at the dosage of 4 mg/kg/day."( Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A.
Bianchi, L; Carboni, I; Chimenti, S; Paro Vidolin, A; Piemonte, P, 2001
)
0.31
"Our aim was to study the potential efficacy of topical 5% imiquimod cream in the treatment of facial or scalp AKs and improve the safety profile by using a novel "cycle" dosing regimen."( Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial.
Levine, N; Morrison, L; Salasche, SJ, 2002
)
0.31
" The identification of a therapeutic interval may prove to be beneficial in formulating individualized dosing regimens."( Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial.
Levine, N; Morrison, L; Salasche, SJ, 2002
)
0.31
" Lack of interaction was assessed by determination of pharmacokinetic characteristics and relative bioavailability of both substances and salicylic acid (CAS 69-72-7, SA), administered in combination and as equally single dosed drugs."( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.75
" No interaction was found for AUCnorm and Cmax, norm between the fixed combination ASA/PSE and the equally single dosed drugs as reference."( Pharmacokinetic interaction study of a fixed combination of 500 mg acetylsalicylic acid/30 mg pseudoephedrine versus each of the single active ingredients in healthy male volunteers.
Birkel, M; Hey, B; Loose, I; Lücker, PW; Schaefer, A, 2003
)
0.55
" With the assistance of the World Health Organization, a field trial was carried out in Yugoslavia to determine the most suitable schedule of dosage with this drug for mass treatment and to ascertain what measures are necessary to reduce the reservoir of infection to a level where the disease ceases to be a public health problem."( A controlled field trial in Yugoslavia of the efficacy of griseofulvin in the mass treatment of tinea capitis.
GRIN, EI, 1962
)
0.24
"6 expression had a different dose-response to PR-1 expression."( Salicylic acid dependent signaling promotes basal thermotolerance but is not essential for acquired thermotolerance in Arabidopsis thaliana.
Clarke, SM; Mur, LA; Scott, IM; Wood, JE, 2004
)
1.77
"The aim of this work was to describe a fully automated system for the in vitro release testing of semisolid dosage forms based on SIA technique."( Automated system for release studies of salicylic acid based on a SIA method.
Klimundová, J; Schaefer, UF; Sklenárová, H; Solich, P, 2005
)
0.6
" Also, the use of ASA as an elicitor resulted in the inhibition of biomass growth and an increase in total ginseng saponin content at every elicitor dosage (0."( Production of antioxidant compounds by culture of Panax ginseng C.A. Meyer hairy roots: I. Enhanced production of secondary metabolite in hairy root cultures by elicitation.
Hwang, B; Jeong, GT; Kim, D; Kim, SW; Park, DH; Ryu, HW; Woo, JC, 2005
)
0.33
" The results showed that methyl jasmonate and salicylic acid enhanced greatly the accumulation of PeG and echinacoside (Echin), but their optimum elicitation dosage and addition time were different."( [Effects of methyl jasmonate and salicylic acid on phenylethanoid glycosides synthesis in suspension cultures of Cistanche deserticola].
Chen, YQ; Fu, CX; Jin, ZP; Xu, LS; Xue, XF; Zhao, DX, 2005
)
0.87
" Patients in the control group took medopa orally in the dosage of 125 mg, 3 times per day for mild, 250 mg, 3 times per day for moderate and 250 mg, 4 times per day for severe cases."( [Effects on electro-scaip acupuncture on cerebral dopamine transporter in patients with Parkinson' s disease].
Huang, Y; Jiang, XM; Li, DJ, 2006
)
0.33
" Competitive, noncompetitive and uncompetitive inhibition mechanisms were incorporated into the GHB-MCT substrate interaction model for inhibitor dosing either pre-, concurrent or post-GHB administration."( Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.
Bhattacharya, I; Boje, KM, 2006
)
0.33
" Total codeine dosage was also similar, except at 4 h postoperatively when it was higher in the block group."( A comparison between scalp nerve block and morphine for transitional analgesia after remifentanil-based anesthesia in neurosurgery.
Ayoub, C; Boudreault, D; Chouinard, P; Girard, F; Moumdjian, R; Ruel, M, 2006
)
0.33
"The modest PD effect, short plasma t1/2 and close PK-PD relationship suggest that multiple daily dosing or sustained release formulations at higher doses will be necessary for AZD5438 to achieve sustained inhibition of CDK in human cancers."( A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Amakye, D; Byth, K; Camidge, DR; Forder, C; Growcott, J; Hughes, A; Pemberton, M; Swaisland, H; Wilkinson, R; Wilson, D, 2007
)
0.34
" The described method was applied for the determination of these combinations in synthetic mixtures and dosage forms."( Derivative-ratio spectrophotometric method for the determination of ternary mixture of aspirin, paracetamol and salicylic acid.
Assi, SA; El-Yazbi, FA; Hammud, HH, 2007
)
0.55
" Our study shows that SA blocks barley seed germination in a dosage dependent manner."( Salicylic acid inhibits gibberellin-induced alpha-amylase expression and seed germination via a pathway involving an abscisic-acid-inducible WRKY gene.
Cook, E; Hanzlik, S; Shen, QJ; Xie, Z; Zhang, ZL, 2007
)
1.78
"Following orally dosing with 650 mg aspirin, saliva and urine samples were collected over a period of 24 h from healthy individuals with homozygous wild-type UGT1A6 *1/*1 (n=19) and homozygous variant UGT1A6 *2/*2 (T181A, R184S) (n=9) genotypes."( UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin.
Bigler, J; Chen, Y; Kuehl, GE; Lampe, JW; Rimorin, CF; Schwarz, Y; Shen, DD, 2007
)
0.65
" Salicylic acid, caffeine and metoprolol were individually dosed to the ligated stomach."( The development of multiple probe microdialysis sampling in the stomach.
Lunte, CE; Woo, KL, 2008
)
1.26
"A 4-year-old child with SWS, who was chronically treated with aspirin at an antiplatelet dosage of 3 mg/kg per day, presented with extensive SGH and significant anemia after a mild head trauma."( Subgaleal hematoma in a child with Sturge-Weber syndrome: to prevent stroke-like episodes, is treatment with aspirin advisable?
Fiumara, A; Greco, F; Pavone, L; Sorge, G, 2008
)
0.35
" To assess the significance of this multiple probe approach, drug concentrations in each probe location were monitored after selected compounds were dosed to the ligated stomach by oral gavage."( The direct comparison of health and ulcerated stomach tissue: a multiple probe microdialysis sampling approach.
Lunte, CE; Woo, KL, 2008
)
0.35
"A patient with recurrent and initially unresectable but non-metastatic DFSP of the scalp received Imatinib over 3 months with increasing dosage from 400 mg/day to 800 mg/day orally."( Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Aklan, T; Hoeffken, K; Lemm, D; Mentzel, T; Muegge, LO; Schultze-Mosgau, S; Thorwarth, M, 2008
)
0.35
" Solid dosage forms may be coated with these polymers to provide an efficient delivery system to the colon with a rapid release mechanism."( Novel salicylazo polymers for colon drug delivery: dissolving polymers by means of bacterial degradation.
Karton, Y; Saphier, S, 2010
)
0.36
" He took orally various acids (nitrobenzoic, camphoric and salicylic) and dosed these compounds and metabolites in his own urines."( [Some notes on Cesare Bertagnini, pioneer of pharmacokinetics].
Marson, P; Pasero, G, 2009
)
0.35
" SA elicitation on the phenolic acid accumulation was depended upon the application dosage and the time-duration."( Accumulation of salicylic acid-induced phenolic compounds and raised activities of secondary metabolic and antioxidative enzymes in Salvia miltiorrhiza cell culture.
Dong, J; Liang, Z; Wan, G, 2010
)
0.71
" Three PK studies were conducted: (1) PK of SA in normal rats after intravenous dosing of SA at 20, 40, 80 mg/kg."( Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats.
Almon, RR; Cao, Y; DuBois, DC; Jusko, WJ, 2012
)
0.66
" Following first dosing on day 5, plasma samples were collected at different time points."( Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin.
Fung, KP; Lau, BS; Leung, PC; Wang, S; Zhang, Z; Zhou, L; Zuo, Z, 2012
)
0.38
"9% or sodium pentobarbital at 30mg/kg dosage via intraperitoneal."( Stimulation of the Po-shen and Shen-hun scalp-acupuncture bands modifies levels of inhibitory and excitatory amino acids in the immature rat brain.
Franco-Santana, LE; González-Ramírez, M; González-Trujano, ME; Torres-Castillo, S, 2013
)
0.39
" Common dosage forms available on the market for those situations are lotions; however, the presence of hair limits their use."( Mometasone furoate hydrogel for scalp use: in vitro and in vivo evaluation.
Marto, J; Raposo, S; Ribeiro, HM; Salgado, A; Silva, AN; Simões, S, 2014
)
0.4
" The time-course and dose-response profiles of the induction process were established by quantifying the isoflavonoids by HPLC."( Effect of salicylic acid and structurally related compounds in the accumulation of phytoalexins in cotyledons of common bean (Phaseolus vulgaris L.) cultivars.
Durango, D; Echeverri, F; Escobar, G; Pulgarin, N; Quiñones, W, 2013
)
0.79
" The final study determined the dose-response relationship for paclitaxel."( Chemical renal denervation in the rat.
Consigny, PM; Davalian, D; Donn, R; Hu, J; Rieser, M; Stolarik, D, 2014
)
0.4
" We report on temporal and dosage effects of such crosstalk on host preference and oviposition-site selection behaviour of the herbivorous spider mite Tetranychus urticae towards Lima bean (Phaseolus lunatus) plants, including underlying mechanisms."( Reciprocal crosstalk between jasmonate and salicylate defence-signalling pathways modulates plant volatile emission and herbivore host-selection behaviour.
Dicke, M; Gols, R; Kang, L; Li, N; Menzel, TR; van Loon, JJ; Wei, J, 2014
)
0.4
"Human abdominal skin was dosed with 20 µL of either [(14)C]-aminophylline or [(14)C]-salicylic acid on 1 cm(2) per skin."( In vitro skin decontamination model: comparison of salicylic acid and aminophylline.
Blickenstaff, N; Coman, G; Maibach, H; Noury, B, 2015
)
0.89
" The variability of the ECT and MST electric fields due to anatomical differences should be considered in the interpretation of existing studies and in efforts to improve dosing approaches for better control of stimulation strength and focality across patients, such as individualization of the current amplitude."( Effect of anatomical variability on electric field characteristics of electroconvulsive therapy and magnetic seizure therapy: a parametric modeling study.
Deng, ZD; Lisanby, SH; Peterchev, AV, 2015
)
0.42
" The mean brain dose and high-dosage volume of all three techniques were low, but IMRT provided larger volume to the brain than did the other two techniques in the low dosage region."( A simpler method for total scalp irradiation: the multijaw-size concave arc technique.
Asakura, H; Fuji, H; Harada, H; Inoue, M; Konno, M; Murayama, S; Nishimura, T; Ogawa, H, 2014
)
0.4
" This reaction may be used as an important consideration to optimize the dosing regime of the two drugs and to help explain some pharmacological reactions between aspirin and biomolecules."( A Reaction of Aspirin with Ferrous Gluconate.
Zhang, J, 2015
)
0.42
"Soil drenches of SA and INA and root dip application of SA and BTH inhibited nematode reproduction, at specific dosage ranges, without affecting plant growth."( Systemic acquired resistance activation in solanaceous crops as a management strategy against root-knot nematodes.
Molinari, S, 2016
)
0.43
" Spray was applied once, at a usual dosage and without any bandage."( Polyurethane dressing, tetracycline and salicylic acid use for treatment of digital dermatitis in cattle. A comparative study.
Fiedler, A; Maierl, J; Sauter-Louis, C, 2015
)
0.68
" It is important to understand the bioavailability of aspirin and its major metabolite, salicylic acid, since dosage and route of administration can vary for treating differing diseases, and the major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent."( Bioavailability of aspirin in rats comparing the drug's uptake into gastrointestinal tissue and vascular and lymphatic systems: implications on aspirin's chemopreventive action.
Dial, EJ; Edler, S; Fang, D; Li-Geng, T; Lichtenberger, LM; Phan, T; Philip, J, 2016
)
0.66
" Effects of ASA dosage on the metabolic profile have not been fully understood."( Quantitative determination of five metabolites of aspirin by UHPLC-MS/MS coupled with enzymatic reaction and its application to evaluate the effects of aspirin dosage on the metabolic profile.
Duan, JA; Guo, JM; Li, JP; Liu, Y; Shang, EX; Tang, ZS; Zhao, BC; Zhao, J; Zhu, ZH, 2017
)
0.46
" No correlation was found between budesonide dosage and HCC levels (r = -0."( Long-Term Cortisol Concentration in Scalp Hair of Asthmatic Children Using Inhaled Corticosteroids: A Case-Control Study.
de Rijke, YB; Kramer van Driel, D; Noppe, G; Smit, MP; van den Akker, ELT; van Leer, EHG, 2017
)
0.46
"Time-course and dose-response experiments were carried out to establish the ability for synthesizing isoflavonoids of soybean seedlings (cv."( Isoflavonoid composition and biological activity of extracts from soybean seedlings treated by different elicitors.
Durango, D; Echeverri, F; Escobar, G; Murillo, J; Quiñones, W, 2018
)
0.48
" This retrospective study evaluates the efficacy, safety, and effective dosage of 308-nm excimer light in the treatment of scalp psoriasis."( Efficacy and safety of 308-nm excimer lamp in the treatment of scalp psoriasis: a retrospective study.
Pakornphadungsit, K; Phusuphitchayanan, P; Rattanakaemakorn, P; Suchonwanit, P; Thadanipon, K, 2019
)
0.51
" Therefore, intraoperative anesthesia-related immunomodulators, such as scalp block, intravenous anesthesia, the opioid dosage administered, and transfusions, may influence oncological outcomes among patients with glioma."( Scalp Block Is Associated With Improved Recurrence Profiles in Patients Undergoing Primary Glioma Resection Surgery.
Chang, JL; Cheng, HL; Lee, TS; Liao, MH; Shih, CC; Sung, CH; Tsuang, FY; Wu, CY; Yang, YW, 2021
)
0.62
" These results provide insight into a new response mechanism towards plant nematode resistance involving haplotype compatibility, gene dosage and hormone signalling."( A pathogenesis-related protein GmPR08-Bet VI promotes a molecular interaction between the GmSHMT08 and GmSNAP18 in resistance to Heterodera glycines.
Bekal, S; Bendahmane, A; Benhamed, M; Bergounioux, C; Boualem, A; Hewezi, T; Jones, K; Kassem, MA; Lakhssassi, A; Lakhssassi, N; Lambert, K; Liu, S; Meksem, J; Meksem, K; Miao, L; Piya, S; Zhou, Z, 2020
)
0.56
"The clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans."( Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
Beal, K; Disa, JJ; Dusza, SW; Freites-Martinez, A; Freret, ME; Friedman, DN; Kukoyi, O; Lacouture, ME; Mechalakos, JG; Phillips, GS; Tinkle, CL; Trelles, S; Unger, RH; Wexler, LH; Wolden, SL, 2020
)
0.56
" Pharmacological treatment often lead to severe complications and require drug dosage adjustment."( The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia: A retrospective study.
Gao, J; Han, X; Huang, L; Mao, E; Wu, G; Yue, A; Zhou, B, 2020
)
0.56
"We sought to describe the therapeutic response to dutasteride and the most effective dosage in FFA compared with other therapeutic options or no treatment."( Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice.
Hermosa-Gelbard, Á; Jaén-Olasolo, P; Moreno-Arrones, ÓM; Pindado-Ortega, C; Rodrigues-Barata, AR; Saceda-Corralo, D; Vañó-Galván, S, 2021
)
0.62
"A recent combination of aspirin (ASP) and omeprazole (OMP) has been presented in a fixed dosage form for the treatment of many cardiovascular diseases, particularly in patients with gastric diseases."( Spectrophotometric Determination of Aspirin and Omeprazole in the Presence of Salicylic Acid as a Degradation Product: A Comparative Evaluation of Different Univariate/Multivariate Post Processing Algorithms.
Badrawy, M; El-Mammli, MY; Elmasry, MS; Hassan, WS; Serag, A, 2022
)
0.95
" Randomized controlled trials are needed to verify the claims from use of these natural products and determine the appropriate dosage for use."( A review of indigenous therapies for hair and scalp disorders in Nigeria.
Enechukwu, NA; Ogunbiyi, AO, 2022
)
0.72
" In the future, further studies are needed to evaluate the chance of adjusting drug dosage according to patients' and actinic keratoses features."( Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.
Bianchi, L; Campione, E; Cosio, T; Di Prete, M; Di Raimondo, C; Diluvio, L; Gaeta Shumak, R; Garofalo, V; Geraci, F; Lambiase, S; Lanna, C; Lozzi, F, 2022
)
0.97
"In the present work, we report a method based on micellar liquid chromatography coupled with ultraviolet detection (MLC/UV), for the simultaneous quantification of combined anti-platelet therapy namely, clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations.
Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022
)
0.9
"The MLC/UV method was successfully applied to the quantitative analysis of CPS, ASP together with SA-as a main degradation product of ASP-in their pharmaceutical dosage form."( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations.
Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022
)
0.72
"The developed method was successfully applied for the determination of clopidogrel bisulfate (CPS), aspirin (ASP), together with salicylic acid (SA), in their pharmaceutical dosage form."( Micelle-Incorporated Liquid Chromatography in the Light of Green Chemistry: An Application for the Quality Control Analysis of Anti-Platelet Fixed-Dose Combinations.
Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS, 2022
)
0.93
"Quantifying subject-specific optical properties (OPs) including absorption and transport scattering coefficients of tissues in the human head could improve the modeling of photon propagation for the analysis of functional near-infrared spectroscopy (fNIRS) data and dosage quantification in therapeutic applications."( Quantifying tissue optical properties of human heads in vivo using continuous-wave near-infrared spectroscopy and subject-specific three-dimensional Monte Carlo models.
Kao, TC; Sung, KB, 2022
)
0.72
" Secondary outcomes included incidence of hypertension and dosage of intraoperative analgesic opioids used."( The effectiveness of scalp nerve block on hemodynamic response in craniotomy: a systematic review and meta-analysis of randomized trials.
Deng, M; Luo, M; Tu, M; Wang, Y; Yang, X; Zhao, X,
)
0.13
" On the other hand, SA utilization is dependent on the dosage of the applied SA, the technique of application, and the status of the plants (e."( Emerging Roles of Salicylic Acid in Plant Saline Stress Tolerance.
Chu, Z; Yang, W; Zhou, Z, 2023
)
1.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (5 Items)

ItemProcessFrequency
Non food productscore-ingredient6
Open Beauty Factscore-ingredient5
Skincarecore-ingredient1
Bifidus yogurtscore-ingredient1
Face washcore-ingredient1

Roles (7)

RoleDescription
plant hormoneA plant growth regulator that modulates the formation of stems, leaves and flowers, as well as the development and ripening of fruit. The term includes endogenous and non-endogenous compounds (e.g. active compounds produced by bacteria on the leaf surface) as well as semi-synthetic and fully synthetic compounds.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
keratolytic drugA drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitorAn EC 1.11.1.* (peroxidases) inhibitor that inhibits the action of L-ascorbate peroxidase (EC 1.11.1.11).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monohydroxybenzoic acidAny hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Salicylic Acid Action Pathway2967
AtMetExpress overview0109

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency63.09570.100020.879379.4328AID588456
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency70.79463.981127.764939.8107AID504842
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
retinoid X nuclear receptor alphaHomo sapiens (human)Potency41.27330.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.50040.000229.305416,493.5996AID743075
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency29.90330.001815.663839.8107AID894
gemininHomo sapiens (human)Potency1.99530.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency11.22020.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Ki670.50001.60005.744010.0000AID678787; AID681340
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)100.00000.03403.987110.0000AID566711
Carbonic anhydrase 12Homo sapiens (human)Ki161.79290.00021.10439.9000AID1798641; AID342484
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1209455
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)560.00000.00582.14107.9000AID349140
Carbonic anhydrase 1Homo sapiens (human)Ki170.94240.00001.372610.0000AID1257050; AID1798641; AID331291; AID342475; AID349142
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)680.00000.00021.10608.3000AID349141
Carbonic anhydrase 2Homo sapiens (human)Ki177.50710.00000.72369.9200AID1257051; AID1798641; AID331292; AID342476; AID349145
Carbonic anhydrase 3Homo sapiens (human)Ki224.37860.00022.010210.0000AID1798641; AID342477
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)1,000.00000.00101.191310.0000AID34782
Prolyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)Ki2,300.00005.00007.66679.0000AID1799825
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Ki19,400.00000.19004.83279.6000AID653541
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)346.00000.00000.933210.0000AID1585833
Carbonic anhydrase 4Homo sapiens (human)Ki161.95710.00021.97209.9200AID1798641; AID342478
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)270.00000.00021.557410.0000AID1307967; AID1691172
Carbonic anhydrase 6Homo sapiens (human)Ki305.88000.00011.47109.9200AID1798641; AID342481; AID607496
Cystathionine gamma-lyaseHomo sapiens (human)IC50 (µMol)200.00000.57002.86098.0000AID1680654
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)Ki209.59290.00001.27259.9000AID1798641; AID342479
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)40.00000.00010.995010.0000AID1691173
Carbonic anhydrase 7Homo sapiens (human)Ki167.02860.00021.37379.9000AID1798641; AID342482
Xanthine dehydrogenase/oxidaseBos taurus (cattle)Ki100,000.00000.00010.83862.6000AID1075889
Carbonic anhydrase 9Homo sapiens (human)Ki160.91330.00010.78749.9000AID1257052; AID1798641; AID342483
Carbonic anhydraseDicentrarchus labrax (European seabass)Ki324.00002.13005.53339.4100AID607497
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)280.00000.27004.53069.9000AID681331
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00020.00000.00060.0019AID1618606
Solute carrier family 22 member 20Mus musculus (house mouse)Ki43.82581.10006.67899.1201AID360149
Solute carrier family 22 member 8Homo sapiens (human)Ki1,020.00000.04004.22979.0000AID681372
Solute carrier family 22 member 6Mus musculus (house mouse)Ki144.77200.40745.02179.4000AID360150
Carbonic anhydrase 15Mus musculus (house mouse)Ki7.20000.00091.884610.0000AID331293
Carbonic anhydrase 13Mus musculus (house mouse)Ki165.95000.00021.39749.9000AID1798641; AID342486
Carbonic anhydrase 14Homo sapiens (human)Ki164.72140.00021.50999.9000AID1798641; AID342485
Carbonic anhydrase 5B, mitochondrialHomo sapiens (human)Ki186.52140.00001.34129.9700AID1798641; AID342480
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))EC50 (µMol)250.00003.22003.22003.2200AID666145
High mobility group protein B1Homo sapiens (human)Kd1.00000.02400.63101.0000AID1494167; AID1494168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 7Rattus norvegicus (Norway rat)Km85.00000.36600.39000.4140AID678818; AID681575
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (359)

Processvia Protein(s)Taxonomy
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
positive regulation of cold-induced thermogenesis5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
response to bacteriumCarbonic anhydrase 3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 3Homo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
myeloid dendritic cell activationHigh mobility group protein B1Homo sapiens (human)
activation of innate immune responseHigh mobility group protein B1Homo sapiens (human)
dendritic cell chemotaxisHigh mobility group protein B1Homo sapiens (human)
inflammatory response to antigenic stimulusHigh mobility group protein B1Homo sapiens (human)
regulation of tolerance inductionHigh mobility group protein B1Homo sapiens (human)
regulation of T cell mediated immune response to tumor cellHigh mobility group protein B1Homo sapiens (human)
DNA topological changeHigh mobility group protein B1Homo sapiens (human)
double-strand break repair via nonhomologous end joiningHigh mobility group protein B1Homo sapiens (human)
DNA recombinationHigh mobility group protein B1Homo sapiens (human)
autophagyHigh mobility group protein B1Homo sapiens (human)
inflammatory responseHigh mobility group protein B1Homo sapiens (human)
signal transductionHigh mobility group protein B1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHigh mobility group protein B1Homo sapiens (human)
positive regulation of autophagyHigh mobility group protein B1Homo sapiens (human)
negative regulation of RNA polymerase II transcription preinitiation complex assemblyHigh mobility group protein B1Homo sapiens (human)
neuron projection developmentHigh mobility group protein B1Homo sapiens (human)
heterochromatin formationHigh mobility group protein B1Homo sapiens (human)
regulation of restriction endodeoxyribonuclease activityHigh mobility group protein B1Homo sapiens (human)
DNA geometric changeHigh mobility group protein B1Homo sapiens (human)
positive regulation of mismatch repairHigh mobility group protein B1Homo sapiens (human)
negative regulation of type II interferon productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-1 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-10 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-12 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-6 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of interleukin-8 productionHigh mobility group protein B1Homo sapiens (human)
positive regulation of tumor necrosis factor productionHigh mobility group protein B1Homo sapiens (human)
V(D)J recombinationHigh mobility group protein B1Homo sapiens (human)
positive regulation of toll-like receptor 9 signaling pathwayHigh mobility group protein B1Homo sapiens (human)
T-helper 1 cell activationHigh mobility group protein B1Homo sapiens (human)
positive regulation of activated T cell proliferationHigh mobility group protein B1Homo sapiens (human)
positive regulation of apoptotic processHigh mobility group protein B1Homo sapiens (human)
apoptotic cell clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processHigh mobility group protein B1Homo sapiens (human)
negative regulation of CD4-positive, alpha-beta T cell differentiationHigh mobility group protein B1Homo sapiens (human)
positive regulation of DNA bindingHigh mobility group protein B1Homo sapiens (human)
positive regulation of MAPK cascadeHigh mobility group protein B1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHigh mobility group protein B1Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationHigh mobility group protein B1Homo sapiens (human)
T-helper 1 cell differentiationHigh mobility group protein B1Homo sapiens (human)
innate immune responseHigh mobility group protein B1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
positive regulation of JNK cascadeHigh mobility group protein B1Homo sapiens (human)
positive regulation of viral entry into host cellHigh mobility group protein B1Homo sapiens (human)
positive chemotaxisHigh mobility group protein B1Homo sapiens (human)
positive regulation of DNA ligationHigh mobility group protein B1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh mobility group protein B1Homo sapiens (human)
cellular response to lipopolysaccharideHigh mobility group protein B1Homo sapiens (human)
positive regulation of monocyte chemotaxisHigh mobility group protein B1Homo sapiens (human)
neutrophil clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationHigh mobility group protein B1Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionHigh mobility group protein B1Homo sapiens (human)
negative regulation of apoptotic cell clearanceHigh mobility group protein B1Homo sapiens (human)
positive regulation of dendritic cell differentiationHigh mobility group protein B1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHigh mobility group protein B1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
cysteine metabolic processCystathionine gamma-lyaseHomo sapiens (human)
lipid metabolic processCystathionine gamma-lyaseHomo sapiens (human)
protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic process via cystathionineCystathionine gamma-lyaseHomo sapiens (human)
cysteine biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
transsulfurationCystathionine gamma-lyaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCystathionine gamma-lyaseHomo sapiens (human)
protein sulfhydrationCystathionine gamma-lyaseHomo sapiens (human)
protein homotetramerizationCystathionine gamma-lyaseHomo sapiens (human)
hydrogen sulfide biosynthetic processCystathionine gamma-lyaseHomo sapiens (human)
positive regulation of aortic smooth muscle cell differentiationCystathionine gamma-lyaseHomo sapiens (human)
cellular response to leukemia inhibitory factorCystathionine gamma-lyaseHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCystathionine gamma-lyaseHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
spermatogenesis5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
import into nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
response to muscle activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose metabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cell population proliferation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to UV5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cold acclimation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to gamma radiation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid and bile salt transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid oxidation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to caffeine5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of peptidyl-serine phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to estrogen5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of skeletal muscle tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of lipid catabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of vesicle-mediated transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
motor behavior5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
CAMKK-AMPK signaling cascade5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuron cellular homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hydrogen peroxide5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to ethanol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to organonitrogen compound5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of bile acid secretion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of mitochondrial transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein targeting to mitochondrion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of adipose tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
negative regulation of ATP-dependent activityUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
regulation of proteasome assemblyUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
protein dephosphorylationUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
glycogen biosynthetic process5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
glycolytic process5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
response to muscle activity involved in regulation of muscle adaptation5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
intracellular signal transduction5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
glycogen metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
negative regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
sterol biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
intracellular signal transduction5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid oxidation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glucose import5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
response to bacteriumCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nail development5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
positive regulation of cold-induced thermogenesis5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (138)

Processvia Protein(s)Taxonomy
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 3Homo sapiens (human)
protein bindingCarbonic anhydrase 3Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 3Homo sapiens (human)
nickel cation bindingCarbonic anhydrase 3Homo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
four-way junction DNA bindingHigh mobility group protein B1Homo sapiens (human)
bubble DNA bindingHigh mobility group protein B1Homo sapiens (human)
transcription cis-regulatory region bindingHigh mobility group protein B1Homo sapiens (human)
lipopolysaccharide bindingHigh mobility group protein B1Homo sapiens (human)
phosphatidylserine bindingHigh mobility group protein B1Homo sapiens (human)
damaged DNA bindingHigh mobility group protein B1Homo sapiens (human)
double-stranded DNA bindingHigh mobility group protein B1Homo sapiens (human)
single-stranded DNA bindingHigh mobility group protein B1Homo sapiens (human)
transcription coactivator activityHigh mobility group protein B1Homo sapiens (human)
transcription corepressor activityHigh mobility group protein B1Homo sapiens (human)
RNA bindingHigh mobility group protein B1Homo sapiens (human)
cytokine activityHigh mobility group protein B1Homo sapiens (human)
integrin bindingHigh mobility group protein B1Homo sapiens (human)
protein bindingHigh mobility group protein B1Homo sapiens (human)
DNA binding, bendingHigh mobility group protein B1Homo sapiens (human)
lyase activityHigh mobility group protein B1Homo sapiens (human)
C-X-C chemokine bindingHigh mobility group protein B1Homo sapiens (human)
chemoattractant activityHigh mobility group protein B1Homo sapiens (human)
receptor ligand activityHigh mobility group protein B1Homo sapiens (human)
RAGE receptor bindingHigh mobility group protein B1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHigh mobility group protein B1Homo sapiens (human)
DNA polymerase bindingHigh mobility group protein B1Homo sapiens (human)
supercoiled DNA bindingHigh mobility group protein B1Homo sapiens (human)
DNA-binding transcription factor bindingHigh mobility group protein B1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
procollagen-proline 4-dioxygenase activityProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
iron ion bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
L-ascorbic acid bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
cystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
protein bindingCystathionine gamma-lyaseHomo sapiens (human)
calmodulin bindingCystathionine gamma-lyaseHomo sapiens (human)
pyridoxal phosphate bindingCystathionine gamma-lyaseHomo sapiens (human)
identical protein bindingCystathionine gamma-lyaseHomo sapiens (human)
L-cystine L-cysteine-lyase (deaminating)Cystathionine gamma-lyaseHomo sapiens (human)
homocysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
L-cysteine desulfhydrase activityCystathionine gamma-lyaseHomo sapiens (human)
selenocystathionine gamma-lyase activityCystathionine gamma-lyaseHomo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau-protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein serine/threonine phosphatase activityUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
protein bindingUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
myosin phosphatase activityUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
metal ion bindingUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
proteasome regulatory particle bindingUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
phosphorylase kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase activator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (76)

Processvia Protein(s)Taxonomy
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit beta-2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
extracellular regionPolymerase acidic proteinInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytosolCarbonic anhydrase 3Homo sapiens (human)
cytoplasmCarbonic anhydrase 3Homo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular spaceHigh mobility group protein B1Homo sapiens (human)
condensed chromosomeHigh mobility group protein B1Homo sapiens (human)
extracellular regionHigh mobility group protein B1Homo sapiens (human)
extracellular spaceHigh mobility group protein B1Homo sapiens (human)
nucleusHigh mobility group protein B1Homo sapiens (human)
nucleoplasmHigh mobility group protein B1Homo sapiens (human)
endosomeHigh mobility group protein B1Homo sapiens (human)
endoplasmic reticulumHigh mobility group protein B1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentHigh mobility group protein B1Homo sapiens (human)
cell surfaceHigh mobility group protein B1Homo sapiens (human)
secretory granule lumenHigh mobility group protein B1Homo sapiens (human)
ficolin-1-rich granule lumenHigh mobility group protein B1Homo sapiens (human)
transcription repressor complexHigh mobility group protein B1Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexHigh mobility group protein B1Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
endoplasmic reticulum lumenProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
endoplasmic reticulumProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCystathionine gamma-lyaseHomo sapiens (human)
extracellular exosomeCystathionine gamma-lyaseHomo sapiens (human)
cytoplasmCystathionine gamma-lyaseHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
membrane5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Golgi apparatus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasmic stress granule5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
apical plasma membrane5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
nucleusUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
nucleoplasmUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
nucleolusUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
nucleusUbiquitin-like domain-containing CTD phosphatase 1Homo sapiens (human)
extracellular space5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-3Homo sapiens (human)
extracellular space5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5B, mitochondrialHomo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (342)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1136213Analgesic activity in po dosed rat by hyperesthesia test1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids.
AID681141TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID681372TP_TRANSPORTER: inhibition of MTX uptake in OAT3-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID1257052Inhibition of human carbonic anhydrase 9 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.
AID1691172Inhibition of human COX1 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate incubated for 10 mins by ELISA2020European journal of medicinal chemistry, May-01, Volume: 193Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation.
AID25613Dissociation constant was determined spectrophotometrically; Experiment 21982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID604741Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID369620Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID369264Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID467611Dissociation constant, pKa of the compound2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1289671Drug level in Sprague-Dawley rat epididymal fat treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po administered for 7 days measured 4 hrs post dose on day 72016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID681118TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003International journal of pharmaceutics, Sep-16, Volume: 263, Issue:1-2
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
AID223690Inhibitory activity against protein tyrosine phosphatases (PTP1B) (Kis=slope inhibitory constant)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B.
AID1656449Inhibition of beta-glucuronidase (unknown origin) at 10 mg/ml relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID369259Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID679522TP_TRANSPORTER: inhibition of PAH uptake (PAH: 1 uM, Salicylate: 100 uM) in Xenopus laevis oocytes1999Biochemical and biophysical research communications, Feb-16, Volume: 255, Issue:2
Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3).
AID1449688Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID369615Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID369255Induction of ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as total RNA content after 30 mins by RT-PCR2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID25608Dissociation constant was determined at pH 7.21982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1289641Inhibition of NFkappaB in mouse RAW 264.7 cells at 3.2 mM preincubated for 2 hrs followed by LPS addition for 3 hrs by luciferase reporter gene assay relative to control2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID1320680Allosteric activation of rat liver AMPK in presence of ATP relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators.
AID349145Inhibition of human carbonic anhydrase 2 esterase activity by non-competitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1189226Activation of AMPK in HEK293 cells relative to control2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.
AID369618Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID342476Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID385427Inhibition of soybean 15-lipoxygenase2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Inhibition of 15-lipoxygenase-catalysed oxygenation of arachidonic acid by substituted benzoic acids.
AID369252Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1238827Retention time of the compound in C57BL/6J mouse colon treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID1145615Dissociation constant, pKa of the compound at pH 7.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID369418Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266761Effective permeability coefficient in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID342478Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID369613Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1449687Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as increase in localization of protein mutant in plasma membrane after 12 hrs by DAPI staining based immunofluorescence microscopic anal2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID369257Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1083150Nematotoxic activity against Meloidogyne incognita (root-knot nematode)2012Journal of agricultural and food chemistry, Nov-28, Volume: 60, Issue:47
Nematotoxic phenolic compounds from Melia azedarach against Meloidogyne incognita.
AID20050Human absorption A (%)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID316997Chemical stability in aqueous buffer at pH 1 after 3 hrs2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID342483Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID107292Compound was evaluated for its analgesic activity in mice by mouse phenylquinone writhing assay, and the activity relative to aspirin was reported; Not tested1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID293934Inhibition of pieris rapae Phenoloxidase2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID619728Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at dose equimolar to 120 mg/kg aspirin, administered intragastrically immediately after carrageenan challenge measured after 3 hrs by water plethysmometer rela2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans.
AID302815Dissociation constant, pKa of the compound2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.
AID1289670Drug level in Sprague-Dawley rat muscle treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po administered for 7 days measured 4 hrs post dose on day 72016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID1163260Cytotoxicity against mouse RAW264.7 cells assessed as reduction in survival rate after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID732290Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced TNFalpha release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1221782Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 1 mM measured up to 72 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID678845TP_TRANSPORTER: inhibition of (Ochratoxin A: 0.5uM) of Salicylate at a concentration of 100uM in Oat5-expressing oocytes2004American journal of physiology. Renal physiology, Aug, Volume: 287, Issue:2
Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney.
AID1271201Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Cytotoxic Activity of Salicylic Acid-Containing Drug Models with Ionic and Covalent Binding.
AID743974Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of swarming motility at 0.1 to 0.5 mM after 24 hrs relative to control2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis of (R)-norbgugaine and its potential as quorum sensing inhibitor against Pseudomonas aeruginosa.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID555372Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.50 % after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1739641Antimycobacterial activity activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of microbial growth incubated for 4 weeks in culture medium at pH 6.82020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
AID288193Flux ionization constant, pKa of the membrane permeability coefficient of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1136212Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis and analgesic-antiinflammatory activity of some 4- and 5-substituted heteroarylsalicylic acids.
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID1104045Induction of systemic resistance (ISR) activity in Nicotiana tabacum (tobacco) seedlings against pectobacterium carotovorum subsp. carotovorum SCC1 assessed as decrease in disease symptoms on leaves at 1 mM applied to roots prior to leaf infection with SC2009Pest management science, Oct, Volume: 65, Issue:10
Identification of an ISR-related metabolite produced by rhizobacterium Klebsiella oxytoca C1036 active against soft-rot disease pathogen in tobacco.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID743972Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of twitching motility at 0.1 to 0.5 mM after 24 hrs relative to control2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis of (R)-norbgugaine and its potential as quorum sensing inhibitor against Pseudomonas aeruginosa.
AID1145608Drug absorption in anesthetized rat colon at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID555341Effect on growth in Staphylococcus aureus MN8 at 0.10 % after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1075889Reversible inhibition of bovine xanthine oxidase2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1691198Induction of apoptosis in LPS-induced hippocampal neuroinflammatory Kunming mouse model at 50 mg/kg, ip administered bid for 6 days by Nissl staining based microscopic method2020European journal of medicinal chemistry, May-01, Volume: 193Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation.
AID604742Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID460784Inhibition of IKK-beta by tome resolved fluorescence assay2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Inhibition of IKK-beta: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32.
AID1257051Inhibition of human carbonic anhydrase 2 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.
AID332455Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA at 0.8 mM1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID288210Antifungal activity against Aspergillus parasiticus MTCC 8189 by serial dilution method2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID1237124Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration at 0.75 uM applied topically 6 mins before to TPA treatment by H and E staining method2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID369265Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1680654Inhibition of human CSE using L-Cys as the substrate by tandem well based HTS assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase.
AID679453TP_TRANSPORTER: inhibition of benzylpenicillin uptake by Salicylate at a concentration of 1000uM in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID449283Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 10 ug/ml treated for 1 hr before LPS challenge measured after 24 hrs by Griess reagent method2009Bioorganic & medicinal chemistry letters, Sep-15, Volume: 19, Issue:18
Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
AID1289660Drug level in Sprague-Dawley rat plasma treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po measured up to 24 hrs post dose2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID607497Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.
AID1221780Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID342480Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1494167Binding affinity to recombinant HMGB1 box A (unknown origin)2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target.
AID1449693Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as translocation of mutant protein from cytoplasm to plasma membrane at 10 mM measured after 12 hrs by DAPI staining based immunofluores2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1083149Nematotoxic activity against freshly hatched Meloidogyne incognita J2 (root-knot nematode) isolated from tomato roots assessed as induction of nematode paralysis measured 24 hr after immersion in compound test solutions2012Journal of agricultural and food chemistry, Nov-28, Volume: 60, Issue:47
Nematotoxic phenolic compounds from Melia azedarach against Meloidogyne incognita.
AID1289669Drug level in Sprague-Dawley rat liver treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po administered for 7 days measured 4 hrs post dose on day 72016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID1238826Retention time of the compound in C57BL/6J mouse feces treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1691173Inhibition of human COX2 assessed as reduction in PGF2alpha formation using arachidonic acid as substrate incubated for 10 mins by ELISA2020European journal of medicinal chemistry, May-01, Volume: 193Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation.
AID631930Dissociation constant, pKa of the compound2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1699027Inhibition of quorum sensing system in Pseudomonas aeruginosa2020Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21
Next generation quorum sensing inhibitors: Accounts on structure activity relationship studies and biological activities.
AID24263Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of N,N-diethylglycolamide ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID639952Inhibition of TNF-alpha-induced NF-kappaB activation in human HCT116 cells at 1 mM after 6 hrs by luciferase reporter gene assay2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID342481Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID397153Antioxidant activity against Cu2+-induced lipid peroxidation in human plasma LDL preincubated for 1 hr before Cu2+ challenge2001Journal of natural products, Apr, Volume: 64, Issue:4
Specific antioxidant activity of caffeoyl derivatives and other natural phenolic compounds: LDL protection against oxidation and decrease in the proinflammatory lysophosphatidylcholine production.
AID1449703Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as fluorescence intensity ratio of plasma membrane to cytoplasm at 10 mM measured after 12 hrs by DAPI staining based immunofluorescence2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID454619Inhibition of beta-glucuronidase at 10 uM2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents.
AID1238829Retention time of the compound in C57BL/6J mouse urine treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID681340TP_TRANSPORTER: inhibition of PAH uptake in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID342485Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID743966Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation at 4 mM after 24 hrs by crystal violet staining method relative to control2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis of (R)-norbgugaine and its potential as quorum sensing inhibitor against Pseudomonas aeruginosa.
AID369250Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID631927Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID369263Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID604744Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1289672Drug level in Sprague-Dawley rat brain treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po administered for 7 days measured 4 hrs post dose on day 72016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID266760Permeability coefficient in silicon membrane using diffusion cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID369266Effect on ompF-lacZ fusion transcription in marA-negative Escherichia coli CH164 mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID34782In vitro inhibition of rabbit lens aldose reductase.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1449742Selectivity ratio of Ki for recombinant human carbonic anhydrase 2 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID653541Inhibition of PTP1B expressed in Escherichia coli BL21 (DE3) cells using p-nitrophenyl phosphate as substrate after 2 to 3 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1238825Retention time of the compound in C57BL/6J mouse intestine content treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID1257050Inhibition of human carbonic anhydrase 1 incubated for 15 mins prior to testing by stopped flow CO2 hydration assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.
AID1223491Apparent permeability across human differentiated Caco2 cells at 500 uM after 1 hr by HPLC-DAD analysis2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID384955Intrinsic aqueous solubility at pH 10 by shake-flask method2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Molecular characteristics for solid-state limited solubility.
AID1163261Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP+ multinucleated cells level at 10 uM incubated for 4 days by TRAP staining assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1494168Binding affinity to recombinant HMGB1 box B (unknown origin)2018Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12
High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target.
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID342486Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID342477Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1083148Nematotoxic activity against freshly hatched Meloidogyne incognita J2 (root-knot nematode) isolated from tomato roots assessed as induction of nematode paralysis at 1000 ug/mL measured 24 hr after immersion in compound test solutions2012Journal of agricultural and food chemistry, Nov-28, Volume: 60, Issue:47
Nematotoxic phenolic compounds from Melia azedarach against Meloidogyne incognita.
AID369617Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID342484Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID34789In vitro inhibition of rabbit lens aldose reductase at 10e-6 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID28926Effective permeability corrected for ionization2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID369616Effect on ompF-lacZ fusion translation in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID55746Inhibitory activity against family of dihydroorotate dehydrogenase 1A (1A DHOD) from Lactococcus lactis at 1 uMolar concentration2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Specific inhibition of a family 1A dihydroorotate dehydrogenase by benzoate pyrimidine analogues.
AID208331Binding to stromelysin (MMP-3) in place of acetohydroxamic acid.2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
AID170137Compound was evaluated for its ability to reduce carrageenan induced inflammation of rat paw and activity relative to phenylbutazone was reported; Not tested1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID369251Increase in ompX-lacZ expression in Escherichia coli JM109 assessed as increase in beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1145610Dissociation constant, pKa of the compound at pH 6.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1656450Inhibition of beta-glucuronidase (unknown origin) at 1 mM relative to control2020European journal of medicinal chemistry, Feb-01, Volume: 187Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.
AID436417Gastrointestinal toxicity in Wistar rat assessed as ulcer index at 2290 mg/kg, po by Rainsford's cold stress method2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
AID28921Partition coefficient (logP) (hexadecane)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID331291Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID1238830Retention time of the compound in C57BL/6J mouse plasma treated with RAH at 200 mg/kg, ig by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID743973Inhibition of quorum sensing system in Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of swimming motility at 0.1 to 0.5 mM after 24 hrs relative to control2013Bioorganic & medicinal chemistry letters, Apr-15, Volume: 23, Issue:8
Synthesis of (R)-norbgugaine and its potential as quorum sensing inhibitor against Pseudomonas aeruginosa.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1307967Inhibition of human recombinant COX1 expressed in Sf9 cell microsomes assessed as reduction in conversion of arachidonic acid to PGE2 incubated for 5 mins by HTRF assay2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Impact of Binding Site Comparisons on Medicinal Chemistry and Rational Molecular Design.
AID342475Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID91481Binding constant against human serum albumin (HSA)2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Cheminformatic models to predict binding affinities to human serum albumin.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1237111Anti-inflammatory activity in BALB/c mouse model of TPA-induced ear edema assessed as reduction in inflammatory cells infiltration applied topically in combination with curcumin at at 1:1 mol/mol 6 mins before to TPA treatment by H and E staining method2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID1238824Drug level in human HCT116 cells treated with RAH at 20 uM after 4 to 24 hrs by HPLC-CEAD analysis2015Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16
Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID766251Inhibition of recombinant SPM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using FC4 as substrate assessed as residual activity at 1 mM preincubated for 10 mins prior to substrate addition by fluorescence-based assay relative to contr2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Assay platform for clinically relevant metallo-β-lactamases.
AID369619Effect on ompF-lacZ fusion translation in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID316998Chemical stability in aqueous buffer at pH 7.4 after 3 hrs2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID332912Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method1994Journal of natural products, Jan, Volume: 57, Issue:1
Naturally occurring antiacne agents.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID24265Ability to undergo in vitro ester hydrolysis in 80% human plasma ( pH of 7.4) at 37 degree Celsius expressed as half life of methyl ester hydrolysis1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Esters of N,N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents.
AID369253Increase in ompX-lacZ expression in Enterobacter aerogenes ATCC 15038 assessed as increase in beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID342482Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1289631Drug level in Sprague-Dawley rat plasma treated with N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)-2-hydroxybenzamide at 300 mg/kg, po administered for 7 days measured 4 hrs post dose on day 72016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID607496Inhibition of human CA6 using 4-nitrophenylacetate substrate by esterase assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID331293Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID349140Inhibition of human carbonic anhydrase 1 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID732289Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced IL-1beta release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID566711Inhibition of mushroom tyrosinase after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1424231Antioxidant activity assessed as DPPH free radical scavenging activity2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID678787TP_TRANSPORTER: inhibition of MTX uptake in Xenopus laevis oocytes2000European journal of pharmacology, Dec-01, Volume: 409, Issue:1
Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter.
AID680187TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Salicylate: 500 uM) in Xenopus laevis oocytes2000The Journal of biological chemistry, Feb-11, Volume: 275, Issue:6
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
AID288194Intrinsic artificial membrane permeability coefficient, log P0 of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID409741Inhibition of PTP1B expressed in Escherichia coli2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Derivatives of 1,4-bis(3-hydroxycarbonyl-4-hydroxyl)styrylbenzene as PTP1B inhibitors with hypoglycemic activity.
AID1145605Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID666145Plaque growth inhibition2012ACS chemical biology, Mar-16, Volume: 7, Issue:3
Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.
AID1090826Antifeedant activity against Hylobius abietis (pine weevil ) in compound pre-treated Scots pine twig at 50 mM measured after 24 hr by two-choice laboratory bioassay2007Journal of agricultural and food chemistry, Nov-14, Volume: 55, Issue:23
Quantitative structure-activity relationships of pine weevil antifeedants, a multivariate approach.
AID639957Inhibition of NF-kappaB-mediated iNOS protein expression in LPS-stimulated mouse RAW264.7 cells at 2 to 4 mM by Western blot analysis2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID604743Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions.
AID1163259Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 10 uM after 24 hrs by MTT assay2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
AID369262Effect on ompF-lacZ fusion transcription in wild type Escherichia coli AG100 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID25612Dissociation constant was determined spectrophotometrically; Experiment 11982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID93781Inhibitory activity against proteolytic release of C5a in activated human serum was determined2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Synthesis and complement inhibitory activity of B/C/D-ring analogues of the fungal metabolite 6,7-diformyl-3',4',4a',5',6',7',8',8a'-octahydro-4,6',7'-trihydroxy- 2',5',5',8a'-tetramethylspiro[1'(2'H)-naphthalene-2(3H)-benzofuran].
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID680161TP_TRANSPORTER: uptake of Salicylic acid at a concentration of 1.43uM in OATP2B1-expressing HEK293 cells2005Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 33, Issue:4
Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B.
AID38551Inhibitory activity against binding of [125I]IMSB to amyloid beta in brain2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID28928Intrinsic permeability of the compound2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID555340Effect on growth in Staphylococcus aureus MN8 at 0.50 % after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID639955Inhibition of NF-kappaB-mediated iNOS protein expression in LPS-stimulated mouse RAW264.7 cells at 5 mM by Western blot analysis2012European journal of medicinal chemistry, Feb, Volume: 48Structure-activity relationship of salicylic acid derivatives on inhibition of TNF-α dependent NFκB activity: Implication on anti-inflammatory effect of N-(5-chlorosalicyloyl)phenethylamine against experimental colitis.
AID1209592Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID679487TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999Molecular pharmacology, May, Volume: 55, Issue:5
Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID12234891-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake flask method2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1691192Antiinflammatory activity against LPS-induced hippocampal neuroinflammatory Kunming mouse model assessed as reduction in GFAP level in hippocampus at 50 mg/kg, ip administered bid for 6 days by DAPI staining based microscopic method2020European journal of medicinal chemistry, May-01, Volume: 193Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation.
AID401415Inhibition of bovine brain PI-PLCgamma11998Journal of natural products, Jul, Volume: 61, Issue:7
Phospholipase Cgamma1 inhibitory principles from the sarcotestas of Ginkgo biloba.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID40626Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined; No inhibition at 5*10e-2 M1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID332456Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID1695183Inhibition of recombinant bovine liver ARGI at 500 uM using L-arginine as substrate incubated for 60 mins by spectroscopic analysis relative to control2020RSC medicinal chemistry, May-01, Volume: 11, Issue:5
Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.
AID681046TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Salicylate: 5 uM) in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1449741Selectivity ratio of Ki for recombinant human carbonic anhydrase 1 to Ki for recombinant Malassezia globosa beta-carbonic anhydrase2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID349141Inhibition of human carbonic anhydrase 2 esterase activity by spectrophotometry2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID1223492Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID342479Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1449689Cytotoxicity against HEK293 cells harboring pendrin P123S mutant assessed as decrease in cell viability at 15 mM after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID679539TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, Salicylate: 1000 uM) in OAT1-expressing S2 cells2002The Journal of pharmacology and experimental therapeutics, Aug, Volume: 302, Issue:2
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
AID34786In vitro inhibition of rabbit lens aldose reductase at 10e-4 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1252320Antioxidant activity assessed as DPPH free radical scavenging activity at 0.01 to 1 mM after 30 mins2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
The antioxidant properties of salicylate derivatives: A possible new mechanism of anti-inflammatory activity.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1449738Inhibition of Malassezia globosa recombinant beta-carbonic anhydrase preincubated for 15 mins prior to testing measured for 10 to 100 secs by phenol red-based stopped-flow CO2 hydration assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Inhibition of Malassezia globosa carbonic anhydrase with phenols.
AID331292Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.
AID454618Inhibition of ovine COX2 at 1 mM by colorimetric assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents.
AID309363Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs2007Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20
Synthesis and anti-inflammatory activity of 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid and its ester derivatives.
AID1236243Inhibition of Mycobacterium tuberculosis protein tyrosine phosphatase B expressed in Escherichia coli BL21/DE using pNPP substrate by spectrophotometry2014MedChemComm, Oct, Volume: 5, Issue:10
Diversity-Oriented Synthesis for Novel, Selective and Drug-like Inhibitors for a Phosphatase from Mycobacterium Tuberculosis.
AID1237122Anti-inflammatory activity in BALB/c mouse assessed as reduction in TPA-induced ear edema by measuring weight of ear punches applied topically in combination with curcumin at at 1:1 mol/mol 6 mins before to TPA treatment2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Synthesis and biological evaluation of curcumin derivatives containing NSAIDs for their anti-inflammatory activity.
AID288209Antifungal activity against Aspergillus ficuum MTCC 8184 by serial dilution method2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis, antimicrobial, and QSAR studies of substituted benzamides.
AID1449702Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as increase in fluorescence intensity ratio of plasma membrane to cytoplasm measured after 12 hrs by DAPI staining based immunofluoresce2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID369624Induction of ompX transcription in marA-positive Escherichia coli K12 relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID34788In vitro inhibition of rabbit lens aldose reductase at 10e-5 M.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Antiinflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids.
AID1271200Cytotoxicity against human 3215LS cells after 24 hrs by MTT assay2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Cytotoxic Activity of Salicylic Acid-Containing Drug Models with Ionic and Covalent Binding.
AID369258Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID369614Effect on ompF-lacZ fusion translation in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID349142Inhibition of human carbonic anhydrase 1 esterase activity by noncompetitive Lineweaver-Burke plot2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.
AID7596The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID1167300Antioxidant activity assessed as DPPH radical scavenging activity incubated at room temperature for 20 mins by UV-visible spectrophotometry2014Bioorganic & medicinal chemistry letters, Nov-01, Volume: 24, Issue:21
Design, synthesis and exploring the quantitative structure-activity relationship of some antioxidant flavonoid analogues.
AID454616Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID681371TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Molecular pharmacology, Jul, Volume: 62, Issue:1
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID681575TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998FEBS letters, Jun-12, Volume: 429, Issue:2
Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID1271202Aqueous solubility of compound at room temperature2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Cytotoxic Activity of Salicylic Acid-Containing Drug Models with Ionic and Covalent Binding.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID369248Increase in ompX-lacZ expression in Escherichia coli deltaompX mutant assessed as ompX upregulation after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID653544Inhibition of Yersinia pseudotuberculosis YopH2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors.
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1397963Inhibition of mouse recombinant glycolate oxidase expressed in Escherichia coli at 25 uM using glycolate as substrate after 1 min by sulfonated DCIP dye-based assay relative to control2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID369260Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 90 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID679947TP_TRANSPORTER: uptake of Salicylic acid at a concentration of 9uM in MCT1-expressing MDA-MB231 cells1999The Journal of pharmacy and pharmacology, Oct, Volume: 51, Issue:10
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
AID1449694Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as intracellular localization of mutant protein in plasma membrane at 10 mM incubated for 12 hrs followed by compound washout measured a2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1585833Inhibition of acetylcholinesterase (unknown origin)2018Bioorganic & medicinal chemistry, 12-15, Volume: 26, Issue:23-24
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID619730Ulcerogenicity in Wistar rat assessed as damage in gastric mucosa-lesion index at dose equimolar to 120 mg/kg aspirin, administered intragastrically after 3 hrs by stereomicroscopy2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans.
AID369261Effect on ompF-lacZ fusion transcription in ompX-negative Escherichia coli mutant assessed as percent decrease in Miller units of beta-galactosidase activity after 120 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID19419Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.
AID732288Antiinflammatory activity in human macrophages assessed as inhibition of LPS-induced IL-8 release at 10 uM preincubated for 30 mins before LPS-challenge measured after 24 hrs post challenge by ELISA2013European journal of medicinal chemistry, Apr, Volume: 62Peroxisome proliferator-activated receptor-γ mediates the anti-inflammatory effect of 3-hydroxy-4-pyridinecarboxylic acid derivatives: synthesis and biological evaluation.
AID1136196Antiinflammatory activity against carrageenan-induced foot edema in rat administered via gastric gavage1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Novel analgesic-antiinflammatory salicylates.
AID681168TP_TRANSPORTER: uptake in Oat3-expressing oocyte cells2004The Journal of pharmacology and experimental therapeutics, Jun, Volume: 309, Issue:3
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID369256Effect on ompF-lacZ fusion transcription in wild type Escherichia coli MC1061 assessed as percent decrease in Miller units of beta-galactosidase activity after 60 mins relative to control2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
An early response to environmental stress involves regulation of OmpX and OmpF, two enterobacterial outer membrane pore-forming proteins.
AID454617Inhibition of trypsin at 10 uM2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents.
AID1424230Electrochemical behaviour of the compound assessed as peak potential using disposable screen-printed carbon electrodes2017European journal of medicinal chemistry, Jun-16, Volume: 133Free radicals and polyphenols: The redox chemistry of neurodegenerative diseases.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1206774Inhibition of His6-tagged UBLCP1 (unknown origin) expressed in Escherichia coli BL21 cells using pNPP as substrate at pH 6 at 25 degC by spectrophotometric analysis2015Bioorganic & medicinal chemistry, Jun-15, Volume: 23, Issue:12
A potent and selective inhibitor for the UBLCP1 proteasome phosphatase.
AID555373Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 0.10 % after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1798641CA Inhibition Assay from Article 10.1016/j.bmc.2008.06.013: \\Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.\\2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.
AID1799825Inhibition Assay from Article : \\Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.\\1986The Journal of biological chemistry, Jun-15, Volume: 261, Issue:17
Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21,281)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905099 (23.96)18.7374
1990's2738 (12.87)18.2507
2000's4166 (19.58)29.6817
2010's6408 (30.11)24.3611
2020's2870 (13.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.34 (24.57)
Research Supply Index10.07 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index277.91 (26.88)
Search Engine Supply Index3.90 (0.95)

This Compound (76.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials771 (3.37%)5.53%
Reviews1,468 (6.42%)6.00%
Case Studies5,974 (26.13%)4.05%
Observational68 (0.30%)0.25%
Other14,583 (63.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Resilient Occlusal Splints in the Control of Patients With Temporomandibular Disorder (TMD) [NCT01150110]Early Phase 10 participants Interventional2007-07-31Completed
The Evaluation of the Usefulness of Shear Wave Sonoelastography in the Diagnosis and Monitoring of the Management of Masseter Muscles Disorders in the Course of Temporomandibular Disorders [NCT03844854]150 participants (Anticipated)Interventional2019-04-20Not yet recruiting
CLINICAL ASSESSMENT OF THE EFFECTIVENESS OF ASSOCIATION MONETASONE FUROATE 0.1% SALICYLIC ACID AND 5% FOR SUBMISSION OF OINTMENT TOPICAL DERMATOLOGICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS. [NCT01229085]Phase 371 participants (Actual)Interventional2006-09-30Completed
Evaluation of the Effectiveness of Infrared LED Photobiomodulation in Children With Sleep Bruxism: Study Protocol for Randomized Clinical Trial. [NCT03710174]Phase 220 participants (Anticipated)Interventional2017-08-01Recruiting
Effectiveness of a Jaw Exercise Program in Temporomandibular Disorders Patients [NCT02397070]30 participants (Anticipated)Interventional2015-01-31Recruiting
Forward Head Posture Correction Impact on Temporomandibular Dysfunction: A Randomized Controlled Trial [NCT06123351]63 participants (Anticipated)Interventional2024-02-29Not yet recruiting
Digitally Fabricated Inter-occlusal Wafer Versus Wafer-less Distal Segment Repositioning for Bilateral Sagittal Split Osteotomy in Skeletal Mandibular Deformities (Randomized Controlled Trial) [NCT05151042]24 participants (Anticipated)Interventional2021-11-15Recruiting
Evaluation of Postoperative Pain Intensity Following Occlusal Reduction in Teeth Associated With Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis: A Randomized Clinical Study [NCT03117062]44 participants (Actual)Interventional2014-09-30Completed
Influence of Dental Occlusion on the Performance of High Level Rowers (IODPR) [NCT03648125]7 participants (Actual)Interventional2017-10-27Terminated(stopped due to Limited time between the beginning and the end of the inclusions, only 7 high level rowers available within the time compatible with research realization)
Climatotherapy at Red Sea - Hurghada Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis [NCT03156062]30 participants (Anticipated)Interventional2017-07-01Not yet recruiting
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial [NCT05611242]Phase 3404 participants (Anticipated)Interventional2023-11-01Recruiting
Survival Rate and Cost Effectiveness From Two Different Materials of GIC Using in Occlusol-proximal ART Restorations in Primary Molars [NCT02267720]70 participants (Anticipated)Interventional2014-11-30Active, not recruiting
Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart [NCT02151630]Phase 2/Phase 360 participants (Anticipated)Interventional2014-05-31Recruiting
Use of an Occlusal Support Device During the Second Stage of Labor [NCT02807493]347 participants (Actual)Interventional2017-04-01Completed
Quantitative Evaluation of Osteopathic Treatment in Temporomandibular Joint Disorders Using Magnetic Resonance Imaging [NCT04468464]19 participants (Anticipated)Interventional2018-09-15Active, not recruiting
Multicentre, Randomized, Parallel, Double-Blind, Vehicle Controlled Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In The Field-Directed Treatment Of Actinic Keratoses Grade I To II (Field Cancerization) [NCT02289768]Phase 3166 participants (Actual)Interventional2014-10-31Completed
Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. [NCT01139749]Phase 450 participants (Anticipated)Interventional2011-10-31Recruiting
Effects of Occlusal Splint and Therapeutic Home Exercises on Neuropathic Pain and Oral Health-related Quality of Life in Temporomandibular Disorders: a Randomized Prospective Study [NCT04116255]101 participants (Actual)Interventional2019-10-05Completed
Evaluation of the Antidandruff Effect of a Shampoo on Subjects With Dandruff and Slight Itching. Single-blind, Monocentric Study Realized Under Dermatological Control [NCT05503706]40 participants (Anticipated)Interventional2022-09-30Not yet recruiting
Effect of Laser Irradiation Versus Anterior Repositioning Splint in Treatment of Disc Displacement With Reduction A Randomized Controlled Clinical Trial [NCT03576079]30 participants (Actual)Interventional2015-09-01Completed
Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris [NCT05712837]60 participants (Actual)Interventional2022-06-01Completed
Topical Silymarin Cream Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: Split Face Study [NCT04490967]Phase 430 participants (Anticipated)Interventional2021-04-30Not yet recruiting
Evaluation of Postural Balance in Individuals With Temporomandibular Disorder by Means of Force Platform After Using Occlusal Stabilizer Splint Disorder [NCT02251015]Phase 349 participants (Actual)Interventional2011-07-31Completed
Effect of Occlusal Reduction on Post-operative Pain in Patients With Irreversible Pulpitis and Symptomatic Apical Periodontitis Treated in a Single-visit: A Randomized Clinical Trial [NCT03189771]52 participants (Anticipated)Interventional2017-06-27Not yet recruiting
Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial [NCT06108947]300 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Randomized Controlled Trial of Efficiency of Moisturizer Containing Licochalcone A, Decanediol, L-carnitine and Salicylic Acid in Reducing Relapsing of Acne in Thai Acne Subjects [NCT04002024]50 participants (Actual)Interventional2019-06-01Completed
Randomized, Single Blind, Placebo Controlled Clinical Trial to See the Effect of Combination of Neem, Propylene Glycol and Salicylic Acid in the Treatment of Arsenical Palmar Keratosis [NCT02352987]Phase 230 participants (Actual)Interventional2015-03-31Completed
[NCT00904631]20 participants (Anticipated)Interventional2009-05-31Recruiting
Clinical Evaluation of Stabilizing Splint (Michigan-type Occlusal Splint) Versus Anterior Repositioning Splint in Patients With Temporomandibular Joint Anterior Disc Displacement With Reduction . ( Randomized Controlled Clinical Study) [NCT02960048]60 participants (Anticipated)Interventional2016-11-30Not yet recruiting
Postendodontic Pain Following Occlusal Reduction in Mandibular Posterior Teeth: a Single-centre Randomized Controlled Trial [NCT04186897]308 participants (Actual)Interventional2014-09-30Completed
An Follow-up Study of Occlusal Adjustment for Orofacial Pain [NCT02856906]30 participants (Anticipated)Interventional2016-08-31Recruiting
Clinical Performance of Two CAD/CAM Fabricated Ceramic Restorations With Different Preparation Designs for Rehabilitation Of Permanent First Molars Affected With Molar Incisor Hypomineralisation (MIH): Clinical Randomized Trial [NCT05434884]64 participants (Actual)Interventional2020-07-10Completed
The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma [NCT00616239]Phase 420 participants (Actual)Interventional2008-01-31Completed
A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State [NCT01409616]Phase 1100 participants (Actual)Interventional2009-04-30Completed
"Comparative Study of the Accuracy of Dental Contacts of an Occlusal Splint Made According to Conventional or Digital Techniques Using GeoMagic®." [NCT05317182]40 participants (Actual)Interventional2022-02-17Completed
Clinical Performance Of Lithium Disilicate Crowns Restoring Endodontically Treated Teeth With Two Occlusal Preparation Schemes [NCT04054674]40 participants (Actual)Interventional2019-10-10Completed
Evaluation Of Zirconia Crowns Restoring Endodontically Treated Posterior Teeth With Two Finish Line Designs And Occlusal Reduction Schemes [NCT04052490]66 participants (Actual)Interventional2019-10-01Completed
Comparison of a Biofeedback-Based Cognitive Behavioral Treatment and Occlusal Splint Therapy for Temporomandibular Disorders. A Randomized Clinical Trial. [NCT00769561]Phase 2/Phase 358 participants (Actual)Interventional2008-08-31Completed
Evaluation of Muscle Activity, Bite Force and Salivary Cortisol in Children With Bruxism Before and After Laser Use of Low Power in Acupoints- Controlled Clinical Trial [NCT02757261]Early Phase 176 participants (Anticipated)Interventional2016-06-30Not yet recruiting
A Multi-Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments [NCT02755545]Phase 4127 participants (Actual)Interventional2016-05-01Completed
The Effect of Occlusal Splints on Sleep and Respiratory Variables of OSA Patients [NCT01004692]Phase 110 participants (Actual)Interventional2008-12-31Enrolling by invitation
[NCT01874041]42 participants (Actual)Interventional2010-01-31Completed
Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis: Randomized, Double Blind, Placebo-controlled Trial [NCT01731756]50 participants (Actual)Interventional2013-01-31Completed
U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne [NCT01706263]Phase 428 participants (Actual)Interventional2009-08-01Completed
The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk [NCT00898950]21 participants (Actual)Interventional2004-08-31Completed
Assessment of Virtual Digital Articulation Versus Hand-articulation Accuracy for Occlusal Registration in Orthognathic Surgery (Randomized Clinical Trial) [NCT06168279]18 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Single-centre Randomised, Active-controlled, Observer-blinded, Parallel Group Trial to Evaluate the Efficacy and Safety of a Topical Dimeticone Formulation (Loion®) Compared to 10% Salicylic Acid in the Removal of Scaling in Patients With Chronic Psoria [NCT01914627]Phase 290 participants (Actual)Interventional2013-08-31Completed
Anwendung Von Elektromyographie Mit Gleichzeitigem Bio-Feedback Zur Behandlung Von Craniomandibulären Dysfunktionen Und/Oder Bruxismus. [NCT01949064]Phase 244 participants (Actual)Interventional2011-07-31Completed
How Does Orthognathic Surgery Affect Jaw and Neck Motor Function? [NCT05876169]40 participants (Anticipated)Interventional2022-09-06Enrolling by invitation
Behavioral Therapy and Self-care vs Thermoformed Occlusal Splints in the Treatment of Masticatory Muscles Pain: a Controlled Clinical Trial. [NCT04588636]46 participants (Actual)Interventional2017-10-16Completed
Cost Effectiveness Analysis for Combination Of Aspirin And Warfarin Versus Warfarin Alone In Egyptian Patients With Heart Valve Prosthesis [NCT02022527]Phase 4300 participants (Anticipated)Interventional2013-06-30Recruiting
Additional Effect of Pain Neuroscience Education, Motor Imagery and Action Observation in Patients With Chronic Temporomandibular Disorders. A Randomized Controlled Trial [NCT05003349]50 participants (Anticipated)Interventional2021-08-31Recruiting
A Prospective, Randomized, Controlled, Open-labelled Investigation to Assess Performance and Safety of Orkla Corn Plaster [NCT04601259]55 participants (Actual)Interventional2020-10-21Completed
Characteristics of Cytokine Response in Patients With Temporomandibular Disorders Treated With Occlusal Splint Therapy [NCT06043024]28 participants (Anticipated)Interventional2023-08-16Recruiting
Which is More Effective in Management of Bruxism for Implant Overdenture Patients: Botox or Occlusal Splints - A One Year Clinical Study [NCT04366869]42 participants (Actual)Interventional2019-07-07Completed
Single-group, Comparative Biomechanical Study of Maxillary and Mandibular Splints Used for the Treatment of Masticatory Muscle Parafunction [NCT05007691]12 participants (Actual)Interventional2021-07-16Active, not recruiting
Relief of Signs and Symptoms in Patients With Tempro-mandibular Disorders Using Occlusal Stabilization Splints Equilibrated by T-scan Versus Articulating Paper: A Randomized Clinical Trial [NCT04661670]28 participants (Anticipated)Interventional2021-05-01Recruiting
Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women. [NCT02797249]Phase 31,000 participants (Actual)Interventional2016-12-07Completed
Use of Botox Versus Conventional Treatment for Pain Decrease of Muscular Pain: a Randomized Controlled Trial [NCT03456154]Phase 460 participants (Actual)Interventional2018-03-15Completed
A Randomized, Open Label, Three-way Crossover Study to Evaluate the Pharmacodynamic Interactions Between Darexaban (YM150)/Darexaban Glucuronide (YM-222714) and Acetyl Salicylic Acid (ASA) in Healthy Male Subjects [NCT01424332]Phase 124 participants (Actual)Interventional2007-12-31Completed
Analyzing the Relationship Between Periodontal Health Status and Alzheimer's Disease [NCT05807100]90 participants (Actual)Observational [Patient Registry]2022-03-02Completed
Prospective Investigation of the Effects of Different Treatment Techniques on Myofascial Trigger Points in Patients With Temporomandibular Dysfunction (TMD) [NCT04456946]40 participants (Actual)Interventional2022-04-12Completed
The Effect of Occlusal Splint Type on Sleep Quality and Occlusal Force in Patients With Sleep Bruxism [NCT04934449]100 participants (Actual)Interventional2021-08-06Completed
Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study [NCT02812719]Early Phase 10 participants (Actual)Interventional2018-07-31Withdrawn(stopped due to Study did not receive funding and will not be implemented.)
Anti-microbial Role of Non-antibiotic Agents Against Cutibacterium Acnes in Patients With Acne Vulgaris [NCT06179056]24 participants (Actual)Observational2023-03-01Completed
Association of Occlusal Force Distribution and Bone Resorption in Implant Supported Overdentures [NCT03026894]46 participants (Actual)Interventional2015-11-30Completed
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension [NCT05056896]Early Phase 1160 participants (Anticipated)Interventional2022-03-08Recruiting
Randomised Clinical Trial, Parallel, Double Blind, to Evaluate the Influence of the ASA-SR (Slow-Release) in the Platelet Parameters and the Oxidative Status, in Patients With Coronary Disease of Chronic Evolution During 12 Months [NCT00501254]Phase 2/Phase 3100 participants (Actual)Interventional2005-02-28Completed
Use of Acetylsalicylic Acid and Terbutalin in ART [NCT00518141]300 participants (Actual)Interventional2006-03-31Completed
Conservative Therapies in the Treatment of Temporomandibular Disorders: a Randomized Controlled Clinical Trial. [NCT05989217]96 participants (Anticipated)Interventional2023-03-01Recruiting
Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris [NCT00624676]80 participants (Actual)Interventional2006-01-31Completed
CLINICAL EVALUATION OF EFFECTIVENESS OF ASSOCIATION MOMETASONE FUROATE 0.1% AND SALICYLIC ACID 5% COMPARED WITH 0.1% MOMETASONE FUROATE INSULATED TOPICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS IN PLATE [NCT01228656]Phase 240 participants (Actual)Interventional2006-09-30Suspended
New Formulation of Salicylate to Improve Treatment of Common Skin Warts [NCT01712295]Phase 4100 participants (Anticipated)Interventional2011-11-30Recruiting
Pharmacodynamic- Pharmacokinetic Trial, Comparative Double Blind, of the Chronic Administration of 150 mg of Slow Release ASA Versus 150 mg of Normal Release ASA, in the Platelet Functionalism. [NCT00425074]Phase 150 participants (Actual)Interventional2007-01-31Completed
Evaluation of the Effect of Muscle Activity on Subjective Tinnitus in Temporomandibular Disorders [NCT05830604]70 participants (Actual)Interventional2021-12-21Completed
The Influence of of a Stabilization Splint on the Body Posture in TMD Cases and Controls [NCT00154128]Phase 140 participants Interventional2005-04-30Completed
Methodology for Developing an Occlusal Appliance With CBD Active Carrier [NCT04775030]Phase 2/Phase 340 participants (Anticipated)Interventional2021-01-01Recruiting
Effect of Cryotherapy and Occlusal Reduction on Post-endodontic Pain in Patients With Symptomatic Apical Periodontitis [NCT05722704]60 participants (Actual)Interventional2022-09-12Completed
COMPARISON OF SENTRIC OCCLUSION DATA OBTAINED FROM TWO DIFFERENT COMPUTER-ASSISTED RECORDING METHODS [NCT04798729]40 participants (Actual)Observational2019-01-02Completed
The Efficacy of Occlusal Stabilization Appliance Associated to Counseling in the Management of Myofascial Pain Chronic and in the Improvement of the Quality of Life of Patients With Temporomandibular Disorders [NCT01544439]Phase 340 participants (Anticipated)Interventional2012-03-31Recruiting
Pressure Algometry Evaluation of Two Occlusal Splint Designs in Bruxism Management - Randomized, Controlled Clinical Trial [NCT04733573]30 participants (Anticipated)Interventional2021-01-01Recruiting
Comparison of Two Exercise Therapy Protocols in Patients With Bruxism: A Randomized Controlled Trial [NCT05555628]24 participants (Anticipated)Interventional2022-07-15Recruiting
Restoring Masticatory Function as Treatment for Chronic Pain: a Randomized Placebo-controlled Trial [NCT02144233]77 participants (Actual)Interventional2014-08-31Terminated(stopped due to Interim analysis showed benefice of one therapy over the other one.)
A Pilot Study Comparing the Efficacy of Glycolic Acid Peels vs. Salicylic Acid Peels for the Treatment of Melasma: A Randomized Control Trial [NCT01976286]21 participants (Actual)Interventional2015-01-31Active, not recruiting
Clinical and Dermoscopic Study Using a Combination of Salicylic and Azaleic Acid Verus Trichloroacetic Acid 25% Peel in Treatment of Mild to Moderate Acne , A Split Face, Double Blinded, Randomised Controlled Trial [NCT03071549]Phase 334 participants (Actual)Interventional2016-04-30Completed
Evaluation of Digital Stabilizing Splint in Management of Masticatory Muscle Disorder [NCT06138535]8 participants (Actual)Interventional2022-09-30Completed
U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne [NCT02524665]Phase 420 participants (Actual)Interventional2009-09-30Completed
Comparison Between Occlusal Versus Apical Bent Wires in Patients on Erich Arch Bar: A Prospective Split-mouth Randomized Clinical Trial [NCT05801328]24 participants (Anticipated)Interventional2023-04-01Not yet recruiting
Neuro Occlusal Rehabilitation in Patient With Peripheral Facial Paralysis - a Randomized Clinical Trial [NCT01327157]14 participants (Actual)Interventional2009-03-31Completed
Multicentric, Parallel, Randomized, Double Blind Study Under Dermatological Control to Evaluate the Anti-acne Efficacy of a Dermo-cosmetic Product (Fla 688977 33) Associated With the Fixed Combination Adapalene 0.1%/ Benzoyl Peroxide 2.5% Treatment Versus [NCT03832647]Phase 4200 participants (Actual)Interventional2019-02-18Completed
Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease [NCT01778465]7 participants (Actual)Interventional2013-05-31Completed
An Internet-based Multimodal Pain Program With Telephone Support for Adults With Chronic Temporomandibular Disorder Pain: Pilot Randomized Controlled Trial [NCT04363762]40 participants (Actual)Interventional2016-04-30Completed
A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System [NCT01589978]Phase 42,681 participants (Actual)Interventional2012-05-31Completed
Effect of High-frequency Bio-oxidative Ozone Therapy for Masticatory Muscle Pain: a Double-blind Randomized Clinical Trial [NCT02997410]60 participants (Actual)Interventional2014-12-31Active, not recruiting
U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects With Acne [NCT01706250]Phase 420 participants (Actual)Interventional2009-09-01Completed
A Randomized, Double-Blind, Placebo Controlled Pilot Trial of Oral Salsalate in the Treatment of the Subset of Unexplained Anemia in Elderly Patients With Elevated Interleukin-6 [NCT01506726]Phase 211 participants (Actual)Interventional2012-03-31Terminated(stopped due to Study drug expiration and supply shortage)
A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea [NCT04889703]0 participants (Actual)Interventional2022-12-31Withdrawn(stopped due to Plan to move forward with this study has been dropped)
Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis. [NCT05684484]Phase 452 participants (Anticipated)Interventional2023-02-01Not yet recruiting
The Value of Addition of Prednisolone to Acetylsalicylic Acid Prior to Embryo Transfer in Patients With First ICSI Cycles: A Randomized Controlled Trial [NCT03503227]Phase 2/Phase 3250 participants (Actual)Interventional2018-04-23Completed
Influence of Resin Cement Composition on the Longevity of Intraradicular Post in the Rehabilitation of Endodontically Treated Teeth - Randomized Clinical Trials [NCT03491527]20 participants (Anticipated)Interventional2018-05-01Not yet recruiting
Effect of Occlusal Accommodation of the Mouthguard on the Degree of Satisfaction of Water Polo Players: A Randomized Crossover Study [NCT03845621]26 participants (Actual)Interventional2019-02-21Completed
Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts: a Randomized Controlled Trial [NCT05617950]174 participants (Anticipated)Interventional2022-11-30Not yet recruiting
Efficacy and Safety of Topical Metformin Emulgel Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: A Split Face Study [NCT05536193]Phase 434 participants (Anticipated)Interventional2022-09-10Not yet recruiting
Basis for an Etiological Diagnosis and Treatment of the Chronic TMD-pain: RCT Study [NCT00899717]Phase 1/Phase 221 participants (Actual)Interventional2009-05-31Completed
A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design [NCT01578070]Phase 1/Phase 2130 participants (Actual)Interventional2012-03-31Completed
Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) 200/25 mg Capsules Bid and in a Combination of Persantin Immediate Release Tablets (100 mg Qid) and ASA Tablets (25 mg Bid) in an Open, Randomized, 2-way Crossover Study in [NCT02273505]Phase 120 participants (Actual)Interventional2000-04-30Completed
Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts [NCT05588999]Phase 170 participants (Actual)Interventional2022-03-01Completed
The Effect of Filmed Modelling on the Anxious and Cooperative Behaviour of 4-6 Years Old Children During Dental Treatment [NCT01908127]50 participants (Actual)Interventional2010-09-30Completed
Topical Clindamycin Salicylic Acid Preparation for the Treatment of Acne Vulgaris [NCT00361322]Phase 1/Phase 240 participants Interventional2005-04-30Completed
Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department [NCT04697017]690 participants (Actual)Interventional2018-01-10Completed
Temporary Hydrostatic Splint Therapy and Its Effects on Occlusal Forces [NCT05827263]51 participants (Actual)Interventional2021-12-01Completed
The Effect of Earplugs on Myogenous Temporomandibular Disorders [NCT05362877]120 participants (Actual)Interventional2022-04-01Completed
Clinical Evaluation of Ultrathin Occlusal Veneers for the Treatment of Severe Dental Erosion [NCT03112278]10 participants (Anticipated)Interventional2015-11-30Active, not recruiting
Mechanism and Risk Factors of Tracheal Tube-related Tongue Injury [NCT05987293]54 participants (Anticipated)Observational2023-10-19Recruiting
Effect of the Use of an Occlusal Plate on the Postural Alignment and Balance of Individuals With Signs and Symptoms of Temporomandibular Joint Disorder [NCT02490605]46 participants (Anticipated)Interventional2015-07-31Not yet recruiting
The Effect of Conservative Treatment of Temporomandibular Disorders on Somatic Tinnitus [NCT03209297]120 participants (Actual)Interventional2017-03-27Completed
Effectiveness of Two Oral Appliances on the Degree of Satisfaction of Patients With Amyotrophic Lateral Sclerosis for Managing Oral Self-biting Injuries: a Randomized Crossover Study [NCT04809675]31 participants (Anticipated)Interventional2019-11-29Recruiting
Checking Occlusion During Stainless Steel Crown Placement in Children Under General Anesthesia - Evaluation of a Novel Technique [NCT02437565]60 participants (Actual)Interventional2013-08-31Completed
The Effectiveness of Anterior Deprogrammers as a Tool for Reducing Pain and Masticatory Muscles Tension [NCT03180671]80 participants (Anticipated)Interventional2017-04-01Recruiting
Evaluation of the Effects of Occlusal Splint and Intramuscular Injection in Patients With Myofascial Pain [NCT05228327]64 participants (Actual)Interventional2020-08-01Completed
A Cross-over Randomized Clinical Trial of Canine Guidance and Bilateral Balanced Occlusion in Complete Denture Wearers [NCT01420536]44 participants (Actual)Interventional2009-02-28Completed
Early Anticoagulation Therapy After Bioprosthetic Aortic Valve Implantation: Comparing Warfarin Versus Aspirin [NCT01452568]Phase 4370 participants (Actual)Interventional2005-06-30Completed
Salicylic Augmentation in Depression [NCT03152409]Phase 274 participants (Anticipated)Interventional2018-11-15Recruiting
The Copenhagen Analgesic Study [NCT04369222]600 participants (Anticipated)Observational2020-03-01Recruiting
Photomodulation in the Treatment of Pain in Patients With Tmd: Analysis of Cost-effectiveness. [NCT03096301]45 participants (Anticipated)Interventional2017-10-10Recruiting
Effect of Occlusal Reduction on Relief of Pain and Sensitivity to Percussion in Patients With Irreversible Pulpitis and Symptomatic Apical Periodontitis Treated in a Single Visit- a Randomized Clinical Trial [NCT05306535]56 participants (Actual)Interventional2022-04-01Completed
Effect of Low-Level Laser Therapy Versus CAD/CAM Michigan Splint on Patients With Temporomandibular Muscle Disorders Randomized Clinical Trial [NCT05901701]56 participants (Actual)Interventional2022-11-20Completed
Interest of the BRUXENSE Occlusal Splints for Bruxism Diagnosis: a Feasibility Study [NCT03363204]7 participants (Actual)Interventional2018-02-08Completed
Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome [NCT02067819]21 participants (Actual)Interventional2014-03-31Completed
Comparison of Topical Analgesic With Saline Rinses in Post Extraction Healing Among Hypertensive and Non-Hypertensive Patients [NCT03130153]Early Phase 160 participants (Actual)Interventional2016-01-01Completed
Treatment of Plantar Keratosis With Medicinal Plant in Diabetic Patients: Randomized, Double-Blind and Controlled Clinical Trial [NCT03447925]Phase 290 participants (Actual)Interventional2017-06-01Completed
Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical) [NCT03825757]150 participants (Anticipated)Interventional2019-01-31Recruiting
Evaluation of Different Treatment Modalities in Children With Myalgia or Arthralgia in the Temporomandibular Region - a Randomized, Single-blinded, Controlled Non-inferiority Study [NCT03849534]150 participants (Anticipated)Interventional2023-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00616239 (1) [back to overview]Number of Participants Showing Improvement of Melasma Based on Mexameter Readings
NCT00769561 (8) [back to overview]TMD Related Symptoms
NCT00769561 (8) [back to overview]Depressive Symptoms (Centers for Epidemiologic Studies Depression Scale)
NCT00769561 (8) [back to overview]General Anxiety Symptoms (GAD-7)
NCT00769561 (8) [back to overview]Jaw Use Limitations (JDL)
NCT00769561 (8) [back to overview]Pain Coping (FESV)
NCT00769561 (8) [back to overview]Pain Disability (Pain Disability Index)
NCT00769561 (8) [back to overview]Pain Intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))
NCT00769561 (8) [back to overview]Somatoform Symptoms (Screening for Somatoform Disorders, SOMS)
NCT00899717 (5) [back to overview]Visual Analogic Scale for Pain Intensity (0-10)
NCT00899717 (5) [back to overview]Symptom Checklist-90-Revised (SCL-90-R®)
NCT00899717 (5) [back to overview]Preferred Chewing Side
NCT00899717 (5) [back to overview]Maximum Mouth Opening (mm)
NCT00899717 (5) [back to overview]Condylar Path Angles
NCT01327157 (5) [back to overview]Visual Analog Scale
NCT01327157 (5) [back to overview]Correlation Between the Increase of the Number of Dental Contact Points and the Improvement in the Subjective Evaluation Measured Through the Visual Analogic Scale Whithout the Outlier.
NCT01327157 (5) [back to overview]The Visual Analog Scale for Pain Was Used to Grade Discomfort in Chewing After the Installation of Facial Paralysis. Level Zero is the Lack of Discomfort and 10 is the Maximum Degree of Discomfort.
NCT01327157 (5) [back to overview]Correlation Between the Increase of the Number of Dental Contact Points and the Improvement in the Subjective Evaluation Measured Through the Visual Analogic Scale .
NCT01327157 (5) [back to overview]Brand Carbon Count on Gnathostats Models
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (3.c) Mandibular Chewing Movement, Left-right Axis
NCT01420536 (13) [back to overview]Denture Satisfaction
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (4.c) Upper Denture Base Movement, Left-right Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (4.a) Upper Denture Base Movement, Vertical Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (4.b) Upper Denture Base Movement, Anteroposterior Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (1.a) Maximum Mouth Opening, Vertical Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (2.c) Rest Position, Left-right Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (1.b) Maximum Mouth Opening, Anteroposterior Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (1.c) Maximum Mouth Opening, Left-right Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (2.a) Rest Position, Vertical Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (2.b) Rest Position, Anteroposterior Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (3.a) Mandibular Chewing Movement, Vertical Axis
NCT01420536 (13) [back to overview]Kinesiographic Parameters -- (3.b) Mandibular Chewing Movement, Anteroposterior Axis
NCT01506726 (18) [back to overview]Assessment of Serum Biomarkers of Erthropoiesis
NCT01506726 (18) [back to overview]Change in Markers of Inflammation
NCT01506726 (18) [back to overview]Association Between Change in Hemoglobin and Change in Markers of Inflammation.
NCT01506726 (18) [back to overview]Assessment of Serum Biomarkers of Erthropoiesis
NCT01506726 (18) [back to overview]Change in Self Reported Outcomes Measures as Reported by FACIT-AN Total Score
NCT01506726 (18) [back to overview]Change in Self Reported Outcomes Measures as Reported by Short Form-36 (SF-36) Physical Component Score (PCS)
NCT01506726 (18) [back to overview]Change in the 6 Minute Walk Test (6MWT) Distance.
NCT01506726 (18) [back to overview]Change in Frailty Component Related to Fatigue/ Exhaustion
NCT01506726 (18) [back to overview]Change in Frailty Component as Determined by the 4 Meter Walk Speed
NCT01506726 (18) [back to overview]Change in Frailty Component as Determined by Grip Strength
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures-Trail Making Test Part B
NCT01506726 (18) [back to overview]Change in the Frailty Component as Determined by Self-reported Activity Level
NCT01506726 (18) [back to overview]Change in Markers of Inflammation
NCT01506726 (18) [back to overview]Change in Hemoglobin Level From Baseline to 6 Month Visit
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Speed of Processing
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Composite Learning and Memory
NCT01506726 (18) [back to overview]Change in Cognitive Outcome Measures as Determined by Composite Complex Attention/Executive Processing
NCT01506726 (18) [back to overview]Change in Serum Hepcidin Levels
NCT01589978 (21) [back to overview]Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients
NCT01589978 (21) [back to overview]Cardiac Death Rate
NCT01589978 (21) [back to overview]Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients
NCT01589978 (21) [back to overview]Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients
NCT01589978 (21) [back to overview]Major Adverse Cardiac Event Rate (MACE)
NCT01589978 (21) [back to overview]Myocardial Infarction (MI) Rate
NCT01589978 (21) [back to overview]Non-cardiac Death Rate
NCT01589978 (21) [back to overview]Rate of Cardiac Death Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]Rate of Cardiac Death or Myocardial Infarction Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]Rate of Longitudinal Stent Deformation
NCT01589978 (21) [back to overview]Target Vessel Revascularization (TVR) Rate
NCT01589978 (21) [back to overview]Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients
NCT01589978 (21) [back to overview]Target Vessel Failure (TVF) Rate
NCT01589978 (21) [back to overview]Rate of Target Vessel Revascularization (TVR) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]Rate of Target Vessel Failure (TVF) Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]Rate of Myocardial Infarction (MI) Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]Rate of Major Adverse Cardiac Events Related to the PROMUS Element Stent
NCT01589978 (21) [back to overview]All Death or Myocardial Infarction Rate
NCT01589978 (21) [back to overview]All Death Rate
NCT01589978 (21) [back to overview]ARC ST Rate in PLATINUM-like Population.
NCT01589978 (21) [back to overview]Cardiac Death or Myocardial Infarction (MI) Rate
NCT01706250 (13) [back to overview]Mean Percent Change in IL Count From BL (Day 1) to Wks 1, 2 and 4
NCT01706250 (13) [back to overview]Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8.
NCT01706250 (13) [back to overview]Mean Change in Investigator's Static Global Assessment (ISGA) From BL (Day 1) to Wks 1, 2, 4 and 8.
NCT01706250 (13) [back to overview]Mean Percent Change in NIL Count From BL (Day 1) to Wks 1, 2 and 4
NCT01706250 (13) [back to overview]Mean Percent Change in TL Count From BL (Day 1) to Wks 1, 2 and 4
NCT01706250 (13) [back to overview]Mean Change in Each of the Participant Tolerability Assessments-Redness
NCT01706250 (13) [back to overview]Mean Change in Each of the Evaluator Tolerability Assessments-Dryness
NCT01706250 (13) [back to overview]Mean Change in Each of the Evaluator Tolerability Assessments-Erythema
NCT01706250 (13) [back to overview]Mean Change in Each of the Evaluator Tolerability Assessments-Peeling
NCT01706250 (13) [back to overview]Mean Change in Each of the Participant Assessments of Tolerability-Burning
NCT01706250 (13) [back to overview]Mean Change in Each of the Participant Assessments of Tolerability-Dryness
NCT01706250 (13) [back to overview]Mean Change in Each of the Participant Assessments of Tolerability-Itching
NCT01706250 (13) [back to overview]Mean Change in Each of the Participant Assessments of Tolerability-Scaling
NCT01706263 (6) [back to overview]Mean Change in Investigator's Static Global Assessment (ISGA) From Baseline to Weeks 1, 2, 4 and 8
NCT01706263 (6) [back to overview]Percentage of Participants Who Improved by at Least One Grade on the ISGA
NCT01706263 (6) [back to overview]Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Weeks 1, 2, and 4
NCT01706263 (6) [back to overview]Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Week 8
NCT01706263 (6) [back to overview]Change in Participant Assessment of Tolerability (Redness, Dryness, Burning, Itching and Scaling) From Baseline to Weeks 1, 2, 4 and 8
NCT01706263 (6) [back to overview]Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) From Baseline to Weeks 1, 2, 4 and 8.
NCT01778465 (5) [back to overview]Urinary Salicyluric Acid Levels
NCT01778465 (5) [back to overview]Urinary Salicylic Acid Levels
NCT01778465 (5) [back to overview]Urinary Levels of Cys-Leukotrienes
NCT01778465 (5) [back to overview]Urinary Creatinine Levels
NCT01778465 (5) [back to overview]Sino-Nasal Outcome Test (SNOT-22)
NCT01908127 (2) [back to overview]Behaviors of Children
NCT01908127 (2) [back to overview]Index of Heart Rate
NCT02067819 (2) [back to overview]Change in Global Severity of Tics and Clinical Condition as Measured by YGTSS
NCT02067819 (2) [back to overview]Change in Number, Frequency, and Intensity of Motor and Vocal Tics as Measured by the Clinical Global Impressions Scale - Severity
NCT02144233 (11) [back to overview]Adverse Events
NCT02144233 (11) [back to overview]Number of Participants With Neuropathic Pain
NCT02144233 (11) [back to overview]Chewing Side
NCT02144233 (11) [back to overview]Pain Interference on Daily Activity
NCT02144233 (11) [back to overview]Maximum Unassisted Jaw Opening
NCT02144233 (11) [back to overview]Jaw-pain-Intensity (Affected Side)
NCT02144233 (11) [back to overview]Headache-intensity
NCT02144233 (11) [back to overview]Credibility (of Participants)
NCT02144233 (11) [back to overview]Condylar Path Angles
NCT02144233 (11) [back to overview]Change in Global Severity Index Scores (Symptom Checklist-90-Revised (SCL-90-R))
NCT02144233 (11) [back to overview]Lateral Guidance Angles (LG)
NCT02524665 (6) [back to overview]Percentage of Participant Who Improved by at Least One Grade on the ISGA
NCT02524665 (6) [back to overview]Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8.
NCT02524665 (6) [back to overview]Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 1, 2 and 4.
NCT02524665 (6) [back to overview]Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) From Baseline to Weeks 1, 2, 4 and 8.
NCT02524665 (6) [back to overview]Mean Change in Investigator's Static Global Assessment (ISGA) From Baseline to Week 1, 2, 4 and 8
NCT02524665 (6) [back to overview]Change in Participant Assessment of Tolerability (Redness, Dryness, Burning, Itching and Scaling) From Baseline to Weeks 1, 2, 4 and 8.
NCT02755545 (1) [back to overview]Percent Change From Baseline in Total Lesions at Week 12
NCT02807493 (3) [back to overview]Average Apgar Score
NCT02807493 (3) [back to overview]Stage 2 Duration of Labor
NCT02807493 (3) [back to overview]Number of Participants With a Cesarian Section

Number of Participants Showing Improvement of Melasma Based on Mexameter Readings

Improvement of melasma on the peel side using mexameter reading (NCT00616239)
Timeframe: 14 weeks

Interventionparticipants (Number)
20% to 30% Salicylic Acid Peels + 4% Hydroquinone Cream18

[back to top] [back to top]

Depressive Symptoms (Centers for Epidemiologic Studies Depression Scale)

Depressive symptoms were measured using the Centre for Epidemiological Studies Depression scale (CES-D). The CES-D asks for the frequency of 20 symptoms of depression during the past week on a scale ranging from 0 ('less than 1 day') to 3 ('5 to 7 days') (range 0-60). Higher scores indicate more depressive symptoms. It is suitable for use in chronic pain patients as it relies less on physical symptoms of depression than do other measures. Cronbach's alpha level in the current sample was α = .89. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment Depressive symptomsPost-Treatment Depressive symptoms (after 8 weeks)6-months follow up Depressive symptoms
BFB-CBT18.5113.0515.05
Occlusal Splint17.3816.0916.67

[back to top]

General Anxiety Symptoms (GAD-7)

General anxiety symptoms were assessed using the 7-item scale from the Patient Health Questionnaire (GAD-7). The GAD-7 asks for anxiety symptoms during the past month on a 1 ('not at all') to 3 ('more than half of the days') rating scale (range 7-21). Higher scores indicate higher levels of anxiety. Cronbach's alpha level in the current sample was α = .64. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-treatment anxietyPost-Treatment anxiety (after 8 weeks)6-months follow up anxiety
BFB-CBT15.1513.0712.79
Occlusal Splint14.1513.3313.04

[back to top]

Jaw Use Limitations (JDL)

Jaw use limitations were measured using the Jaw Disability List (JDL) from the RDC/TMD. The JDL asks the patient to rate interference with eleven oral activities, for example chewing or talking. We used an 11-point numeric rating scale (from 0 'no limitation' to 10 'maximum limitation') instead of ratings of 'yes' and 'no' (range 0 - 110). Higher values indicate higher levels of jaw use limitations. Cronbach's alpha was .86 in the current sample. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment Jaw use limitationsPost-Treatment Jaw use limitations (after 8 weeks)6-months follow up Jaw use limitations
BFB-CBT25.8718.5218.39
Occlusal Splint27.0418.7718.11

[back to top]

Pain Coping (FESV)

Cognitive and behavioral pain coping strategies were assessed with Coping Strategies Scale from the German Pain Coping Questionnaire (Fragebogen zur Erfassung der Schmerzverarbeitung, FESV). The scale asks for the use of 24 cognitive (e.g. cognitive restructuring) and behavioral (e.g. use of relaxation techniques) strategies for coping with pain on a scale ranging from 1 ('fully disagree') to 6 ('fully agree') (range 24-144). A sum score was used with higher scores indicating more adaptive coping. Cronbach's alpha level was α = .80. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment Pain CopingPost-Treatment Pain Coping (after 8 weeks)6-months follow up Pain Coping
BFB-CBT62.1581.8077.11
Occlusal Splint59.3564.6960.13

[back to top]

Pain Disability (Pain Disability Index)

Pain related disability was assessed using the Pain Disability Index (PDI). The PDI is a brief self-rating scale which assesses the level of pain related disability in seven areas of daily life (e.g., social activity, self-care) on a 0 (no disability) -10 (maximum disability) numeric rating scale (range 0 - 70). Higher values indicate higher disability levels. Cronbach's alpha was .87 in the current sample. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment pain disabilityPost-Treatment pain disability (after 8 weeks)6-months follow up pain disability
BFB-CBT17.6711.0713.24
Occlusal Splint13.8811.6211.61

[back to top]

Pain Intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))

"Characteristic pain intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)):~Characteristic pain intensity was calculated by averaging ratings of current pain, average pain, and worst pain in the past month on a numeric rating scale from 0 (no pain) to 10 (maximum pain), as recommended by RDC/TMD (range 0 - 10). Higher values indicate higher pain levels." (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment pain intensityPost-Treatment pain intensity (after 8 weeks)6-months follow up pain intensity
BFB-CBT5.403.903.62
Occlusal Splint5.533.894.21

[back to top]

Somatoform Symptoms (Screening for Somatoform Disorders, SOMS)

Somatoform complaints during the past week were assessed using the Screening for Somatoform Symptoms (SOMS-7). 32 medically unexplained symptoms (29 for male subjects) representing DSM-IV criteria for somatization disorder were rated on a 0 ('not at all') to 4 ('very much') scale (range 0 - 128 for women and 0 - 116 for men). A sum score was calculated with higher scores indicating higher intensity and burden of somatoform complaints. In the current sample, Cronbach's alpha level was α = .88. (NCT00769561)
Timeframe: Pre-Post-Design including 3 assessment points: pre-treatment, post-treatment (after 8 weeks), and 6-month follow up

,
Interventionunits on a scale (Mean)
Pre-Treatment Somatoform symptomsPost-Treatment Somatoform symptoms (after 8 weeks)6-months follow up Somatoform symptoms
BFB-CBT14.9710.6410.69
Occlusal Splint11.8111.309.81

[back to top]

Visual Analogic Scale for Pain Intensity (0-10)

"The primary outcome was self-reported pain intensity on a 0 to 10 cm visual analog scale considering the temporomandibular disorder side, being 0=No pain and 10=Worst imaginable pain" (NCT00899717)
Timeframe: Baseline, immediately after therapy, 3 months and 6 months after therapy

,
Interventionunits on a scale (Mean)
BaselineImmediately after therapy3 months after therapy6 months after therapy
Placebo Occlusal Adjustment4.82.053.804
Real Occlusal Adjustment6.52.812.25.40

[back to top]

Symptom Checklist-90-Revised (SCL-90-R®)

Scale name: Global Severity Index. Scale graded from 0 to 4. Scores increases as the symptoms severity increases. (NCT00899717)
Timeframe: Before and 6 months after therapy

,
Interventionunits on a scale (Mean)
Baseline Global Severity Index6 months after therapy Global Severity Index
Placebo0.580.51
Real1.320.75

[back to top]

Preferred Chewing Side

The change in the habitual chewing side of each participant across the study (NCT00899717)
Timeframe: Before and 6 months after therapy

,
Interventionparticipants (Number)
Baseline6 months after therapy
Placebo Occlusal Adjustment01
Real Occlusal Adjustment08

[back to top]

Maximum Mouth Opening (mm)

Maximum voluntary unassisted mouth opening (NCT00899717)
Timeframe: 6 months (before and after therapy) including 4 assessment points: pre-treatment, post-treatment, 3- and 6-month follow up

,
Interventionmm (Mean)
BaselineImmediately after therapy3 months after therapy6 months after therapy
Placebo Occlusal Adjustment42.3645.0741.2741.73
Real Occlusal Adjustment41.645.5047.1049.20

[back to top]

Condylar Path Angles

Parasagittal plane condylar path angles tracings in relation to the Frankfort line were made following the Gysi extraoral method. (NCT00899717)
Timeframe: Baseline

,
Interventiondegrees (Mean)
Right condylar path angleLeft condylar path anglePain side condylar path angleNon-pain side condylar path angle
Placebo Occlusal Adjustment4948.2751.0946.18
Real Occlusal Adjustment52.3349.2056.7544.78

[back to top]

Visual Analog Scale

"It is a scale-shaped ruler, which is associated with faces used to grade the degree of pain for patients, before and after treatments, or just graduating pain and its severity for the patient (Souza, 2002).~Patients were asked to fill the VAS with the following questions. Do you chew well? How would you classify your chewing at the moment? If you have no trouble chewing, the rating is zero. If you have any discomfort when you chew, your reference level is five. If the discomfort is intense, its reference level is ten. The greater the discomfort, the greater the scale." (NCT01327157)
Timeframe: After 90 days of treatment (Day 180 for Treatment participants first receiving Placebo)

Interventionunits on a scale (Mean)
Placebo-Vas, Dental Cleaning5.4
Treatment VAS,Dental Cleaning,Occlusal Adjustment.3.0

[back to top]

Correlation Between the Increase of the Number of Dental Contact Points and the Improvement in the Subjective Evaluation Measured Through the Visual Analogic Scale Whithout the Outlier.

"The correlation between the increase of the number of the dental contacts and VAS evaluation final result from chronic peripheral facial paralysis patients.~On this measure was excluded one outlier patient whose facial paralysis appeared in her childhood.~Observing the outlier patient, it was carried out a new scatterplot, ignoring her." (NCT01327157)
Timeframe: Day 01 and after 90 days of treatment (Day 180 for Treatment participants first receiving Placebo)

Interventioncorrelation coefficient (Number)
Treatment-VAS Dental Cleaning Occlusal Adjustment0.638

[back to top]

The Visual Analog Scale for Pain Was Used to Grade Discomfort in Chewing After the Installation of Facial Paralysis. Level Zero is the Lack of Discomfort and 10 is the Maximum Degree of Discomfort.

"It is a scale-shaped ruler, which is associated with faces used to grade the degree of pain for patients, before and after treatments, or just graduating pain and its severity for the patient (Souza, 2002).~Patients were asked to fill the VAS with the following questions.~Do you chew well?~How would you classify your chewing at the moment?~If you have no trouble chewing, the rating is zero.~If you have any discomfort when you chew, your reference level is five.~If the discomfort is intense, its reference level is ten. The greater the discomfort, the greater the scale." (NCT01327157)
Timeframe: Day 1 (Day 91 for Treatment participants first receiving Placebo)

Interventionunits on a scale (Mean)
Placebo-VAS, Dental Cleaning5.6
Treatment- VAS,Dental Cleaning,Occlusal Adjustment.6.1

[back to top]

Correlation Between the Increase of the Number of Dental Contact Points and the Improvement in the Subjective Evaluation Measured Through the Visual Analogic Scale .

The correlation between the increase of the number of the dental contacts and the VAS evaluation final result from chronic peripheral facial paralysis patients, according to control and treated groups by the neuro occlusal rehabilitation technic. (NCT01327157)
Timeframe: Day 01 and after 90 days of treatment (Day 180 for Treatment participants first receiving Placebo)

Interventioncorrelation coefficient (Number)
Treatment-VAS Dental Cleaning Occlusal Adjustment0.111

[back to top]

Brand Carbon Count on Gnathostats Models

Only in the treatment group were done gnatostatic models.The models were placed occluding brought with carbon, using the willis compass to keep occluding the posterior base of the model which are aligned with the rear. A model of the teeth was made to measure the occlusion of the teeth (i.e., the amount of contact between the upper and lower mandibles), and used carbon to count the the number of dental contacts, through the brand carbon made on the model, The dental contacts were counted in the models before and after treatment. The models are made in the first and last query. (NCT01327157)
Timeframe: Day 01 and after 90 days of treatment (Day 180 for Treatment participants first receiving Placebo)

Interventionnumber of dental contacts (Mean)
First Query9.6
Last Query14.6

[back to top]

Kinesiographic Parameters -- (3.c) Mandibular Chewing Movement, Left-right Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance1.2
Bilateral Balanced Occlusion1.3

[back to top]

Denture Satisfaction

"Assessed by a questionnaire questionnaire based on the criteria used by Celebic and Knezovic-Zlataric (A comparison of patient's satisfaction between complete and partial removable denture wearers. J Dent. 2003;21:445-451) and used by Souza et al. (Validation of the Brazilian versions of two inventories for measuring oral health-related quality of life of edentulous subjects. Gerodontology. 2012;29:e88-95.).~Eight questions were answered according to a three-point scale (0=unsatisfactory; 1=regular; 2=good), whose sum provided a summary satisfaction score that ranged from 0 (the participant is completely dissatisfied with existing dentures) to 16 (maximum satisfaction)." (NCT01420536)
Timeframe: 30 days

Interventionunits on a scale (Median)
Canine Guidance15
Bilateral Balanced Occlusion15

[back to top]

Kinesiographic Parameters -- (4.c) Upper Denture Base Movement, Left-right Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance-0.1
Bilateral Balanced Occlusion-0.1

[back to top]

Kinesiographic Parameters -- (4.a) Upper Denture Base Movement, Vertical Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance-0.5
Bilateral Balanced Occlusion-0.6

[back to top]

Kinesiographic Parameters -- (4.b) Upper Denture Base Movement, Anteroposterior Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance-0.4
Bilateral Balanced Occlusion-0.4

[back to top]

Kinesiographic Parameters -- (1.a) Maximum Mouth Opening, Vertical Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance30.3
Bilateral Balanced Occlusion30.9

[back to top]

Kinesiographic Parameters -- (2.c) Rest Position, Left-right Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance0.5
Bilateral Balanced Occlusion0.4

[back to top]

Kinesiographic Parameters -- (1.b) Maximum Mouth Opening, Anteroposterior Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance25.1
Bilateral Balanced Occlusion25.8

[back to top]

Kinesiographic Parameters -- (1.c) Maximum Mouth Opening, Left-right Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance1.4
Bilateral Balanced Occlusion1.7

[back to top]

Kinesiographic Parameters -- (2.a) Rest Position, Vertical Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance2.1
Bilateral Balanced Occlusion2.3

[back to top]

Kinesiographic Parameters -- (2.b) Rest Position, Anteroposterior Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance1.9
Bilateral Balanced Occlusion1.9

[back to top]

Kinesiographic Parameters -- (3.a) Mandibular Chewing Movement, Vertical Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance12.0
Bilateral Balanced Occlusion12.1

[back to top]

Kinesiographic Parameters -- (3.b) Mandibular Chewing Movement, Anteroposterior Axis

"Mandibular physiologic movements and the pattern of maxillary denture movement during chewing, as recorded by a kinesiograph (K6-I Diagnostic System, Myotronics research Inc., Seatle, WA).~Specific measures involved: (1) Mouth opening; (2) Movement of the mandible from rest position to maximal occlusion (tooth clenching position); (3) Movement of the mandible during chewing; and (4) Movement of the upper denture base during chewing. Data from each measure was not combined into new variables, and collected in a single time point after each intervention.~All measures were taken according to the vertical, anteroposterior and left-right axes separately." (NCT01420536)
Timeframe: 30 days

Interventionmm (Mean)
Canine Guidance4.2
Bilateral Balanced Occlusion4.3

[back to top]

Assessment of Serum Biomarkers of Erthropoiesis

To assess whether oral salsalate improves serum biomarkers of erythropoiesis by decreasing growth differentiation factor-15 (GDF-15) in UAE subjects. Change in the GDF-15 from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionpg/ml (Mean)
Active Drug - Oral Salsalate16.688
Placebo Arm187.240

[back to top]

Change in Markers of Inflammation

To assess whether oral salsalate reduces markers of inflammation including IL-6 and Tumor Necrosis Factor Receptor1 (TNF-R1) in UAE subjects. Change in the marker from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

,
Interventionpg/ml (Mean)
IL6Tumor Necrosis Factor Receptor1 (TNF-R1),
Active Drug - Oral Salsalate-1.096133.48
Placebo Arm0.703-189.40

[back to top]

Association Between Change in Hemoglobin and Change in Markers of Inflammation.

To examine whether there is an association between change in hemoglobin and changes in markers of inflammation from prior to study drug to 6 months. Inflammatory markers to be measured are iL-6, Tumor Necrosis Factor alpha Receptor1 (TNF-R1), and C-reactive protein (CRP) in anemia subjects.Correlation between change in the inflammatory markers and the change in HB from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

,
Interventioncorrelation coefficient (Number)
IL6 correlationTNF correlationCRP correlation
Active Drug - Oral Salsalate-0.1130.9480.156
Placebo Arm-0.446-0.977-0.166

[back to top]

Assessment of Serum Biomarkers of Erthropoiesis

To assess whether oral salsalate improves serum biomarkers of erythropoiesis by increasing erythropoietin (Epo) in UAE subjects. Change in the Epo from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

InterventionmIU/ml (Mean)
Active Drug - Oral Salsalate-0.014
Placebo Arm-1.540

[back to top]

Change in Self Reported Outcomes Measures as Reported by FACIT-AN Total Score

To quantify the impact of anemia treatment by salsalate on self -reported outcomes measures by subjects answering 47 questions for patients with anemia and or fatigue. This test detects self-report functional changes and QoL. Change from baseline to 6 months. Scores range from 0-188 with higher scores indicating better function. (NCT01506726)
Timeframe: baseline; 6 months

Interventionscores on a scale (Mean)
Active Drug - Oral Salsalate18.9
Placebo Arm7.7

[back to top]

Change in Self Reported Outcomes Measures as Reported by Short Form-36 (SF-36) Physical Component Score (PCS)

To quantify the impact of anemia treatment by salsalate on self-reported outcomes measures by change in SF36 physical component score. The SF-36 form identifies self-report physical function and global measure of quality of life and is a multi-purpose, short-form health survey consisting of 36 questions. The Physical Component Summary (PCS) is a subscale of the SF-36 that correlates with physical health domains of the SF-36 ( Physical Function, Role-Physical, and Bodily Pain). The change is calculated and compared from baseline to 6 months. The SF-36 PCS score is a norm based sore with a mean of 50 and standard deviation of 10 where results above and below 50 are above and below the average, respectively, in the 2009 general US population. (NCT01506726)
Timeframe: baseline; 6 months

Interventiont score (Mean)
Active Drug - Oral Salsalate1.63
Placebo Arm3.77

[back to top]

Change in the 6 Minute Walk Test (6MWT) Distance.

To assess the impact of treatment of anemia with oral salsalate will improve 6 minute walk test (6MWT) distance from baseline to 6 months as measured in meters and centimeters. (NCT01506726)
Timeframe: baseline; 6 months

Interventionmeters (Mean)
Active Drug - Oral Salsalate-20.77
Placebo Arm29.24

[back to top] [back to top]

Change in Frailty Component as Determined by the 4 Meter Walk Speed

"To quantify the impact of anemia treatment by salsalate on change in the speed of the 4 meter walk speed. Subjects are asked to walk as fast as they can for 4 meters. Frailty was determined by the subject's speed. (change from frail at baseline to not frail at 6 months). 4 m walking speed is stratified by gender and height. For men, (height of <= 173 cm and a walking speed of <= 0.65 meter/sec) or a (height > 173, <= .76 meter/sec) were classified as frail. For women, (height of <= 159 cm and a walking speed of <=.65 meter/sec) or (height >159 cm <= 0.76 meter/sec) were classified as frail.The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate0
Placebo Arm0

[back to top]

Change in Frailty Component as Determined by Grip Strength

"To quantify the impact of anemia treatment by salsalate on change in the frailty as measured by change in grip strength. Subjects squeeze the grip strength machine 3 times with each hand. For the frailty outcome the maximum grip strength from the dominant hand is used. (change from frail at baseline to not frail at 6 months). Grip strength is stratified by gender and BMI. For men with (BMI <= 24 and a grip strength (GS) <= 29) or (BMI 24.1-28 and grip strength <= 30) or (BMI >28 and a grip strength <= 32) were classified as frail. For women with (BMI <= 23 and a grip strength of <= 17) or (BMI 23.1-26 and a GS <= 17.3) or (BMI 26.1-29 and a GS <= 18) or (BMI > 29 and a GS <= 21) were classified as frail.The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate0
Placebo Arm1

[back to top]

Change in Cognitive Outcome Measures-Trail Making Test Part B

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on the Trail Making Test (TMT) Part B as measured by subjects drawing a line from 25 circled numbers to letters in 300 seconds. The change in seconds per completed circle from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionsecond per completed circle (Mean)
Active Drug - Oral Salsalate-0.18
Placebo Arm1.23

[back to top]

Change in the Frailty Component as Determined by Self-reported Activity Level

"To quantify the impact of anemia treatment by salsalate on change in the frailty as measured by change in self-reported activity level. Frailty for activity level is classified by subjects responses to 6physical activity questions on the short version of the Minnesota Leisure Time Activity Questionnaire , were related to walking for exercise, moderately strenuous outdoor chores, dancing, bowling, and regular exercise. The Women's Health And Aging Study (WHAS) scoring algorithm was used to define frailty for self-reported activity level. The answers to these questions were used to calculate kilocalories (Kcals) per week, using the WHAS algorithm, which is further satisfied by by gender. For men, Kcals < 128 per week is frail. For women, Kcals < 90 per week is frail. This is a categorical measurement of yes or no. The outcome is the number of participants who were classified as frail at baseline and changed to not frail at 6 months." (NCT01506726)
Timeframe: baseline; 6 months

Interventionparticipants (Number)
Active Drug - Oral Salsalate1
Placebo Arm0

[back to top]

Change in Markers of Inflammation

To assess whether oral salsalate reduces C-reactive protein (CRP) in UAE subjects. Change in the CRP from prior to study drug to 6 months. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionug/ml (Mean)
Active Drug - Oral Salsalate-1.976
Placebo Arm1.890

[back to top]

Change in Hemoglobin Level From Baseline to 6 Month Visit

To test whether the administration of oral salsalate to a subset of elderly subjects with unexplained anemia (UAE) and high interleukin (IL-6) levels will improve hemoglobin level (NCT01506726)
Timeframe: baseline; 6 months

Interventiong/dL (Mean)
Active Drug - Oral Salsalate0.06
Placebo Arm1.00

[back to top]

Change in Cognitive Outcome Measures as Determined by Speed of Processing

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on speed of processing was derived using the z-scores of the following three tests: (1) TMT Part A seconds per completed circle, (2) simple reaction time from the CogState Detection Task, and (3) choice reaction time from the CogState Identification Task. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the subject's score at the time point from the overall baseline mean of the test and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average.The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.29
Placebo Arm1.42

[back to top]

Change in Cognitive Outcome Measures as Determined by Composite Learning and Memory

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on Learning and memory was derived using the z-scores of the following three tests: (1) CogState ISL immediate recall score (total score from three learning trials), (2) CogState ISL immediate recall score from the first learning trial, and (3) CogState ISL delayed recall scores. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the overall baseline mean of the test from the subject's score at the time point and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average. The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.15
Placebo Arm-0.34

[back to top]

Change in Cognitive Outcome Measures as Determined by Composite Complex Attention/Executive Processing

To quantify the impact of anemia treatment by salsalate on cognitive outcomes based on Complex attention/executive processing was derived using the z-scores of the following three tests: (1) TMT Part B seconds per completed circle, (2) time score from the CogState One Back Task, and (3) accuracy score from the CogState One Back Task. The composite score for a subject at each time point was defined as the mean of the Z-scores for the three tests at the time point. For each subject, the Z-score for each test at time point was derived by subtracting the overall baseline mean of the test from the subject's score at the time point (accuracy score) or by subtracting the subject's score at the time point from the overall baseline mean of the test (TMT and time score) and then dividing by the overall baseline standard deviation of the test. Positive z-scores indicate a better performance compared to the baseline average. The change in the Z-score from baseline to month 6. (NCT01506726)
Timeframe: baseline; 6 months

Interventionchange in Z-Score (Mean)
Active Drug - Oral Salsalate0.71
Placebo Arm-0.07

[back to top]

Change in Serum Hepcidin Levels

To compare the change in serum hepcidin levels between treatment groups and whether such a change is proportional to the decline in IL-6 levels. Change in the hepcidin from prior to study drug to 6 months. Positive changes represent increases in hepcidin levels and negative changes represent decreases. (NCT01506726)
Timeframe: prior to study drug; 6 months

Interventionng/ml (Mean)
Active Drug - Oral Salsalate0.879
Placebo Arm15.462

[back to top]

Cardiac Death or Myocardial Infarction Rate in PLATINUM-like Patients

Cardiac death or myocardial infarction rate at 12 months post implantation in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and <2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if rate meets the performance goal (3.2%) (NCT01589978)
Timeframe: 12 months

Interventionpercentage of patients (Number)
PROMUS Element1.78

[back to top]

Cardiac Death Rate

Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element1.4

[back to top]

Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in All Patients

DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days) (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element0.7

[back to top]

Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition in PLATINUM-like Patients

ARC definite/probable ST rate in PLATINUM-like patients (no acute myocardial infarction, graft stenting, chronic total occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial lesion, severe tortuosity, moderate/severe calcification, 3-vessel stenting, cardiogenic shock, left main disease, or acute/chronic renal dysfunction; lesion length ≤28 mm with reference vessel diameter ≥2.25 mm and <2.5 mm, or lesion length ≤24 mm with diameter ≥2.5 mm and ≤4.25 mm); statistical testing will assess if the annual ST rate increase after the first year meets the performance goal (1.0%) (NCT01589978)
Timeframe: 12 months

Interventionpercentage of patients (Number)
PROMUS Element0.3

[back to top]

Major Adverse Cardiac Event Rate (MACE)

Composite of cardiac death, myocardial infarction, and target vessel revascularization (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element6.9

[back to top]

Myocardial Infarction (MI) Rate

New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin >upper limit of normal(ULN); if no new Q-waves total CK levels >3×ULN (peri-percutaneous coronary intervention [PCI]) or >2×ULN (spontaneous) with elevated CK-MB or troponin >3×ULN (peri-PCI) or >2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin >5×ULN (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element1.1

[back to top]

Non-cardiac Death Rate

"Non-cardiac death is defined as death not due to cardiac causes.~Cardiac death is death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident through hospital discharge or cerebrovascular accident suspected of being related to the procedure; death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery; any death in which a cardiac cause cannot be excluded." (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element0.9

[back to top] [back to top] [back to top]

Rate of Longitudinal Stent Deformation

Compression/elongation of a stent along its long axis resulting from interaction with an ancillary device (e.g., guide catheter) which catches the stent end or an internal stent strut; can occur with advancement or withdrawal of ancillary device. Under fluoroscopy, longitudinal compression usually results in increased strut density and elongation in decreased strut density ('pseudo-fracture'); both can occur in the same stent. (NCT01589978)
Timeframe: Index Procedure

Interventionstents (Number)
PROMUS Element2

[back to top]

Target Vessel Revascularization (TVR) Rate

Target vessel revascularization is defined as any attempted or successfully completed percutaneous or surgical revascularization of a target vessel. (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element5.6

[back to top]

Target Vessel Failure (TVF) Rate in PLATINUM-like Medically Treated Diabetic Patients

Any revascularization of the target vessel, myocardial infarction related to the target vessel, or death related to the target vessel. See individual components for descriptions. Statistical testing will determine if the rate meets the performance goal (12.6%) (NCT01589978)
Timeframe: 12 Months

Interventionpercentage of patients (Number)
PROMUS Element3.26

[back to top]

Target Vessel Failure (TVF) Rate

"Target vessel failure (TVF) is defined as any revascularization of the target vessel, myocardial infarction (MI) related to the target vessel, or death related to the target vessel.~For the purposes of this protocol, if it cannot be determined with certainty whether MI or death was related to the target vessel it will be considered TVF." (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element6.7

[back to top] [back to top] [back to top] [back to top] [back to top]

All Death or Myocardial Infarction Rate

See description of individual events. (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element3.2

[back to top]

All Death Rate

All death includes cardiac death and non-cardiac death. (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element2.3

[back to top]

ARC ST Rate in PLATINUM-like Population.

Using the Academic Research Consortium (ARC) definition, the (definite/probable) stent thrombosis (ST) rate in the PLATINUM-like* population will be analyzed. Statistical testing will be used to determine if the annual increase after the first year in ST rates observed in PLATINUM-like patients meets the performance goal of 1.0% (expected rate of 0.4% + a delta of 0.6%). (NCT01589978)
Timeframe: Annually through 5 years

Interventionpercentage of participants (Number)
PROMUS Element Overall Population0.0023

[back to top]

Cardiac Death or Myocardial Infarction (MI) Rate

See individual descriptions of events. (NCT01589978)
Timeframe: ≤24 hours, 30 days, 180 days, annually through 5 years

Interventionpercentage of patients (Number)
PROMUS Element2.3

[back to top]

Mean Percent Change in IL Count From BL (Day 1) to Wks 1, 2 and 4

This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the IL by counting the number of papules and pustules. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of IL) at each individual visit (percent value at wk 1, 2 and 4) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day1) to Wks 1, 2 and 4

,
Interventionpercent change in lesion count (Mean)
Percent change, IL count, BL to Wk 1Percent change, IL count, BL to Wk 2Percent change, IL count, BL to Wk 4
MAXCLARITY II-17.56-35.64-21.35
PROACTIV-19.93-31.64-44.99

[back to top]

Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8.

This was an efficacy variable. An expert grader evaluated each side of the face (included forehead, cheeks and chin), the left and the right side, for IL (presence of papules and pustules), NIL (presence of open and closed comedones) and the TLs. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. The evaluator was also blinded. BL was defined as Day 1. The percent change was calculated as the value at Wk 8 minus the value at BL. (NCT01706250)
Timeframe: BL (Day 1) and Wk 8

,
Interventionpercent change in lesion count (Mean)
Percent change, IL countPercent change, NIL countPercent change in TL count
MAXCLARITY II-55.93-37.97-45.46
PROACTIV-52.64-45.66-47.69

[back to top]

Mean Change in Investigator's Static Global Assessment (ISGA) From BL (Day 1) to Wks 1, 2, 4 and 8.

The evaluator (blinded) evaluated the acne severity of the participants' face using the ISGA scale ranging from 0 to 5. The grading was 0= Clear, skin with no IL or NILs; 1= Almost clear, rare NILs with no more than one small IL ; 2= Mild, some NILs with no more than few ILs (papules/pustules only, no nodular lesions); 3= Moderate Upto many NILs and may have some ILs but no more than one small nodular lesion ; 4= Severe, Upto many NILs and ILs but no more than a few nodular lesions; 5= Very severe, many NILS and ILs more than a few nodular lesions, may have cystic lesions. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each visit (Wks 1,2,4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Change, in ISGA from BL to Wk 1Change, in ISGA from BL to Wk 2Change, in ISGA from BL to Wk 4Change, in ISGA from BL to Wk 8
MAXCLARITY II-0.10-0.47-0.53-0.39
PROACTIV-0.05-0.21-0.42-0.39

[back to top]

Mean Percent Change in NIL Count From BL (Day 1) to Wks 1, 2 and 4

This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the NIL by the presence of open and closed comedones. The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of NIL) at each individual visit (percent value at Wk 1, 2 and 4) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2 and 4

,
Interventionpercent change in lesion count (Mean)
Percent change, NIL count, BL to Wk 1Percent change, NIL count, BL to Wk 2Percent change, NIL count, BL to Wk 4
MAXCLARITY II-3.92-24.12-30.26
PROACTIV-7.13-21.07-37.76

[back to top]

Mean Percent Change in TL Count From BL (Day 1) to Wks 1, 2 and 4

This was an efficacy variable. An expert grader (blinded) evaluated the left and the right side of the face extending from the hairline to the mandible (included forehead, cheeks and chin). The evaluator assessed the total lesions by the sum of both inflammatory and non-inflammatory lesions on each side (left side and right side). The mouth, nose, periocular area, nasogenian, and superior and inferior eyelids were excluded. BL was defined as Day 1. The percent change was calculated as the percent value (count of total lesions) at each individual visit (percent value at Wks 1, 2 and 4) minus the value at baseline respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2 and 4

,
Interventionpercent change in lesion count (Mean)
Percent change, in TL count, BL to Wk 1Percent change, in TL count, BL to Wk 2Percent change, in TL count, BL to Wk 4
MAXCLARITY II-11.34-31.94-34.17
PROACTIV-13.36-26.19-41.17

[back to top]

Mean Change in Each of the Participant Tolerability Assessments-Redness

This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for redness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the redness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Redness; Change from BL to Wk 1Redness; Change from BL to Wk 2Redness; Change from BL to Wk 4Redness; Change from BL to Wk 8
MAXCLARITY II0.500.370.720.61
PROACTIV0.350.210.560.28

[back to top]

Mean Change in Each of the Evaluator Tolerability Assessments-Dryness

This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the dryness was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at baseline respectively. The change from BL was '0' for Wk 2, Wk 4, and Wk 8 and hence statistical analysis was not done. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Dryness; Change from BL to Wk 1Dryness; Change from BL to Wk 2Dryness; Change from BL to Wk 4Dryness; Change from BL to Wk 8
MAXCLARITY II0.150.000.050.11
PROACTIV0.100.000.000.11

[back to top]

Mean Change in Each of the Evaluator Tolerability Assessments-Erythema

This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. Erythema is condition characterized by redness or rash on the skin. The assessment of the erythema was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk 4 and Wk 8, and hence statistical analysis was not done. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Erythema; Change from BL to Wk 1Erythema; Change from BL to Wk 2Erythema; Change from BL to Wk 4Erythema; Change from BL to Wk 8
MAXCLARITY II0.05-0.050.050.06
PROACTIV-0.05-0.110.050.06

[back to top]

Mean Change in Each of the Evaluator Tolerability Assessments-Peeling

This was a tolerability variable. The expert grader (blinded evaluator) assessed each left and right side of the face individually at each study visit. The areas on the face excluding nose, nasogenian, and superior and inferior eyelids were evaluated. The evaluator conducting the assessment for the participant remained blinded for the treatment assigned. The assessment of the peeling was graded on 0 to 5 scale based on severity by the evaluator. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wk 1,2,4 and 8) minus the value at BL respectively. The change from BL was '0' for Wk (1, 4 and 8) and hence statistical analysis was not done. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Peeling; Change from BL to Wk 1Peeling; Change from BL to Wk 2Peeling; Change from BL to Wk 4Peeling; Change from BL to Wk 8
MAXCLARITY II0.000.000.000.00
PROACTIV0.000.110.000.00

[back to top]

Mean Change in Each of the Participant Assessments of Tolerability-Burning

This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for burning. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the burning was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1, 2, 4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1,2, 4 and 8

,
Interventionunits on scale (Mean)
Burning; Change from BL to Wk 1Burning; Change from BL to Wk 2Burning; Change from BL to Wk 4Burning; Change from BL to Wk 8
MAXCLARITY II0.950.841.000.83
PROACTIV0.750.580.440.44

[back to top]

Mean Change in Each of the Participant Assessments of Tolerability-Dryness

This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for dryness. The area on the face was assessed excluding the excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the dryness was graded on 0 to 5 scale based on severity by the participant. 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated severity of the disease. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Dryness; Change from BL to Wk 1Dryness; Change from BL to Wk 2Dryness; Change from BL to Wk 4Dryness; Change from BL to Wk 8
MAXCLARITY II1.201.051.331.33
PROACTIV0.900.681.061.11

[back to top]

Mean Change in Each of the Participant Assessments of Tolerability-Itching

This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for itching. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the itching was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Itching; Change from BL to Wk 1Itching; Change from BL to Wk 2Itching; Change from BL to Wk 4Itching; Change from BL to Wk 8
MAXCLARITY II0.200.370.330.28
PROACTIV0.200.050.060.11

[back to top]

Mean Change in Each of the Participant Assessments of Tolerability-Scaling

This was a tolerability variable, where the participants were instructed to individually assess the right and the left side of the face to indicate the severity that they had experienced during the time period from their last visit for scaling. The area on the face was assessed excluding nose, nasogenian, and superior and inferior eyelids. The assessment of the scaling was graded on 0 to 5 scale based on severity by the participant; 0=None, 1=Very minimal, 2=mild, 3= moderate, 4=severe, and 5= Very severe. Thus higher score indicated more severity. BL was defined as Day 1. The mean change was calculated as value at each individual visit (Wks 1,2,4 and 8) minus the value at BL respectively. (NCT01706250)
Timeframe: BL (Day 1) to Wks 1, 2, 4 and 8

,
Interventionunits on scale (Mean)
Scaling; Change from BL to Wk 1Scaling; Change from BL to Wk 2Scaling; Change from BL to Wk 4Scaling; Change from BL to Wk 8
MAXCLARITY II0.400.260.560.83
PROACTIV0.250.160.390.67

[back to top]

Mean Change in Investigator's Static Global Assessment (ISGA) From Baseline to Weeks 1, 2, 4 and 8

Evaluator assessed the acne severity of participants' faces using the ISGA scale on a five point scale which ranged from 0 to 4 defined as 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe. Change from Baseline to specified time point (Weeks 1, 2, 4 and 8) was calculated as the value at specified time point minus the value at Baseline. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8

InterventionScore on a scale (Mean)
ISGA score, Week 1ISGA score, Week 2ISGA score, Week 4ISGA score, Week 8
MAXCLARITY II-0.07-0.46-0.39-0.61

[back to top]

Percentage of Participants Who Improved by at Least One Grade on the ISGA

Evaluator assessed the acne severity of participants' faces using the ISGA scale on a five point scale which ranged from 0 to 4 defined as 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe. Percent change from Baseline to specified time point was calculated as the value at specified time point minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Up to Week 8

InterventionPercentage of participants (Number)
Atleast one grade improvement,Week 1Atleast two grade improvement,Week 1Atleast one grade improvement,Week 2Atleast two grade improvement,Week 2Atleast one grade improvement,Week 4Atleast two grade improvement,Week 4Atleast one grade improvement,Week 8Atleast two grade improvement,Week 8
MAXCLARITY II17.90.042.93.635.77.150.010.7

[back to top]

Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Weeks 1, 2, and 4

Evaluator assessed the left side and right side of the face as inflammatory (papules [solid elevation of skin with no visible fluid] and pustules [small inflamed elevation of the skin that is filled with pus]) and non-inflammatory (open comedones [blackheads] and closed comedones [whiteheads]) and total lesions for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face from hairline to the mandible (including forehead, cheeks, and chin). Total lesion counts was calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to specified time (Weeks 1, 2, and 4) point was calculated as the value at specified time point minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Baseline (Day 1) and Week 1, 2, 4

InterventionPercent change (Mean)
Inflammatory lesion count, Week 1Inflammatory lesion count, Week 2Inflammatory lesion count, Week 4Non-Inflammatory lesion count, Week 1Non-Inflammatory lesion count, Week 2Non-Inflammatory lesion count, Week 4Total lesion count, Week 1Total lesion count, Week 2Total lesion count, Week 4
MAXCLARITY II-27.9-50.8-49.5-9.9-23.4-34.3-22.6-37.8-44.9

[back to top]

Mean Percent Change in Inflammatory, Non Inflammatory, and Total Lesion Counts From Baseline to Week 8

Evaluator assessed the left and right side of the face as inflammatory (papules [solid elevation of skin with no visible fluid] and pustules [small inflamed elevation of the skin that is filled with pus]) and non-inflammatory (open [blackheads] and closed [whiteheads] comedones) and total lesions (sum of inflammatory and non-inflammatory lesion) for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face from hairline to the mandible (including forehead, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to Week 8 was calculated as the value at Week 8 minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Baseline (Day 1) and Week 8

InterventionPercent change (Mean)
Inflammatory lesion countNon-Inflammatory lesion countTotal lesion count
MAXCLARITY II-62.1-49.8-56.9

[back to top]

Change in Participant Assessment of Tolerability (Redness, Dryness, Burning, Itching and Scaling) From Baseline to Weeks 1, 2, 4 and 8

Redness, dryness, burning, itching and scaling were evaluated independently by the participant on a five point scale ranged from 0 to 4 defined as 0-none, 1-very minimal, 2-mild, 3-moderate, 4-severe. Change from Baseline to specified time point (Weeks 1, 2, 4 and 8) was calculated as the value at specified time point minus the value at Baseline. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8

InterventionScore on scale (Mean)
Redness,Week 1Redness,Week 2Redness,Week 4Redness,Week 8Dryness,Week 1Dryness,Week 2Dryness,Week 4Dryness,Week 8Burning,Week 1Burning,Week 2Burning,Week 4Burning,Week 8Itching,Week 1Itching,Week 2Itching,Week 4Itching,Week 8Scaling,Week 1Scaling,Week 2Scaling,Week 4Scaling,Week 8
MAXCLARITY II-0.39-0.25-0.18-0.360.040.070.000.110.210.360.32-0.070.070.070.140.07-0.14-0.11-0.04-0.18

[back to top]

Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) From Baseline to Weeks 1, 2, 4 and 8.

Erythema , dryness, and peeling, were evaluated independently by the investigator on a five point scale ranged from 0 to 4 defined as 0-none, 1-very minimal, 2-mild, 3-moderate, 4-severe. Change from Baseline to specified time point (Weeks 1, 2, 4 and 8) was calculated as the value at specified time point minus the value at Baseline. Baseline was defined as Day 1 value . (NCT01706263)
Timeframe: Baseline (Day 1) and Week 1, 2, 4, 8

InterventionScore on scale (Mean)
Erythema, Week 1Erythema, Week 2Erythema, Week 4Erythema, Week 8Dryness, Week 1Dryness, Week 2Dryness, Week 4Dryness, Week 8Peeling, Week 1Peeling, Week 2Peeling, Week 4Peeling, Week 8
MAXCLARITY II0.00-0.04-0.04-0.320.140.320.110.110.110.210.040.11

[back to top]

Urinary Salicyluric Acid Levels

(NCT01778465)
Timeframe: 14 days after commencement

Interventionng/ml (Median)
Low Salicylate Diet44.21
Normal Diet23.82

[back to top]

Urinary Salicylic Acid Levels

(NCT01778465)
Timeframe: 14 days after enrollment

Interventionng/ml (Median)
Low Salicylate Diet0.6
Normal Diet0.92

[back to top]

Urinary Levels of Cys-Leukotrienes

(NCT01778465)
Timeframe: 14 days after commencement

Interventionpg/ml (Median)
Low Salicylate Diet874.05
Normal Diet771.99

[back to top]

Urinary Creatinine Levels

(NCT01778465)
Timeframe: 14 days after commencement

Interventionmmol/L (Median)
Low Salicylate Diet9.9
Normal Diet15.3

[back to top]

Sino-Nasal Outcome Test (SNOT-22)

"The Sino-Nasal Outcome Test (SNOT-22) is a validated 22-item Chronic rhinosinusitis-specific instrument which is scored using a scale where 0=No problem, 1=Very mild problem, 2=Mild or slight problem, 3=Moderate problem, 4=Severe problem, and 5=Problem as bad as it can be. Higher scores on the SNOT-22 survey items suggest worse patient functioning or symptom severity (total score range: 0-110)" (NCT01778465)
Timeframe: 14 days after commencement

Interventionscore on a scale (Median)
Low Salicylate Diet44
Normal Diet66

[back to top]

Behaviors of Children

"A video-camera was focused started to record child's behavior. The recorded video tapes were independently evaluated by 2 paediatric dentists who were blind to the grouping of the children. Children's anxiety reactions and cooperative behaviours were scored based on venham scale and Frankle Index ,respectively. quantification was performed at the injection of local anaesthesia and at the beginning of the tooth preparation. An average of both two time points scoring was used.~Table 1: Venham 6-point Index 0 = Relaxed: 1 = Uneasy: 2 = Tense: 3 = Reluctant: 4 = Interference: 5 = Out of contact~Table 2: Frankle 4-point Index~1:Definitely Negative ( uncooperative,Refusal of treatment ) , 2:Negative ( some evidence of negative attitude but not pronounced) , 3:Positive ( Acceptance of treatment, at times cautious) , 4:Definitely Positive( Good rapport with the dentist)" (NCT01908127)
Timeframe: participants followed for the duration of examination and treatment appointment, an expected average of 3 weeks

,
Interventionunits on a scale (Mean)
anxious behaviour quantificationcooperative behaviour quantification
Film Modelling1.092.98
Tell- Show- do Procedure0.972.95

[back to top]

Index of Heart Rate

The heart rate of children was measured before the injection of local anesthesia solution to save a baseline data and it was also measured after the injection to assess the effect of this dental stress. (NCT01908127)
Timeframe: before and after the injection of local anesthesia solution

,
Interventionbeat per Min (Mean)
baseline heart rateheart rate after the injection
Film Modelling102.73113
Tell- Show- do Procedure99.27110.40

[back to top]

Change in Global Severity of Tics and Clinical Condition as Measured by YGTSS

"The primary clinical outcome measures included the Yale Global Tic Severity Scale (YGTSS). The YGTSS is a semi structured interview designed to elicit information regarding the character & anatomical distribution of tics observed during the course of 1 week interval, prior to clinical assessment. Following completion of the interview & construction of a tic inventory, clinicians rate severity of motor and photic tics along with 5 separate dimensions (frequency, intensity, number, complexity, interference).~The YGTSS is comprised of a list of motor and vocal tics & the participant endorses which tics are currently present. Motor and vocal tics are then separately rated for Number, Frequency, Intensity, Complexity, Interference & Impairment, each on a 6 point likert scale ranging from 0 (none) to 5 (Severe).This results in a range of 0-25 for motor tics & 0-25 for vocal tics, for a total score range of 0-50. A score of 0 indicating a lack of tics & 50 represent the most severe tics." (NCT02067819)
Timeframe: Baseline Visit, Week 2 Visit

Interventionscore on a scale (Mean)
Active Oral Orthotic Treatment20.19
Placebo Oral Orthotic Treatment25.82

[back to top]

Change in Number, Frequency, and Intensity of Motor and Vocal Tics as Measured by the Clinical Global Impressions Scale - Severity

To assess global severity of tics and change in the clinical condition over time, the Clinical Global Impressions Scale - Severity (CGI-S) was utilized. The Severity of Illness has a low score of 0 and high score is 7. The low score of 0 represents that the subject was not assessed and the high score of 7 represents among the most extremely ill subjects. (NCT02067819)
Timeframe: Baseline Visit, Week 2 Visit

Interventionscore on a scale (Mean)
Active Oral Orthotic Treatment4.57
Placebo Oral Orthotic Treatment5.27

[back to top]

Adverse Events

Unexpected Adverse Events (NIH, 2009). (NCT02144233)
Timeframe: After therapy, 1-Month, 3-Months, 6-Months

InterventionParticipants (Count of Participants)
Occlusal Adjustmen Therapy0
Placebo Occlusal Adjustment Therapy0

[back to top]

Number of Participants With Neuropathic Pain

Neuropathic pain Questionnaire (DN4). Over 4 scores indicates neuropathic facial pain. (NCT02144233)
Timeframe: Baseline, 6-Months

InterventionParticipants (Count of Participants)
baseline72094318baseline72094319at month 672094318at month 672094319
neuropathic painwithout neuropathic symptoms
Occlusal Adjustmen Therapy13
Placebo Occlusal Adjustment Therapy12
Occlusal Adjustmen Therapy26
Placebo Occlusal Adjustment Therapy25
Occlusal Adjustmen Therapy3
Placebo Occlusal Adjustment Therapy4
Occlusal Adjustmen Therapy36
Placebo Occlusal Adjustment Therapy33

[back to top]

Chewing Side

A consistent chewing side was considered if at lees 5 out of 7 almonds (or at lees 7 of 10 cycles of chewing gum), the participant report to use same side, and same side was used during kinesiography recordings of spontaneous chewing. Any other results lead to alternate chewing allocation. (NCT02144233)
Timeframe: Baseline and 6-months

InterventionParticipants (Count of Participants)
baseline72094318baseline720943196-Months720943186-Months72094319
AlternateRightLeft
Occlusal Adjustmen Therapy16
Placebo Occlusal Adjustment Therapy14
Placebo Occlusal Adjustment Therapy13
Occlusal Adjustmen Therapy15
Placebo Occlusal Adjustment Therapy11
Occlusal Adjustmen Therapy6
Placebo Occlusal Adjustment Therapy6
Occlusal Adjustmen Therapy25
Placebo Occlusal Adjustment Therapy27
Occlusal Adjustmen Therapy8
Placebo Occlusal Adjustment Therapy5

[back to top]

Pain Interference on Daily Activity

"In the past 6 months, how much has facial pain interfered with your daily activities rated on a 0-10 scale where 0 is no interference and 10 is unable to carry on any activities? 0-10 VAS/NRS (0=No interference to 10=Unable to carry on any activities). N.B. Only one item was choose to simplify." (NCT02144233)
Timeframe: Baseline; 6-Months

,
Interventionunits on a scale (Mean)
baseline6-Months
Occlusal Adjustmen Therapy5.23.1
Placebo Occlusal Adjustment Therapy4.52

[back to top]

Maximum Unassisted Jaw Opening

Vertical jaw-opening (incisal level) measured using a ruler. Higher values represent a better outcome. (NCT02144233)
Timeframe: Baseline, 3- and 6-Months

,
Interventionmm (Mean)
baseline3-Months6-Months
Occlusal Adjustmen Therapy41.545.6647.7
Placebo Occlusal Adjustment Therapy43.946.7346.4

[back to top]

Jaw-pain-Intensity (Affected Side)

Self-reported affected-side pain-intensity across the trial in a 0-10 visual analogue scale (VAS) (0=no pain, 10=worst possible pain). Higher values represent a worse outcome. (NCT02144233)
Timeframe: Baseline and 6-months

,
Interventionunits on a scale (Median)
baseline6-Months
Occlusal Adjustmen Therapy72
Placebo Occlusal Adjustment Therapy73.5

[back to top]

Headache-intensity

Headache intensity in recent months (If any) in a 0-10 numerical pain rating scale with 0=no pain and 10= worst possible pain. (NCT02144233)
Timeframe: Baseline 3- and 6-Months

,
Interventionscore on a scale (Median)
baseline3-Months6-Months
Occlusal Adjustmen Therapy744
Placebo Occlusal Adjustment Therapy5.7533

[back to top]

Credibility (of Participants)

"Confidence of participants in the goodness of treatment.~These items were simplified here to the following single question:~How confident would you be that this treatment would be successful in eliminating your pain and/or limited mouth opening? 0-10 numerical rating scale, with 0=nothing to 10= totally." (NCT02144233)
Timeframe: Baseline, 6-Months

,
Interventionunits on a scale (Mean)
baseline6-Months
Occlusal Adjustmen Therapy88
Placebo Occlusal Adjustment Therapy8.37.6

[back to top]

Condylar Path Angles

Parasagittal plane condylar path tracings in relation to the Frankfort Horizontal Plane following the Gysi extraoral method. (NCT02144233)
Timeframe: Baseline

,
Interventiondegrees (Mean)
right jointleft joint
Occlusal Adjustmen Therapy50.550.1
Placebo Occlusal Adjustment Therapy47.349.3

[back to top]

Change in Global Severity Index Scores (Symptom Checklist-90-Revised (SCL-90-R))

Mean change in Global Severity Index scores from a self-administered Spanish validated questionaire SCL-90-R. Higher values represent a worse outcome. Range (0-4). (NCT02144233)
Timeframe: Baseline, 6-Months

,
Interventionscore on a scale (Mean)
baseline6-Months
Occlusal Adjustmen Therapy0.890.52
Placebo Occlusal Adjustment Therapy0.810.5

[back to top]

Lateral Guidance Angles (LG)

The angle between the tangent of the LG tracings and the horizontal Frankfort line, starting from the midsagittal point up 2 mm: using a calibrated Model K7 diagnostic system. Both sides recordings of each patient were measured and considered individually. The mean of both sides of each patient was not used. (NCT02144233)
Timeframe: Baseline

Interventiondegrees (Mean)
Occlusal Adjustmen Therapy42
Placebo Occlusal Adjustment Therapy40.6

[back to top]

Percentage of Participant Who Improved by at Least One Grade on the ISGA

During each study visit, investigators/expert grader evaluated the acne severity of participants' faces using the ISGA scale on right and left side of face on a five point scale from 0 to 4 defined as 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe. Percent change from Baseline to scheduled time point was calculated as the value at scheduled time point minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Up to Week 8

,
InterventionPercentage of participants (Number)
One or more grade improvement-Week 1Two or more grade improvement-Week 1One or more grade improvement-Week 2Two or more grade improvement-Week 2One or more grade improvement-Week 4Two or more grade improvement-Week 4One or more grade improvement-Week 8Two or more grade improvement-Week 8
MAXCLARITY II10.50.015.85.347.45.378.942.1
Murad10.50.010.50.057.90.068.421.1

[back to top]

Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8.

During each study visit, expert grader (blinded evaluator) assessed the left side and right side of the face as inflammatory (papules [solid elevation of skin with no visible fluid] and pustules [small inflamed elevation of the skin that is filled with pus]) and non-inflammatory (open [blackheads] and closed [whiteheads] comedones) and total lesions for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face from hairline to the mandible (including forehead, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to Week 8 was calculated as the value at Week 8 minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Baseline and Week 8

,
InterventionPercent change (Mean)
Inflammatory lesion counts- Week 8, n=19, 17Non-inflammatory lesion counts- Week 8, n=19, 19Total lesion counts-Week 8, n=19, 19
MAXCLARITY II-78.70-69.32-76.67
Murad-61.52-77.09-75.01

[back to top]

Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 1, 2 and 4.

During each study visit, expert grader (blinded evaluator) assessed the left side and right side of the face as inflammatory (papules [solid elevation of skin with no visible fluid] and pustules [small inflamed elevation of the skin that is filled with pus]) and non-inflammatory (open comedones [blackheads] and closed comedones [whiteheads]) and total lesions for each participant. Each type of lesion was counted separately; the lesion counts were taken from the face from hairline to the mandible (including forehead, cheeks, and chin). Total lesion counts were calculated as the sum of the inflammatory and non-inflammatory lesion counts. Percent change from Baseline to scheduled time point was calculated as the value at scheduled time point minus the value at Baseline divided by the Baseline value multiplied by 100. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Baseline and Week 1, 2, 4

,
InterventionPercent change (Mean)
Inflammatory lesion counts- Week 1, n=19, 17Inflammatory lesion counts- Week 2, n=19, 17Inflammatory lesion counts- Week 4, n=19, 17Non-inflammatory lesion counts- Week 1, n=19, 19Non-inflammatory lesion counts- Week 2, n=19, 19Non-inflammatory lesion counts- Week 4, n=19, 19Total lesion counts-Week 1, n=19, 19Total lesion counts-Week 2, n=19, 19Total lesion counts-Week 4, n=19, 19
MAXCLARITY II-17.69-46.69-55.35-4.94-28.07-52.85-12.57-37.06-60.93
Murad-7.85-14.25-51.95-15.92-37.07-60.27-18.29-35.84-60.73

[back to top]

Change in Investigator Assessment of Tolerability (Erythema, Dryness and Peeling) From Baseline to Weeks 1, 2, 4 and 8.

Erythema (redness), dryness, and peeling, were evaluated independently by the investigator on a five point scale from 0 to 4 defined as 0-none, 1-very minimal, 2-mild, 3-moderate, 4-severe. Change from Baseline to scheduled time point was calculated as the value at scheduled time point minus the value at Baseline. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Baseline and Week 1, 2, 4, 8

,
InterventionScore on a scale (Mean)
Erythema score-Week 1Erythema score -Week 2Erythema score -Week 4Erythema score -Week 8Dryness score-Week 1Dryness score -Week 2Dryness score -Week 4Dryness score -Week 8Peeling score-Week 1Peeling score -Week 2Peeling score -Week 4Peeling score -Week 8
MAXCLARITY II0.16-0.21-0.37-0.320.11-0.11-0.050.000.05-0.11-0.05-0.11
Murad0.00-0.16-0.32-0.320.00-0.11-0.050.05-0.11-0.11-0.05-0.05

[back to top]

Mean Change in Investigator's Static Global Assessment (ISGA) From Baseline to Week 1, 2, 4 and 8

During each study visit, investigators/expert grader evaluated the acne severity of participants' faces using the ISGA scale on right and left side of face on a five point scale from 0 to 4 defined as 0-clear, 1-almost clear, 2-mild, 3-moderate, 4-severe. Change from Baseline to scheduled time point was calculated as the value at scheduled time point minus the value at Baseline. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Baseline and Week 1, 2, 4, 8

,
InterventionScore on a scale (Mean)
ISGA score-Week 1ISGA score -Week 2ISGA score -Week 4ISGA score -Week 8
MAXCLARITY II-0.05-0.16-0.47-1.16
Murad-0.11-0.05-0.58-0.89

[back to top]

Change in Participant Assessment of Tolerability (Redness, Dryness, Burning, Itching and Scaling) From Baseline to Weeks 1, 2, 4 and 8.

Redness, dryness, burning, itching and scaling were evaluated independently by the participant on a five point scale from 0 to 4 defined as 0-none, 1-very minimal, 2-mild, 3-moderate, 4-severe. Change from Baseline to scheduled time point was calculated as the value at scheduled time point minus the value at Baseline. Baseline is defined as value at Day 1. (NCT02524665)
Timeframe: Baseline and Week 1, 2, 4, 8

,
InterventionScore on a scale (Mean)
Redness score-Week 1Redness score -Week 2Redness score -Week 4Redness score -Week 8Dryness score-Week 1Dryness score -Week 2Dryness score -Week 4Dryness score -Week 8Burning score-Week 1Burning score -Week 2Burning score -Week 4Burning score -Week 8Itching score-Week 1Itching score -Week 2Itching score -Week 4Itching score -Week 8Scaling score-Week 1Scaling score -Week 2Scaling score -Week 4Scaling score -Week 8
MAXCLARITY II-0.11-0.11-0.32-0.42-0.21-0.16-0.37-0.420.11-0.11-0.26-0.26-0.210.00-0.26-0.210.05-0.26-0.160.11
Murad-0.32-0.26-0.11-0.26-0.11-0.26-0.11-0.110.160.00-0.050.000.000.110.110.11-0.11-0.260.110.21

[back to top]

Percent Change From Baseline in Total Lesions at Week 12

"Percent change from baseline in total lesions at week 12 was assessed by investigator or designee. Investigator or designee counted and recorded the number of open comedones, closed comedones, papules, and pustules on each subject's face. Lesions were counted globally on the following facial locations/quadrants: forehead, left cheek, chin, and right cheek. Each of the following lesion types were analyzed separately for forehead, left cheek, chin, right cheek, and the total of the 4 areas:~Inflammatory acne lesions (sum of papules and pustules)~Non-inflammatory acne lesions (sum of open comedones and closed comedones)~Total lesion counts (sum of inflammatory and non-inflammatory acne lesions counts)" (NCT02755545)
Timeframe: Baseline and 12 weeks

,
InterventionPercent change in lesions (Mean)
Open comedonesClosed comedonesPapulesPustulesInflammatory acne lesionsNon-inflammatory acne lesionsTotal lesion counts
Adapalene-17.1-13.0-4.2-30.1-10.0-34.7-28.3
Salicylic Acid-45.67.66.4-18.21.1-22.8-17.5

[back to top]

Average Apgar Score

"Determine if the use of an OSD can improve Apgar scores in newborns. The Apgar test is done by a doctor, midwife, or nurse. The provider examines the baby's:~Breathing effort Heart rate Muscle tone Reflexes Skin color Each category is scored with 0, 1, or 2, depending on the observed condition. Higher scores are better. Scores are added for a total ranging from 0-10." (NCT02807493)
Timeframe: at minute 1 and minute 5

,
Interventionscore on a scale (Mean)
APGAR at min 1APGAR at min 5
Control7.98.8
Occlusal Support Device7.88.8

[back to top]

Stage 2 Duration of Labor

Determine if an Occlusal Support Device (OSD) can reduce the duration of the second stage of labor (NCT02807493)
Timeframe: Duration of labor

Interventionminutes (Mean)
Occlusal Support Device120.2
Control107

[back to top]

Number of Participants With a Cesarian Section

Determine if an OSD can reduce the incidence of labor complications including Caesarian Sections (NCT02807493)
Timeframe: Baseline

Interventionparticipants (Number)
Occlusal Support Device12
Control13

[back to top]